



### Nonionic surfactants modulate the transport activity of ATP-binding cassette (ABC) transporters and solute carriers (SLC)

Relevance to oral drug absorption

Al-Ali, A A A; Nielsen, R B; Steffansen, B; Holm, René; Nielsen, Carsten Uhd

Published in: International Journal of Pharmaceutics

DOI: 10.1016/j.ijpharm.2019.05.033

Publication date: 2019

Document Version Peer reviewed version

Citation for published version (APA):

Al-Ali, A. A., Nielsen, R. B., Steffansen, B., Holm, R., & Nielsen, C. U. (2019). Nonionic surfactants modulate the transport activity of ATP-binding cassette (ABC) transporters and solute carriers (SLC): Relevance to oral drug absorption. *International Journal of Pharmaceutics*, *566*, 410-433. https://doi.org/10.1016/j.ijpharm.2019.05.033

#### **General rights**

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
  You may not further distribute the material or use it for any profit-making activity or commercial gain.
  You may freely distribute the URL identifying the publication in the public portal.

#### Take down policy

If you believe that this document breaches copyright please contact rucforsk@kb.dk providing details, and we will remove access to the work immediately and investigate your claim.

### Accepted Manuscript

### Review


Nonionic surfactants modulate the transport activity of ATP-binding cassette (ABC) transporters and solute carriers (SLC): Relevance to oral drug absorption

Ahmed A. Abdulhussein Al-Ali, Rasmus Blaaholm Nielsen, Bente Steffansen, René Holm, Carsten Uhd Nielsen

PII:	S0378-5173(19)30385-0
DOI:	https://doi.org/10.1016/j.ijpharm.2019.05.033
Reference:	IJP 18363
To appear in:	International Journal of Pharmaceutics

International Journal of Pharmaceutics

**Received Date:** 23 March 2019 **Revised Date:** 10 May 2019 11 May 2019 Accepted Date:



Please cite this article as: A.A. Abdulhussein Al-Ali, R. Blaaholm Nielsen, B. Steffansen, R. Holm, C. Uhd Nielsen, Nonionic surfactants modulate the transport activity of ATP-binding cassette (ABC) transporters and solute carriers (SLC): Relevance to oral drug absorption, International Journal of Pharmaceutics (2019), doi: https://doi.org/ 10.1016/j.ijpharm.2019.05.033

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

### 1 Nonionic surfactants modulate the transport activity of ATP-binding cassette (ABC) transporters

2

### and solute carriers (SLC): Relevance to oral drug absorption

- 3
- 4 Running title: Nonionic surfactants modulate membrane transport proteins
- 5 Ahmed A. Abdulhussein Al-Ali<sup>a</sup>, Rasmus Blaaholm Nielsen<sup>a</sup>, Bente Steffansen<sup>a, 1</sup>, René Holm<sup>b, c</sup> and
- 6 Carsten Uhd Nielsen<sup>a\*</sup>
- <sup>7</sup> <sup>a</sup>: Department of Physics, Chemistry and Pharmacy, University of Southern Denmark, Campusvej 55,
- 8 DK-5230 Odense M, Denmark.
- 9 <sup>b</sup>: Drug Product Development, Janssen R&D, Johnson & Johnson, Turnhoutseweg 30, 2340 Beerse,
  10 Belgium
- 11 <sup>c</sup>: Department of Science and Environment, Roskilde University, 4000 Roskilde, Denmark
- 12
- 13 \*: Corresponding author at: Department of Physics, Chemistry and Pharmacy, University of Southern
- 14 Denmark, Campusvej 55, DK-5230 Odense M, Denmark. Phone: +45 6550 9427 e-mail: cun@sdu.dk
- 15 (Carsten Uhd Nielsen)
- <sup>1</sup>: Present address: Leo Pharma, Industriparken 55, 2750 Ballerup, Denmark
- 17
- 18
- 19

### 20 Abstract:

Recently, it has become evident that pharmaceutical excipients may interfere with the activity of ATP-21 binding cassette (ABC) transporters and solute carriers (SLC). The present review aims to provide an 22 overview of surfactants shown to modulate substrate transport via SLCs and ABCs, and to discuss the 23 relevance for oral drug absorption. In vitro, more than hundred surfactants have been suggested to 24 decrease the efflux activity of P-glycoprotein (P-gp, ABCB1), and many of these surfactants also 25 inhibit the breast cancer resistance protein (BCPR, ABCG2), while conflicting results have been 26 reported for multidrug resistance-associated protein 2 (MRP2, ABCC2). In animals, surfactants such as 27 pluronic<sup>®</sup> P85 and polysorbate 20 have been shown to enhance the oral absorption of P-gp and BCRP 28 substrates. Many surfactants, including cremophor<sup>®</sup> EL and Solutol<sup>®</sup> HS 15 inhibiting ABC 29 transporters, were also found to inhibit SLCs in cell cultures. These carriers were SLC16A1, SLC21A3, 30 SLC21A9, SLC15A1-2, and SLC22A1-3. This overlap in specificity of surfactants that inhibit both 31 transporters and carriers might influence the oral absorption of various drug substances, nutrients, and 32 vitamins. Such biopharmaceutical elements may be relevant for future drug formulation design. 33

34

Key words: Nonionic surfactant, Co-surfactant, ATP-binding cassette transporters, Solute carriers,
Oral absorption, Lipid-based formulations.

37

38

39

### 40 **1. Introduction:**

Today, many drug substances approved for oral and parenteral use are prepared in surfactant containing 41 formulations such as lipid-based formulations, suspensions and solid dosage forms (Savla et al., 2017). 42 In these formulations, nonionic surfactants are used as solubilizes, stabilizers, wetting agents etc. In the 43 lastrecent years, it has become evident that some surfactants may affect the function of biological 44 membrane transport proteins by altering drug substance uptake (Engel et al., 2012; Rege et al., 2002) 45 and/or cellular efflux (Batrakova et al., 2003a; Rege et al., 2002; Yamagata et al., 2007b). Membrane 46 transport proteins relevant to drug transport are from two major families, i.e. the ATP-binding cassette 47 (ABC) family of efflux transporters and the solute carrier (SLC) family of cellular influx and efflux 48 carriers. In brief, members of the ABC family (hereafter termed "transporter") depend directly on the 49 use of cellular ATP to complete their transport cycle, which in mammals result in cellular efflux. 50 Members of the SLC family do not directly depend on using cellular ATP, but are driven by substrate 51 concentrations and in many cases the concentration gradient of other substrates such as ions. A SLC 52 facilitates either cellular influx or efflux, and are hereafter termed "carrier". Currently, the ABC and 53 SLC families consist of 51 and 417 members (HUGO Gene Nomenclature Committee, 2019), 54 respectively. The first indication that pharmaceutical excipients could alter the transport function of 55 56 transporters and carriers came from observations that nonionic surfactants such as cremophor<sup>®</sup> EL (Woodcock et al., 1990), Solutol® HS 15 (Coon et al., 1991), and polysorbate 80 (Woodcock et al., 57 1992) reversed multidrug resistance in cancer cells. In cell cultures, nonionic surfactants inhibited 58 59 different members of the ABC family such as P-glycoprotein (P-gp, MDR1, ABCB1) (Lo, 2003; Rege et al., 2002), breast cancer resistance protein (BCRP, ABCG2) (Yamagata et al., 2007a, b), and 60 multidrug resistance-associated protein 2 (MRP2, ABCC2), although conflicting results have been 61

observed for MRP2 (Hanke et al., 2010; Li et al., 2013a, 2014). In vivo, in wild type animals, nonionic 62 63 surfactants have been shown to enhance the intestinal absorption and bioavailability of P-gp substrates such as digoxin (Cornaire et al., 2004; Nielsen et al., 2016; Zhang et al., 2003), etoposide (Akhtar et al., 64 2017; Al-Ali et al., 2018a), and paclitaxel (Varma and Panchagnula, 2005), and the BCRP substrate 65 66 topotecan (Yamagata et al., 2007b). Interestingly, corresponding control experiments in transporter deficient animals showed that co-administration of nonionic surfactants with digoxin (Nielsen et al., 67 2016) or etoposide (Al-Ali et al., 2018a) in *mdr1a* deficient rats, or topotecan (Yamagata et al., 2007b) 68 69 in *abcg2* deficient mice did not alter the oral absorption and bioavailability of these substrates. This indeed indicates that surfactants increase intestinal absorption through P-gp or BCRP inhibition, and 70 for the drug substances in question, not through unspecific effects related to solubilizing of the drug 71 72 substances or through permeation enhancing effects.

Recently, in vitro studies have also shown that nonionic surfactants such as polysorbate 20 and 73 74 cremophor<sup>®</sup> EL inhibit the transport via several SLCs expressed ion the apical membrane of enterocytes such as the organic anion transporting polypeptide 1A2 (OATP1A2, SLC21A3) (Engel et 75 al., 2012) and organic cation transporters (OCT1-3, SLC22A1-3) (Otter et al., 2017; Soodvilai et al., 76 2017). These observations indicate that biopharmaceutical considerations need to be an important part 77 78 of new formulation development when formulations contain pharmaceutical excipients such as 79 surfactants and co-surfactants because these excipients may have different impacts on transporters and 80 carriers. Therefore, addition of surfactants to obtain an enabling formulation may potentially influence 81 the oral absorption (positively or negatively) of a co-administered drug substance if this is a substrate for a carrier and/or transporter. On the other hand, enabling formulations provide the formulation 82 scientist with the possibility to adjust drug absorption to become more consistent by selecting 83

appropriate excipients for drug substances that are ABC and/or SLC substrates. To do so, it becomes important to understand: 1) the different impacts of nonionic surfactants on carriers and/or transporters, 2) the mechanism behind surfactant-protein interactions, and 3) whether such impacts of surfactants on substrate-protein interactions observed in cell cultures may affect the pharmacokinetics parameters of the substrates *in vivo*. Currently, the translational aspects of how excipients affect carriers and transporters *in vivo* and how this may be exploited for formulation design are largely unexplored.

This review aims to provide an overview of surfactants shown to modulate substrate transport via transporters and carriers, and to discuss the relevance for oral drug absorption, and when possible the mechanism behind the interaction. In this paper, essential data is presented in tables, whereas more comprehensive overviews are provided in <u>a</u> supplementary tables in order to enhance the readability of the review.

95

### 96 2. Modulation of intestinal transporters and carriers

In the 1980s, modulation of membrane transport proteins was originally proposed as a strategy for 97 chemo-sensitizing cancer cells and to increase the oral bioavailability of drug substances that were 98 substrates for the efflux transporter P-gp in humans. Therefore, inhibitors of efflux transporters such as 99 P-gp and BCRP were then-identified and these inhibitors, for example verapamil (Tsuruo et al., 1981), 100 dexverapamil (Gramatté and Oertel, 1999), valspodar (vanAsperen et al., 1997), and GF120918 (Hyafil 101 et al., 1993), showed promising results in inhibiting P-gp (GF120918 also inhibited BCRP) 102 (Maliepaard et al., 2001a), in pre-clinical studies. However, this strategy failed to produce safe and 103 effective treatment in human clinical trials (Dalton et al., 1995; Greenberg et al., 2004; Lehnert et al., 104

1998; Mross et al., 1999; Planting et al., 2005; Ries and Dicato, 1991; Sparreboom et al., 1999; Warner 105 106 et al., 1998). Subsequently, other strategies based on natural products (Appendino et al., 2003; Yoshida et al., 2005) and pharmaceutical excipients (Lo, 2003; Rege et al., 2002; Regev et al., 1999; Zhang et 107 al., 2003) were suggested. In the latter group of compounds, nonionic surfactants gained quite some 108 109 attention since many surfactants were found to enhance the intracellular accumulation of anticancer 110 drugs including daunorubicin, vinblastine, and etoposide in cancer cells (Buckingham et al., 1995; Woodcock et al., 1990), and to influence the translocation activity of several transporters (Batrakova et 111 al., 2001; Lo, 2003; Rege et al., 2002) and carriers (Rege et al., 2002). In terms of intestinal absorption, 112 it has been reported that nonionic surfactants such as cremophor<sup>®</sup> EL (Rege et al., 2002), polysorbate 113 80 (Lo, 2003), and d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS 1000) (Bogman et al., 114 115 2005) increased the absorptive permeability and decreased the secretory permeability of the P-gp 116 substrates drug substances rhodamine 123, epirubicin, and talinolol, respectively, in vitro using the Caco-2 cell monolayers model. Likewise, in intestinal segments of rats, surfactants such as TPGS 1000 117 (Varma and Panchagnula, 2005) and polysorbate 40 (Zhu et al., 2009) enhanced mucosal to serosal (M-118 S) permeability and decreased S-M permeability of P-gp substrates paclitaxel and rhodamine 123, 119 respectively. Moreover, in vivo, it has been shown that Solutol<sup>®</sup> HS 15 (Bittner et al., 2002), 120 polysorbate 80 (Zhang et al., 2003), and pluronic<sup>®</sup> P85 (Föger et al., 2006) enhanced the oral 121 absorption and exposure of P-gp substrates colchicine, digoxin, and rhodamine 123, respectively. 122 123 Consequently, it was evident that nonionic surfactants could be potential alternatives to conventional Pgp inhibitors. 124

Since the majority of research performed until now, has been focused on investigating the influence of nonionic surfactants on P-gp, BCRP, and MRP2 transporters, and on carriers including monocarboxylic

acid transporter (MCT), OATP1A2, OATP2B1, OCT1-3 and peptide transporters 1 and 2 (PEPT1 and
2), this review will therefore summarize and discuss the impact of nonionic surfactants on these
transporters and carriers *in vitro* and on the intestinal absorption of substrate drug substances *in vivo*.

130

### 131 **3.** Expression of selected transporters and carriers along the human intestine

The intestinal expression of transporters and carriers have been studied for years using various mRNA-132 based techniques, such as northern blotting and RT-PCR, as well as protein quantification methods, e.g. 183 134 western blotting. As an example, Broberg et al. studied the expression of the proton-coupled amino acid transporter PAT1 along the length of the rat intestine taking samples from each 5 cm and 135 measured the *pat1* mRNA expression in each segment (Broberg et al., 2012). Recently, the emerging of 136 high-resolution MS/MS-based techniques, membrane proteomics has received attention as a tool to 137 describe the absolute transporter or carrier abundance in enterocytes. Knowing transporter and carrier 138 abundancies in the intestine is important for understanding the absorption windows of drug substances 139 (Oswald et al., 2006) and drug-drug interactions (Giacomini et al., 2010). Furthermore, absolute 140 transporter and carrier abundance in different segments of the intestine is necessary for PBPK 141 142 modelling (Harwood et al., 2013). The present section will briefly review the transporter and carrier abundance in the human intestine and Caco-2 cells of the selected transporter and carriers discussed in 143 the present review. 144

Table 1 shows protein concentrations of selected transporters and carriers in Caco-2 cells and in different regions of the human intestine. Naturally, cell differentiation affects transport and carrier protein expression, which is was also shown by Uchida et al. (Uchida et al., 2015). Therefore, we only

compare expression levels in cells with a similar degree of differentiation, and all three studies have shown-investigated the expression in Caco-2 cells cultured for three weeks. Expression levels in cells obtained from different cell banks may vary to a high degree as illustrated for the glucose carrier <u>SGLT1</u> by Steffansen and co-workers (Steffansen et al., 2017). For this reason, we have compared studies of Caco-2 cells from different cell banks (DSMZ, ECACC, and ATCC). The most extensive and systematic work in regional transporter and carrier expression in the intestine has been performed by Drozdzik and co-workers (Drozdzik et al., 2019; Drozdzik et al., 2014)

Regarding transporters, the P-gp expression rangeds from low to high (Akazawa et al., 2018; Drozdzik 155 et al., 2019; Drozdzik et al., 2014; Gröer et al., 2013; Harwood et al., 2015; Lloret-Linares et al., 2016), 156 and the expression increaseds from the proximal small intestine towards the distal small intestine 157 (Akazawa et al., 2018; Drozdzik et al., 2014; Gröer et al., 2013) and drops-decreased in the colon to 158 levels similar to those in the proximal small intestine (Table 1) (Drozdzik et al., 2019; Drozdzik et al., 159 2014). Caco-2 cells expressed slightly elevated levels of P-gp, compared to the small intestine (Brück 160 et al., 2017; Uchida et al., 2015; Ölander et al., 2016). BCRP expression varieds between the studies 161 from low (Drozdzik et al., 2014) to very high (Akazawa et al., 2018) expression in the small intestine 162 with an increasing expression from the proximal to the distal part of small intestine (Drozdzik et al., 163 164 2019; Drozdzik et al., 2014). In the colon, very low to intermediate expression of BCRP has been reported (Drozdzik et al., 2019; Drozdzik et al., 2014). Similarly, reported expression of BCRP in 165 166 Caco-2 cells varieds greatly. MRP2 and MRP3 generally seemwere intermediately to highly expressed 167 along the entire intestine (Akazawa et al., 2018; Drozdzik et al., 2019; Drozdzik et al., 2014; Gröer et al., 2013; Harwood et al., 2015) with a slight tendency of elevated expression in the colon (Drozdzik et 168 169 al., 2019; Drozdzik et al., 2014). The expression of MRP2 in Caco-2 cells is-was similar to the

expression in the small intestine (Brück et al., 2017; Uchida et al., 2015) with one exception, where lower expression was reported (Ölander et al., 2016). Ölander and co-workers quantified MRP3 in Caco-2 cells, and the expression of this protein was similar to the expression in the small intestine (Ölander et al., 2016). Brück et. al. and Uchida et. al. could not quantify MRP3 in Caco-2 cells (Brück et al., 2017; Uchida et al., 2015).

Regarding carriers, PEPT1 exhibiteds high to very high expression in the small intestine (Akazawa et al., 2018; Drozdzik et al., 2019; Drozdzik et al., 2014; Gröer et al., 2013; Miyauchi et al., 2016), and increasing expression in the proximal to distal direction in the small intestine (Drozdzik et al., 2019; Drozdzik et al., 2014), however, the expression in the colon is was highly reduced (approx. 10- to 30-fold) (Drozdzik et al., 2019; Drozdzik et al., 2014); (see Table 1). In Caco-2 cells, PEPT1 showeds different levels of expression from colon-like levels to small intestine-like levels (Brück et al., 2017; Uchida et al., 2015; Ölander et al., 2016) (Table 1).

Absolute amounts of transporters and carriers in the human gastrointestinal tract highly depend on the 182 site of sampling for the determination. Therefore, it is important to note that the site of sampling from 183 anatomical structures varies between studies in the field (Drozdzik et al., 2019; Drozdzik et al., 2014; 184 Lloret-Linares et al., 2016; Miyauchi et al., 2016). Additionally, tissue samples are occasionally only 185 defined as 'jejunal', 'ileal', 'distal jejunum', or 'distal ileum' with no further definition (Akazawa et al., 186 2018; Gröer et al., 2013; Harwood et al., 2015). Likewise, great inter-individual variation of intestinal 187 transporter and carrier protein expression is likely, and we have left out all statistical deviation 188 parameters in (Table 1) to enhance the overview. Moreover, protein expression is affected by external 189 factors, for example certain drug compounds (Lin and Yamazaki, 2003) and dietary elements (Erickson 190

et al., 1995) along with general health condition and diseases (Englund et al., 2007; Wojtal et al.,
2009).

Finally, inter-laboratory variation is a well-documented factor, and we refer to the excellent cross-193 laboratory study by Wegler and co-workers (Wegler et al., 2017). Herein, the authors have shown large 194 variabilities, depending on the methods applied for quantification, especially when they compare 195 whole-lysate and membrane fractionation techniques in the sample preparation. Depending on the drug 196 formulation, pharmaceutical excipients, such as nonionic surfactants, are likely to be present at 197 different concentrations in different segments of the intestine. To firmly understand how the excipients 198 will affect drug absorption influenced by transporters or carriers, it is crucial to obtain more PBPK 199 modelling knowledge regarding transporter and carrier expression patterns. 200

201

### **4.** Nonionic surfactants modulate the transport activity of several ABC transporters

203

### 4.1 Impact of nonionic surfactants on P-glycoprotein

The first discovered member of the ABC family, P-glycoprotein (Juliano and Ling, 1976), has until 204 205 now been the most investigated transporter. Since P-gp was found to mediate the cellular efflux of drug substances belonging to different drug classes, e.g. anticancer drugs and antibiotics, extensive 206 research has been performed to modulate the transport activity of the transporter in vitro and in vivo. 207 The next sections will focus on P-gp molecular characterization and substrate transport via P-gp, and 208 cellular expression and tissue distribution of P-gp. In the subsequent sections, the effects of surfactants 209 210 and co-surfactants on P-gp activity in vitro and on the intestinal absorption of P-gp substrates in vivo will be discussed. 211

### 212 P-glycoprotein molecular characterization and substrate transport

P-glycoprotein is a 170 kDa efflux transporter that requires energy from ATP hydrolysis to pump 213 214 substrates out or across cellular membranes. It has been estimated that P-gp requires two ATP molecules to transport one substrate (Ambudkar et al., 1997; Sauna and Ambudkar, 2001). Due to the 215 direct use of ATP, the transporter is able to transport its substrates against the concentration gradient, 216 and therefore P-gp can limit the cellular accumulation and retention of certain drug substances. In 217 human, P-gp is expressed in the cell membrane in different tissues such as the luminal membrane in 218 enterocytes, the canalicular membrane in hepatocytes, in the luminal membrane in proximal tubular 219 cell, in the luminal membrane of endothelial cells of the central nervous system and testes, bronchial 220 cells of lungs, and placenta (Cordon-Cardo et al., 1990), hence affecting the ADMET properties of its 221 substrates. P-gp substrates include a wide range of hydrophobic and amphipathic substrates such as 222 drug substances and toxins with diverse molecular weight ranging from approximately 300-4000 Da 223 (Fromm, 2004; Rao et al., 1999; Su et al., 2009). Hundreds of drug substances are P-gp substrates 224 (Drugbank, 2019) including anti-cancer drugs, antibiotics, cardiac drugs, immuno-suppressants, lipid-225 226 lowering agents, HIV drugs, and hormones (Chan et al., 2004; Fromm, 2004; Seelig, 1998).

It has previously been suggested that P-gp substrates might diffuse through the membrane bilayer and reach the cytoplasmic leaflet, where the substrate gets access to the protein (Raviv et al., 1990). P-gp will then according to this mechanistic proposal act as a hydrophobic "vacuum cleaner" that pumps the substrate to the extracellular environment (Raviv et al., 1990). Another model referred as "flippase model" assumed that the P-gp substrate first partition into the lipid bilayer and reach the inner leaflet, where the substrate has access to P-gp. At this stage, the substrate will be pumped directly to the extracellular environment by P-gp or flipped by the protein to the outer leaflet of the lipid bilayer

12

(Higgins and Gottesman, 1992). In both cases, the movement of the substrate would be driven by either
the equilibrium between the concentration of the substrate in the extracellular environment and in the
outer leaflet, or between the concentration of the substrate in the inner leaflet and in the cytoplasm
(Higgins and Gottesman, 1992). There is accumulating evidence supporting the flippase model for P-gp
mediated substrate transport across the membrane bilayer (Abulrob and Gumbleton, 1999; Eckford and
Sharom, 2005; Romsicki and Sharom, 2001; van Helvoort et al., 1996).

240 It was proposed that the transmembrane (TM) organization of P-gp consists of two TM domains (Chen 241 et al., 1986)., which eEach domain has six TM helices and one nucleotide-binding domain (NBD) located in the cytoplasm (Fig. 1a) (Chen et al., 1986) (Fig. 1a). Recently, the inward-facing 242 conformation of mouse P-gp proposed that the TM helices are arranged to form an internal cavity of 243 244 approximately 6000 Å<sup>3</sup>, which is integrated in the lipid bilayer (Aller et al., 2009). It has been suggested that P-gp might have portals open to the cytoplasmic region and to the inner leaflet of the 245 lipid bilayer (Aller et al., 2009). The P gp substrates may therefore via these portals get access to the 246 247 binding sites in the internal cavity of the P-gp, where two P-gp substrates could simultaneously be accommodated (Aller et al., 2009). By using cryo-electron microscopy at 3.4 Å resolution, recent 248 research has also shown the outward-facing conformation of human P-gp (Kim and Chen, 2018). In 249 brief, a P-gp substrate may bind to the internal cavity of the inward-facing conformation of P-gp, as it 250 has been suggested by Aller and co-workers (Aller et al., 2009), and this initiates ATP binding to the 251 252 NBDs of the protein (Kim and Chen, 2018). In the process of reaching the outward-facing 253 confirmation, the NBDs may dimerize resulting in the NBD's becoming closer, while the TM helices re-arrange toward the extracellular space and compress, preventing the binding of the substrate to P-gp 254 (Kim and Chen, 2018) (Fig. 1a). In its outward-facing confirmation, the extracellular part of TM 255 helices seems to be flexible for the substrate release and transport to the extracellular environment. 256

ATP hydrolysis will then reset the P-gp to the inward-facing conformation (Kim and Chen, 2018). as it
has been illustrated for the mouse P-gp (Aller et al., 2009). The inward- and outward-facing
conformations of P-gp which were proposed to occur during the substrates translocation may support
that the substrates transport across the membrane bilayer most likely occur by the flippase model.

261

263

### 262 4.1.1 Nonionic surfactants inhibit P-glycoprotein in vitro via different mechanisms

The most investigated nonionic surfactants that inhibit P-gp transport in vitro are cremophor<sup>®</sup> EL, 264 265 Solutol<sup>®</sup> HS 15, TPGS 1000, polysorbate 20, polysorbate 80 and pluronic<sup>®</sup> P85, (see Table 2). Several in vitro assays have been utilized to investigate the P-gp inhibitory properties of these surfactants 266 including: 1) measuring the impact of surfactants on substrate absorptive and/or secretory transport 267 using cell-based systems or intestinal segments excised from animals, 2) measuring the ATPase activity 268 of P-gp using membrane vesicles from cells overexpressing P-gp, and 3) fluorescence-based (e.g. 269 calcein-AM) efflux assay using cells highly-overexpressinged with P-gp. In bi-directional transport 270 271 assays, nonionic surfactants were shown to enhance the absorptive permeability of model P-gp substrates such as digoxin (Al-Ali et al., 2018b; Batrakova et al., 2001; Collnot et al., 2010; Nielsen et 272 273 al., 2016) and rhodamine 123 (Collnot et al., 2010; Guan et al., 2011; Kiss et al., 2014; Rege et al., 274 2002; Sachs-Barrable et al., 2007; Zhao et al., 2016), and to decrease the secretory permeability of 275 these substrates across cell monolayers. Consequently, the data presented in Table 2 strongly support 276 that these surfactants inhibit the efflux activity of P-gp, thus provide a promising approach to inhibit Pgp-mediated efflux of drug substances. In addition, Table S1 provides a comprehensive overview of 277 many other nonionic surfactants and co-surfactants that have shown different abilities to inhibit P-gp-278

279 mediated transport *in vitro*. The results provided in this table may assist providing an overview of
280 likely interactions.

281 Different mechanisms have been proposed to explain the mechanisms behind how nonionic surfactants 282 increase drug absorption by inhibiting P-gp-mediated cellular efflux (see Fig. 2). Work from Seelig and co-worker has suggested that the inhibition may occur through partitioning of the hydrophobic tail of 283 the surfactant into the cell membrane, while the hydrogen bond acceptor groups in the hydrophilic 284 moiety of the surfactant form hydrogen bonds with the hydrogen bond donor groups in the TM domain 285 of the protein (Li-Blatter et al., 2009; Seelig and Gerebtzoff, 2006), (Fig. 2). These hydrogen bonds 286 between the surfactant and the TM domain in P-gp may explain the higher affinity of surfactants with 287 large number of hydrogen bond acceptor groups such as n-octyl- $\beta$ -D-maltopyranoside (C<sub>8</sub>-malt) and 3-288 cyclohexyl-1-propyl-B-D-maltopyranoside (Cymal-3), than surfactants with fewer hydrogen bond 289 acceptor groups e.g. n-heptyl- $\beta$ -D-glucopyranoside (C<sub>7</sub>-gluc). Thus C<sub>8</sub>-malt and Cymal-3 with a similar 290 number of hydrogen bond acceptor groups exhibit almost the same affinity to the membrane as C<sub>7</sub>-gluc, 291 but a higher affinity to the P-gp protein, due to the duplication of the sugar moiety in maltopyranoside 292 293 based-surfactants compared to the single sugar moiety in glucopyranoside (Li-Blatter et al., 2012; Li-Blatter et al., 2009; Li-Blatter and Seelig, 2010; Xu et al., 2015). This observation may be supported by 294 295 the results from a recent study (Al-Ali et al., 2018b), which reported that polysorbate 20 elicited higher 296 affinity to P-gp in the calcein-AM efflux assay than the mono-saccharide based surfactants, e.g. lauroyl methyl glucamide, and the di-saccharides based surfactants, e.g. lauryl-β-D-maltoside, since the former 297 298 surfactant had a higher number of hydrogen acceptor groups when retaining the laurate side chain in the surfactants (Al-Ali et al., 2018b). The latter study also suggested that extending the alkyl side chain 299 300 to more than laurate e.g. stearate in polysorbate 60 and oleate in polysorbate 80, or attaching multiple

alkyl groups such as tri-stearate in polysorbate 65, while retaining the hydrophilic group in these surfactants, may decrease the affinity of the surfactant to P-gp (Al-Ali et al., 2018b). Therefore, the study concluded that *in vitro* both the hydrophobic and hydrophilic moieties in nonionic surfactant may contribute to the surfactant mediated P-gp inhibition.

The second proposed mechanism of P-gp inhibition by nonionic surfactants relates to the alteration of 305 membrane bilayer fluidity induced by surfactants, an alteration that might indirectly inhibit the ATPase 306 activity (Fig. 2). It was shown that polysorbate 20, Nonidet<sup>™</sup> P-40 and Triton<sup>™</sup> X-100, which all 307 increase the fluidity of artificial membranes, inhibited P-gp ATPase activity in membrane vesicles 308 prepared from Chinese hamster ovary AA8 cells (Regev et al., 1999), (Table 2). In addition, it was 309 reported that polysorbate 80 and cremophor<sup>®</sup> EL, which increased membrane fluidity significantly, also 310 inhibited P-gp. The inhibition resulted in a significant increase in the absorptive permeability across 311 Caco-2 cells of the model P-gp substrate rhodamine 123 and a significant decrease in the secretory 312 permeability (Rege et al., 2002). In a subsequent study, the surfactant N-octyl glucoside did not 313 modulate membrane bilayer fluidity and did not change the absorptive and secretory permeability of 314 rhodamine 123 (Rege et al., 2002). 315

Wei and co-workers proposed that the intracellular depletion of ATP was the main mechanism of P-gp inhibition by pluronic-based surfactants such as pluronic<sup>®</sup> P123 suggesting a third mechanism of P-gp inhibition (Wei et al., 2010; Wei et al., 2013), (see-Fig. 2). This third suggested mechanism of P-gp inhibition is supported by previous studies which reported that pluronic<sup>®</sup> P85 and pluronic<sup>®</sup> L64 enhanced the intracellular accumulation of the P-gp substrate rhodamine 123 and decreased intracellular ATP *in vitro* (Batrakova et al., 2003a), (Table 2).

The fourth proposed mechanism of surfactant mediated P-gp inhibition suggested a combined effect of depleted intracellular ATP and alteration in cellular membrane fluidity (Batrakova et al., 2003a; Batrakova et al., 2003b), (see–Fig. 2). In support of this, it was reported that pluronic<sup>®</sup> P85 and pluronic<sup>®</sup> L81, which enhanced membrane fluidity, were able to deplete the-intracellular ATP, and significantly enhanced the intracellular accumulation of rhodamine 123 in bovine brain microvessel endothelial cells (Batrakova et al., 2003b; Batrakova et al., 2004), (Table S1).

Consequently, the mechanisms of P-gp inhibition by surfactants seem complex. It could be that one <u>or</u> <u>more\_mechanisms\_or\_more\_are involved\_in\_such\_inhibition</u>. However, further research focused on further\_characterizing the underlying mechanism(s) of surfactant-mediated P-gp inhibition is needed, which might assist in choosing the appropriate surfactant(s) or developing new surfactant(s) that could be more potent than the ones available and perhaps transporter specific.

# 3334.1.24.1.1Surfactants used in preparing lipid-based formulations may inhibit334P-glycoprotein *in vitro*

Surfactants can be used in pharmaceutical formulations such as lipid-based formulations (LBF) 335 (Pouton, 2006). Currently, many drug substances available in the market are incorporated into LBFs 336 such as tipranavir (Aptivus<sup>®</sup>), bexarotene (Targretin<sup>®</sup>), and sirolimus (Rapamune<sup>®</sup>), where the 337 surfactants function as solubilizing agents and emulsifiers (Savla et al., 2017). For formulations of P-gp 338 substrates, inclusion of surfactants that have P-gp inhibition properties might be advantageous with 339 respect to enhancement of substrate transport across biological membranes. Therefore, studies have 340 reported the use of the LBFs to enhance the oral absorption of different P-gp substrates (Akhtar et al., 341 2015; Zhao et al., 2013). The self-micro-emulsifying drug delivery systems (SMEDDS) containing 342

cremophor<sup>®</sup> RH 40, cremophor<sup>®</sup> EL, or polysorbate 80 (Zhao et al., 2013), and the self-nano-343 344 emulsifying drug delivery systems (SNEDDS) containing cremophor® RH40 and Transcutol® P (Akhtar et al., 2015) were shown to enhance etoposide permeability across intestinal tissues and cell 345 monolayers partly due to the inhibition of P-gp by these surfactants. In human, several studies showed 346 enhanced oral absorption of the P-gp substrate cyclosporine A when formulated in LBFs compared to 347 348 the oral absorption of cyclosporine A from conventional oral dosage forms (Bekerman et al., 2004; 349 Drewe et al., 1992; Postolache et al., 2002). Cyclosporine A is an immunosuppressant used in 350 prophylaxis and treatment of graft rejection in organ transplantations, and in treatment of autoimmune diseases e.g. rheumatoid arthritis, aplastic anemia, and myasthenia gravis (Italia et al., 2006). 351 Cyclosporine A has low aqueous solubility (0.04 mg mL<sup>-1</sup>) (O'Leary et al., 1986), low permeability in 352 cell cultures (Augustijns et al., 1993; Fricker et al., 1996), and high variations in oral bioavailability 353 among patients (Czogalla, 2009; Lown, 1997). In the studies where cyclosporine A was prepared in 354 LBFs (Bekerman et al., 2004; Drewe et al., 1992; Postolache et al., 2002), the possible P-gp inhibition 355 effect of excipients, e.g. nonionic surfactants, was however not mentioned. Interestingly, the excipients 356 used to prepare LBFs-containing cyclosporine A were polysorbate 80, cremophor RH 40 (Bekerman et 357 al., 2004), sucrose monolaurate, hydrogenated castor oil, and polyethylene glycol (Drewe et al., 1992), 358 which were later shown to possess P-gp inhibitory properties in vitro (Al-Ali et al., 2018a; Al-Saraf et 359 al., 2016; Ashiru-Oredope et al., 2011; Chiu et al., 2003; Cornaire et al., 2004; Gurjar et al., 2018; 360 361 Hanke et al., 2010; Hodaei et al., 2015; Hugger et al., 2002; Johnson et al., 2002; Kiss et al., 2014; Rege et al., 2002; Shono et al., 2004) (Table 2 and S1), and/or in vivo (Shimomura et al., 2016; Zhang 362 et al., 2003; Zhao et al., 2013) (Table 3). 363

Furthermore, previous research have reported that several surfactants such as lauroyl methyl glucamide, lauryl-β-D-maltoside, and trehalose 6-laurate that inhibited the efflux of P-gp substrate calcein-AM in MDCKII MDR1 cells, (Table S1), might also possess paraceullar and/or transcellular permeation enhancing effects in cell cultures (Al-Ali et al., 2018b; Eley and Triumalashetty, 2001; Petersen et al., 2012). Such effects might be advantageous when designing LBFs to enhance the oral absorption of P-gp substrate drug substances with limited oral bioavailability induced by intestinal P-gp.

Additionally, the mixed micelles formulations such as pluronic<sup>®</sup> 105/pluronic<sup>®</sup> F-127, pluronic<sup>®</sup> 371 P123/pPluronic<sup>®</sup> F127, and polysorbate 80/pluronic<sup>®</sup> F-127 were shown to inhibit the P-gp-mediated 372 efflux of docetaxel (Chen et al., 2013), paclitaxel (Wei et al., 2010), and morin (Choi et al., 2015), 373 respectively, in cells highly-over-expressing P-gp (Table S1). Despite the fact, that pluronic® F-127 was 374 used in the latter formulations and proposed to inhibit P-gp in another study (Guan et al., 2011), several 375 studies reported that pluronic<sup>®</sup> F-127 did not inhibit P-gp mediated efflux of several P-gp substrates 376 e.g.such as rhodamine 123 (Batrakova et al., 2003b; Wei et al., 2013), nelfinavir (Shaik et al., 2008), 377 378 etoposide (Al-Ali et al., 2018a), and digoxin (Gurjar et al., 2018). In these types of formulations, one limitation could be that the drug substances might also be adsorbed to the core of surfactant micelles, 379 380 which may decrease the free fraction of unbound substrate in the formulation, thus affecting the subsequent oral absorption and bioavailability of the substrate in vivo. Therefore, investigating the 381 release of drug substances from micelles is important and should be performed *in vitro* in order to 382 383 avoid or understand such impacts of surfactants in vivo. The LBFs containing nonionic surfactants that have P-gp inhibitory properties seem, however, as a promising approach to improve P-gp substrates 384 permeability across cellular membranes. 385

# 386 4.1.34.1.2 Nonionic surfactants inhibited P-glycoprotein *in vitro* at below and 387 above critical micelle concentrations

In several studies performed in cell cultures, it was observed that the inhibition of P-gp transport 388 activity by nonionic surfactants decreased at concentrations at or above the surfactants critical micelles 389 concentration (CMC) compared to concentration below CMC. It was reported that pluronic® P85 390 (Batrakova et al., 2003b; Batrakova et al., 2004), cremophor<sup>®</sup> EL (Shono et al., 2004), and polysorbate 391 40 (Zhu et al., 2009) were effective in inhibiting P-gp transport activity at concentrations lower than 392 their CMCs in vitro; however, this inhibitory effect decreased at or above the surfactants CMC values 393 (Batrakova et al., 2003a; Batrakova et al., 2003b; Batrakova et al., 2004; Shono et al., 2004; Zhu et al., 394 2009) (Table 2 and S1). A possible explanation to this observation could be that most P-gp substrates 395 are lipophilic substances, which after incorporation into the hydrophobic core of micelles, lead to a 396 decrease in the unbound fraction of the substrate available for the transcellular transport, and hence the 397 observed reduction in substrate transport, termed the solubility/permeability interplay (Beig et al., 398 2017; Beig et al., 2015; Dahan et al., 2010; Miller et al., 2011). 399

In addition, using the parallel artificial membrane permeability assay (PAMPA), the passive permeability of the P-gp substrate paclitaxel across artificial membranes have been shown to decrease significantly when the TPGS 1000 concentration in the donor chamber was above the CMC (Varma and Panchagnula, 2005). Furthermore, using PAMPA, increasing the concentration of the surfactants such as sodium lauryl sulfate above the CMC values decreased the passive permeability of etoposide across artificial membranes (Beig et al., 2015). The PAMPA studies may support the hypothesis that the decreased permeability of the substrates was related to the incorporation of paclitaxel and etoposide

in the micelles, this may support the effect of surfactant on the thermodynamic activity of the substraterather than the decreased inhibitory effect of surfactant above the CMC.

Moreover, many studies have reported that nonionic surfactants, used at concentrations above their 409 CMCs, inhibited the efflux of P-gp substrates *in vitro* such as (Surfactant: P-gp substrate/s): 410 (cremophor<sup>®</sup> RH 40: rhodamine 123) (Kiss et al., 2014), (Brij<sup>®</sup> 58: digoxin and rhodamine 123) 411 (Gurjar et al., 2018; Zhao et al., 2016), (cremophor<sup>®</sup> EL: etoposide and digoxin) (Al-Ali et al., 2018a; 412 Gurjar et al., 2018), (Labrasol<sup>®</sup>: rhodamine 123) (Lin et al., 2007), and (polysorbate 20: etoposide, 413 doxorubicin, digoxin, and epirubicin) (Al-Ali et al., 2018b; Al-Saraf et al., 2016; Gurjar et al., 2018; 414 Lo, 2003). Consequently, it seems that nonionic surfactants at concentration higher than their CMC 415 values are able to inhibit P-gp in vitro; however, care should be taken in the interpretation due to the 416 potential influence for of the solubility/permeability interplay. 417

### 418

419

# 4.1.4<u>4.1.3</u> Polyethylene glycol (PEG) derivatives inhibited P-glycoprotein *in vitro*

In addition to nonionic surfactants, co-surfactants such as polyethylene glycol (PEG) derivatives are 420 used in a broad spectrum of drug delivery systems where these excipients are used as solubilizers, 421 422 stabilizers, release-modifiers, and bioavailability enhancers (D'Souza and Shegokar, 2016). From Table 2 and S1, it can be noticed that several PEG derivatives with different molecular weight including PEG 423 300, PEG 400, PEG 2000, PEG 6000, and PEG 20000 were reported to decrease the efflux of several 424 425 P-gp substrates in Caco-2 cells and in rat intestinal segments. In vitro, it has been shown that PEG 400 at concentration of 0.1-20% (w/v, or v/v) may decrease the efflux of several P-gp substrates e.g. 426 digoxin (Johnson et al., 2002), ranitidine (Ashiru-Oredope et al., 2011), and rhodamine 123 (Hodaei et 427

al., 2015; Shen et al., 2006). Furthermore, recent studies have reported that PEG 400 may decrease the
P-gp expression in Caco-2 cells (Hodaei et al., 2015) and increase the P-gp ATPase activity (AshiruOredope et al., 2011), suggesting two different mechanism of P-gp inhibition. The latter effect might
refer to the direct interaction of PEG 400 with P-gp, thus competitively inhibited the protein (AshiruOredope et al., 2011). Moreover, PEG 300 was reported to inhibit P-gp through altering Caco-2
membrane fluidity (Hugger et al., 2002), suggesting a third mechanism of PEG derivatives mediated Pgp inhibition *in vitro*.

# 4354.1.54.1.4Nonionic surfactants increased the oral absorption of P-glycoprotein436substrates in vivo

The impact of nonionic surfactants on the oral absorption of P-gp substrates have mainly been 437 investigated in wild type rats; (Table 3). Several surfactants such as polysorbate 20 and 80 have been 488 shown to increase the oral absorption of different P-gp substrates such as polysorbate 80, which has 489 been shown to enhance the oral absorption of such as digoxin (Zhang et al., 2003), etoposide (Zhao et 440 al., 2013), and rifampicin (Shimomura et al., 2016). The concentrations of surfactants that increased the 441 442 oral absorption of different P-gp substrates range from 1-25% (w/v)<sub>5</sub> (see Table 3). Recently, wild type and *mdr1a* deficient rats have been used to investigate the role of intestinal P-gp for the oral absorption 443 of digoxin (Nielsen et al., 2016) and etoposide (Al-Ali et al., 2018a). In these studies, there was 444 approximately 2- and 8-fold increase in the AUC of digoxin and etoposide, respectively, in mdr1a 445 deficient rats compared to wild type rats. When 5% and 10-25 % (v/v) polysorbate 20 was co-446 administered with etoposide and digoxin, respectively, in wild type rats, the oral bioavailability was 447 enhanced significantly. However, in *mdr1a* deficient rats, the presence or absence of similar doses of 448 449 the surfactant did not influence the bioavailability indicating that the enhanced oral absorption in the

wild type rats was most likely related to P-gp inhibition effects mediated by polysorbate 20 rather thanenhancement of the substrate solubility by the surfactant.

In relation to scaling between *in vitro* and *in vivo* studies of the surfactants, it has been shown that a 452 453 concentration of 20-500 µM polysorbate 20 decreased the efflux ratio of digoxin and etoposide in cell cultures (Al-Ali et al., 2018a; Nielsen et al., 2016), whereas in pre-clinical studies; in wild type rats, 454 the minimum doses of polysorbate 20 required to increase the oral bioavailability of digoxin (Nielsen et 455 al., 2016) and etoposide (Al-Ali et al., 2018a) were 10% (v/v, 90 mM) and 5% (v/v, 45 mM), 456 respectively. However, in *mdr1a* deficient rats, it was noticed that the oral absorption and 457 bioavailability of etoposide decreased when co-administered with 25% (v/v) polysorbate 20 compared 458 to the oral absorption with 0 or 5% (v/v) polysorbate 20, or without the surfactant (Al-Ali et al., 2018a). 459 In vitro dialysis studies demonstrated that etoposide release from a 25% polysorbate 20 containing 460 formulation was minimal, most likely due to the incorporation of etoposide into the micelles formed by 461 the polysorbate (Al-Ali et al., 2018a). Furthermore, it has been reported that 5% labrasol® increased the 462 oral bioavailability of etoposide more when co-administered with 5% labrasol®-than with-10% 463 labrasol<sup>®</sup> (Akhtar et al., 2017), indicating that etoposide release from the micelles was concentration 464 dependent (Akhtar et al., 2017), (see also Table 3). 465

TPGS 1000 enhanced the oral bioavailability of paclitaxel in wild type rats with a factor of six relative to the bioavailability when administered without the surfactant (control) (Varma and Panchagnula, 2005), (Table 3). Verapamil was further demonstrated to enhance the oral bioavailability of similar doses of paclitaxel four times compared to control (Varma and Panchagnula, 2005). With respect to the use of surfactants *in vivo*, it should be noted that some of these <u>surfactants</u> undergo digestion in the intestinal tract (Christiansen et al., 2010; Cuiné et al., 2008; Devraj et al., 2013; Mohsin, 2012), why

472 <u>and might thus be less efficient the use of these relative tothan</u> small-molecular P-gp inhibitors like
473 verapamil, should be considered with respect to the hypothesis of the studies.

From Table 2, 3 and S1, it is evident that research is still needed to establish how inhibition observed in 474 vitro translates into increased absorption in vivo, since many nonionic surfactants such as Brij® 78, 475 pluronic<sup>®</sup> P123, and polysorbate 40, have not yet been investigated for their abilities to inhibit 476 intestinal P-gp in vivo. Moreover, for some surfactants that were extensively investigated in vitro such 477 as cremophor<sup>®</sup> EL, pluronic<sup>®</sup> 85 and Solutol<sup>®</sup> HS 15, (see also Table 2), only few *in vivo* studies have 478 479 reported the effect on PK of these surfactants on PK in animals (Bittner et al., 2002; Föger et al., 2006; Zhao et al., 2013), (Table 3). Consequently, further in vivo studies are needed to advance the 480 481 knowledge about the effect of these surfactants on the oral absorption of different P-gp substrates, which may assist in designing and performing clinical studies in humans. 482

- 483
- 484

### 4.2 Impact of nonionic surfactants on breast cancer resistance protein

The ABC transporter BCRP is as a monomeric protein of 72 kDa (Doyle and Ross, 2003; Mao, 2005) 485 consisting of one TM domain of six TM helices, and one NBD located in the cytoplasm (Chen et al., 486 2015; Mao and Unadkat, 2015; Wang et al., 2008). Two BCRP monomers dimerize to form a 487 488 functional BCRP transporter (Fig. 1b) (Rosenberg et al., 2010; Rosenberg et al., 2015). The helices are arranged to form a cavity, where BCRP substrates bind, while TM helices one and six are attached to 489 amino and carboxyl termini in the cytoplasm, respectively (Wang et al., 2008). BCRP substrates belong 490 to different therapeutic classes such as anticancer drugs, HIV drugs, antihistamines, and anti-491 hyperlipidemia drugs (Mao and Unadkat, 2015). BCRP shares many substrates with P-gp e.g. 492

topotecan (Jonker et al., 2000; Maliepaard et al., 1999), doxorubicin (Allen et al., 1999; Mechetner et 493 494 al., 1998), irinotecan (Gupta et al., 1996; Maliepaard et al., 1999), and etoposide (Allen et al., 2003; Keller et al., 1992). In humans, BCRP is highly expressed in normal tissues such as the apical 495 membrane of small intestinal and colonic enterocytes, canalicular membranes in the liver, endothelial 496 cells of brain microvessels (Mao, 2005), veins and capillaries, and in cancer cells (Doyle and Ross, 497 2003; Maliepaard et al., 2001b). Since BCRP is expressed in different tissues, its modulation in humans 498 499 may influence the ADMET properties of its substrates. In the past, BCRP inhibitors were developed to 500 overcome the multidrug resistance phenomenon, as well as to enhance the oral absorption of the substrates (Gupta et al., 2006; Gupta et al., 2004; Houghton et al., 2004; Matsson et al., 2009). BCRP 501 inhibitors may act as competitive inhibitors at the substrate binding sites, as allosteric inhibitors by 502 503 binding to the protein at a site different from the substrate binding site in the BCRP cavity, or by inhibiting ATPase activity (Mao and Unadkat, 2015). Of the BCRP inhibitors identified; some of these 504 also inhibit P-gp e.g. GF120918, and the tyrosine kinase inhibitors imatinib, and the antifungal drug 505 substance itraconazole (Mao and Unadkat, 2015; Matsson et al., 2009). 506

Until now, few sStudies were performed by Yamagata and co-workersto have investigateding the effect 507 of nonionic surfactants on BCRP transport activity in vitro and in vivo (Sawangrat et al., 2018a; 508 Sawangrat et al., 2018b; Xiao et al., 2016; Xu et al., 2015; Yamagata et al., 2007a, b; Yamagata et al., 509 510 2009). In MDCKII BCRP cells, nonionic surfactants such as cremophor<sup>®</sup> EL, polysorbate 20, span 20, pluronic<sup>®</sup> P85, and Brij<sup>®</sup> 30 increased the uptake of the BCRP substrate mitoxantrone (Yamagata et al., 511 512 2007a) (Table 4). Yamagata and coworkers were also able to enhance the uptake of mitoxantrone in MDCKII MDR1 by the use of the same surfactants indicating the ability of these surfactants to 513 514 modulate both BCRP and P-gp (Yamagata et al., 2007a), effects that wasere demonstrated both in vitro

515 (Al-Ali et al., 2018a; Al-Ali et al., 2018b; Al-Saraf et al., 2016; Gurjar et al., 2018; Li-Blatter and 516 Seelig, 2010; Lo, 2003; Nielsen et al., 2016; Rege et al., 2002; Shaik et al., 2008), and in vivo (Al-Ali et al., 2018a; Föger et al., 2006; Nielsen et al., 2016; Zhao et al., 2013), for further details see (see 517 Table 2, 3 and S1). With respect to the effect of nonionic surfactants on BCRP, it-another study was 518 reported that pluronic<sup>®</sup> P85 and polysorbate 20 enhanced the mucosal-to-serosalM-S transport of 519 520 BCRP substrate topotecan across ileum everted sacs derived from wild type mice (see-Table 4) 521 (Yamagata et al., 2007b). Interestingly, in everted intestinal sacs derived from Abcg2 deficient mice, topotecan absorption rate was significantly enhanced in comparison to the absorption rate in everted 522 intestinal sacs from wild type mice (Yamagata et al., 2007b). However, the presence of surfactants did 523 not further improve the absorption rate of topotecan in Abcg2 deficient everted intestinal sacs, 524 525 demonstrating the surfactants' impacts in mediating the Bcrp inhibition in the wild type animals (Yamagata et al., 2007b). In vivo, pluronic® P85 and polysorbate 20 administered orally 15 min before 526 oral administration of topotecan to wild type mice increased the AUC of topotecan significantly, when 527 compared to the administration of similar doses of topotecan without the surfactant (Yamagata et al., 528 2007b). It was later noticed that the interaction of pluronic<sup>®</sup> P85 and polysorbate 20 with Bcrp was 529 530 reversible and transient upon removal of these surfactants (Yamagata et al., 2009). It is worth noticing 581 that these surfactants were also able to inhibit P-gp in vitro (Al-Ali et al., 2018a; Al-Ali et al., 2018b; Al-Saraf et al., 2016; Batrakova et al., 2003a; Batrakova et al., 2004; Gurjar et al., 2018; Nielsen et al., 582 583 2016; Shaik et al., 2008) (Table 2, S1) and in vivo (Al-Ali et al., 2018a; Föger et al., 2006; Nielsen et al., 2016) (Table 3). 584

535 <u>Moreover</u>, <u>Rr</u>ecent research has reported that several surfactants, including <u>6-tetradecyl- $\beta$ -D-536 <u>maltopyranoside</u>, (C6-malt) (Xu et al., 2015), cremophor<sup>®</sup> EL (Al-Ali et al., 2018a; Al-Saraf et al.,</u>

2016; Gurjar et al., 2018; Rege et al., 2002; Shono et al., 2004), BL-9EX, Brij<sup>®</sup> 92, Brij<sup>®</sup> 97 (Zhao et 587 538 al., 2016), and labrasol<sup>®</sup> (Akhtar et al., 2017; Cornaire et al., 2004; Lin et al., 2007; Ma et al., 2011), which have been shown to inhibit P-gp (Table 2), have also been able to inhibit BCRP in MDCKII 589 BCRP cells (Xiao et al., 2016), in membrane vesicles containing human BCRP (Xu et al., 2015), and 540 541 Berp-in rat intestinal membrane and *in vivo* using the *in situ* closed intestinal loop method (Sawangrat 542 et al., 2018a). The doses of the surfactants used to inhibit BCRP in vitro and in vivo (Sawangrat et al., 543 2018a; Xiao et al., 2016; Xu et al., 2015) were comparable to the doses used to inhibit P-gp (Akhtar et al., 2017; Lin et al., 2007; Ma et al., 2011; Zhao et al., 2016) (Table 2, 3, and S1). As similar doses of 544 nonionic surfactants appeared to be able to inhibit P-gp and BCRP, and since many drug substances 545 that are BCRP substrates share substrate specificity with P-gp, drug formulators should thus consider 546 the surfactants used in their formulations, and avoid using the surfactants that may have overlap in 547 inhibiting effect on both transporters in cases where this may have an influence on the 548 549 biopharmaceutical properties of the compoundsubstrate. Cremophor® EL was shown to enhance the 550 absorptive permeability and decrease the secretory permeability of scutellarin in MDCKII BCRP (Xiao et al., 2016). Scutellarin is a flavonoid glucuronide approved in China to treat patients with cerebral 551 infarction and paralysis caused by cerebrovascular diseases (Xiao et al 2016). In wild type rats, 552 cremophor<sup>®</sup> EL enhanced scutellarin oral absorption, however, this study also reported that the 553 surfactant affected other transporters such as MRP2 and MRP3 (See section 4.3). Another recent study 554 by Sawangrat and co-workers showed that 0.05 % (w/v) cremophor® EL enhanced the absorptive 555 556 permeability and decreased the secretory permeability of topotecan significantly in Caco-2 cells, and enhanced the intestinal absorption of topotecan in rats using the *in situ* closed-loop method (Sawangrat 557 558 et al., 2018b). Similar concentration of cremophor<sup>®</sup> EL did, however, not influence the absorptive or secretory permeability of the BCRP substrate sulfasalazine across rat intestinal segments in diffusion 559

560 chambers (Sawangrat et al., 2018a). Furthermore, using the *in situ* closed-loop method, 0.05% (w/v) 561 polysorbate 20 enhanced the intestinal absorption of topotecan significantly in rats (Sawangrat et al., 2018b). In contrast; however, higher concentration (0.1 and 0.5% w/v) of the surfactant did not 562 enhance the absorption of sulfasalazine in another study (Sawangrat et al., 2018a). The effect of 563 564 nonionic surfactants on the transport of BCRP substrates across the intestine therefore seems to differ 565 as a function of substrate and/or method used. Further studies are needed to investigate the effects of 566 nonionic surfactants on the transport activity of BCRP in vitro and in vivo. It is recommended that different BCRP substrates and different methods are used in the prospective investigations. 567

568

569 4.3 Impact of nonionic surfactants on the multidrug resistance-associated protein 2 In human tissues, the efflux transporter multidrug resistance-associated protein 2 (MRP2) is expressed 570 in the hepatocyte canalicular membrane, gallbladder epithelial cells, the proximal tubule of the kidney, 571 duodenum, jejunum, ileum, brain, bronchi, and placenta (Jedlitschky et al., 2006; Kool et al., 1997; 572 Nies and Keppler, 2007). MRP2 is highly expressed in cancer cells, such as non-small cell lung cancer 573 and adeno-lung carcinoma (Kool et al., 1997). MRP2 consists of two TM domains, each has six TM 574 575 helices, linked intracellularly with two NBDs located in the cytoplasm (Fig. 1c) (Jedlitschky et al., 2006). To the NBDs, ATP molecules bind, which is required for hydrolysis initiating substrate 576 transport (Jedlitschky et al., 2006). In addition, a third TM domain consisting of five helices is attached 577 to the first TM domain via a linker (L0), which is located in the cytoplasm. The third TM domain is 578 579 extracellularly attached to NH<sub>2</sub> terminus of the first TM domain (see Fig. 1c) (Jedlitschky et al., 2006). MRP2 transports different endogenous compounds such as glutathione, leukotrienes, bilirubin 580

glucuronides and steroids, and drug substances of different classes, e.g. anticancer drugs, HIV drugs,
antibiotics, and the metabolites of these substances (Dietrich et al., 2003; Jedlitschky et al., 2006).

The effect of nonionic surfactants on MRP2 has been investigated in vitro using different assays, e.g. 583 bi-directional transport, uptake assay, ATP measurements, and phosphate release measurements. It was 584 reported that pluronic<sup>®</sup> P85 enhanced the intracellular accumulation of the MRP2 substrates vincristine 585 and doxorubicin in MDCKII MRP2 cells (Batrakova et al., 2003a). This was confirmed by decreased 586 ATP levels in MDCKII MRP2 cells and decreased ATPase activity in the membrane vesicles isolated 587 from these cells (Batrakova et al., 2004). Based upon these data, Batrakova and co-workers proposed 588 that the mechanism of MRP2 inhibition could be related to the change in membrane fluidity or binding 589 of the surfactant to the cell membrane, thereby competitively preventing the drug-protein interaction 590 (Batrakova et al., 2004). Beside the effect of pluronic® P85 on MRP2, it was found that similar 591 concentrations of the surfactant inhibited MRP1 and P-gp (Batrakova et al., 2004). 592

Recent studies have shown that surfactants including cremophor<sup>®</sup> EL, cremophor<sup>®</sup> RH 40, pluronic<sup>®</sup> 593 F68, and pluronic® P-127, and co-surfactants PEG 400, and PEG 2000 decreased the efflux ratio of the 594 MRP2 substrate scutellarin in Caco-2 cells (Li et al 2013, Li et al 2014). Scutellarin is a flavonoid 595 glucuronide approved in China to treat patients with cerebral infarction and paralysis caused by 596 cerebrovascular diseases (Xiao et al 2016). Scutellarin has a poor oral bioavailability, which is partly 597 related to the efflux effect of membrane transporters such as MRP2 and BCRP (see Table 4 and 5). In 598 agreement with Li and co-workers (Li et al 2013, Li et al 2014), Chen et al. have shown that pluronic® 599 F68, pluronic® F-127, pluronic® P85, and pluronic® P105 increased A-B permeability and decreased B-600 A permeability of the MRP2 substrate, baicalein, in MDCK MRP2 cells (Chen et al., 2017), (Table 5). 601

602 Chen and co-workers have suggested that these observations were due to MRP2 inhibition (Chen et al.,603 2017).

In contrast, vinblastine transport across MDCKII MRP2 cells was not affected significantly by 0.1 % (w/v) pluronic<sup>®</sup> L61 (Evers et al., 2000). Likewise, using a 5-chloromethylfluorescein diacetate (CMFDA) based accumulation assay in MDCK-MRP2 cells, Bogman *et al.* (2003) found that the surfactants TPGS 1000, cremophor<sup>®</sup> EL, polysorbate 80, pluronic<sup>®</sup> F68, pluronic<sup>®</sup> L61, and pluronic<sup>®</sup> L81 were unable to inhibit MRP2-mediated methylfluorescein-sulfoglutathione complex (MF-SG) transport (Bogman et al., 2003).

From Table 4 and 5, it can be noticed that the dose of cremophor® EL needed to inhibit MRP2 or 610 BCRP in cell cultures and in rats are similar (Xiao et al 2016). Xiao and co-workers have also reported 611 that cremophor<sup>®</sup> EL was able to activate the efflux protein MRP3 (Xiao et al 2016), which was found 612 to be expressed on the basolateral membrane of enterocytes (Kool et al., 1997; Kool et al., 1999). 613 Therefore, effects of cremophor<sup>®</sup> EL on scutellarin seems to be related to the effect on multiple efflux 614 transporters. Thus, activating the efflux transporters, being located in the basolateral membrane in 615 616 enterocytes by surfactants could also be a strategy to improve the absorption of substrate drug substances across intestinal membranes; however, further investigations are needed for this to be a 617 robust formulation strategy. 618

An interesting finding reported was that pluronic<sup>®</sup> F-127 decreased the efflux ratio of scutellarin and baicalein in Caco-2 cells (Li et al 2013, Li et al 2014) and MDCKII MDRP2 (Chen et al., 2017), respectively, but had no inhibitory effect on the P-gp substrates rhodamine 123 (Batrakova et al., 2003b), nelfinavir (Shaik et al., 2008), etoposide (Al-Ali et al., 2018a), and digoxin (Gurjar et al., 2018). Consequently, it may be that there is limited cross inhibitory effects for surfactants inhibiting

MRP2 towards other efflux membrane transporters and vice versa. The ability of nonionic surfactants 624 625 to inhibit MRP2-mediated transport seems to be complex and dependent on the model system employed to investigate and understand the influence of the surfactant. Therefore, further studies and 626 specific MRP2 model systems are needed to understand the consequences of MRP2 inhibition by 627 628 nonionic surfactants. CF

629

#### 5. Nonionic surfactants modulate solute carriers in vitro 630

In humans, solute carriers transport endogenous and exogenous (Yu Liang Sigi Li Ligong, 2015), 631 charged, and uncharged substrates (Koepsell et al., 2007), in and/or out of cells in different tissues, e.g. 632 intestine, kidney, liver and brain (Giacomini et al., 2010). The SLC family consists of 62 sub-families 633 (HUGO Gene Nomenclature Committee, 2019). For a protein to be assigned to the SLC family they 634 need to be responsible for membrane solute transport and to have an amino acid identity of > 20% to 635 other members of the family (Hediger et al., 2013). Within the SLC family uniporters, symporters and 636 antiporters are found. The symporters may depend on the driving force of ions such as K<sup>+</sup>, Na<sup>+</sup>, H<sup>+</sup>, or 637 Cl<sup>-</sup>, and at a cellular level, they are therefore known as secondary-active transporters (e.g. K<sup>+</sup>, Na<sup>+</sup>, or 638 Cl<sup>-</sup>-dependent carriers) or tertiary-active transporters (H<sup>+</sup>-dependent carriers), because the cellular 639 homeostasis of ions eventually will involve transport by the active NA<sup>+</sup>/K<sup>+</sup>-ATPase enzyme. The use of 640 transporter in this context is a reminiscence of a notion and literature source present prior to the 641 establishment of the SLC system, which was pioneered by Hediger (Hediger, 2004; Hediger et al., 642 2013). 643

SLC proteins are diverse in their structures, however, the most common predicted folds of this family 644 645 proteins are the Major Facilitator Superfamily (MFS, LacY) and the Leucine transporter (LeuT) that has folding consisting of 12 and 10 TM helices, respectively. However, some carriers in the SLC 646 family may possess a lower number of helices, e.g. the glucose uniporter that has a unique fold of 647 seven TM helices (Colas et al., 2016). For the LacY like fold (Fig. 1d), the protein is oriented in a V-648 shape conformation opened to the extracellular side of plasma membrane where the substrate is 649 650 assumed to bind. The substrate may then move to an intermediate state inside the protein, before it may release from the inverted V-shape conformation of the SLC to the cytoplasm (Fig. 1d) (Colas et al., 651 2016). 652

The oral absorption of a large variety of important nutrient such as amino acids, sugars, peptides, fatty 653 acids, and vitamins are mediated by carriers, which are important for oral absorption of drug substances 654 that are structurally similar to the nutrients (Steffansen et al., 2004). Despite the large number of 655 carriers expressed in the intestine, the effect of nonionic surfactant on these transport systems is largely 656 uninvestigated. In 2002, Rege and co-workers reported that polysorbate 80 decreased the absorptive 657 permeability of the prototypic PEPT1 substrate glycyl-sarcosine and cremophor<sup>®</sup> EL decreased the 658 transport of the monocarboxylic acid transporter (MCT) substrate benzoic acid in Caco-2 cells (Rege et 659 660 al., 2002), (Table 6). Recently, these surfactants have been shown to inhibit other carriers in transfected cells models. Polysorbate 80 and cremophor® EL inhibited OCT1-3 and PEPT2 in MDCKII OCT1-3 661 cells and MDCKII PEPT2 cells, respectively. From Table 6, it can be noticed that polysorbate 80 662 appeared more potent than cremophor<sup>®</sup> EL with respect to inhibition of OCT1-3 and PEPT2 in cell 663 cultures (Otter et al., 2017; Soodvilai et al., 2017). In addition, it was reported that cremophor® EL 664 inhibited OATP1A2 and OATP2B1 in HEK OATP1A2 and HEK OATP2B1 cells, respectively (Engel 665

et al., 2012). Furthermore, poloxamer 188 and 407 (Otter et al., 2017), and polysorbate 20 and 60 (Otter et al., 2017; Soodvilai et al., 2017), have shown different abilities to inhibit the organic cation transporters in cell cultures. In MDCKII OCT1 cells, the estimated  $IC_{50}$  of poloxamer 407 (pluronic<sup>®</sup> F-127) was approximately 2600-fold and 900-fold higher than the estimated  $IC_{50}$  of polysorbate 80 and polysorbate 20, respectively (Otter et al., 2017).

Surfactants inhibiting carriers (Table 6) were also reported to inhibit transporters (Table 2-5, and S1) in 671 cell cultures as exemplified by the observations that Solutol<sup>®</sup> HS 15 inhibited OATP1A2, OATP2B1 672 (Engel et al., 2012), OCT1-3, PEPT2 (Otter et al., 2017), and P-gp (Akhtar et al., 2017; Buckingham et 673 al., 1995; Coon et al., 1991; Cornaire et al., 2004; Gurjar et al., 2018; Lamprecht and Benoit, 2006); 674 polysorbate 80 inhibited OCT1-3, PEPT1-2 (Otter et al., 2017; Rege et al., 2002; Soodvilai et al., 675 2017), P-gp (Al-Ali et al., 2018b; Al-Saraf et al., 2016; Cornaire et al., 2004; Hanke et al., 2010; Kiss 676 et al., 2014; Lo, 2003; Nerurkar et al., 1996; Nielsen et al., 2016; Shono et al., 2004; Woodcock et al., 677 1992; Yu et al., 2011), and MRP2 (Hanke et al., 2010); and cremophor® EL inhibited OATP1A2, 678 OATP2B1 (Engel et al., 2012), OCT1-3, PEPT2 (Otter et al., 2017), MCT (Rege et al., 2002), P-gp 679 (Al-Ali et al., 2018a; Al-Saraf et al., 2016; Buckingham et al., 1995; Chiu et al., 2003; Nerurkar et al., 680 1996; Rege et al., 2002; Shono et al., 2004; Woodcock et al., 1990; Woodcock et al., 1992), BCRP 681 682 (Sawangrat et al., 2018a; Xiao et al., 2016; Yamagata et al., 2007a), and MRP2 (Hanke et al., 2010; Li et al., 2013a; Xiao et al., 2016). Cremophor<sup>®</sup> EL seems to be the surfactant with the widest range of 683 inhibition of different carriers and transporters. Importantly, impact of surfactant on transporters and 684 685 carriers simultaneously may lead to unpredictable drug-transporter interactions. Therefore, further knowledge about the ability of nonionic surfactants to inhibit carriers under relevant in vivo conditions 686

is needed for drug formulators to make enlightened choices on nonionic surfactants as pharmaceutical 687 688 excipients.

As generally presented in this review, a broader class of surfactants that are often used as 689 pharmaceutical excipients, may have effects on drug absorption through interactions with either 690 transporters, or carriers, or both. While a lot of insights have been generated in vitro, less is available in 691 *vivo* from non-clinical trials, and no information is publicly available from human trials systematically 692 investigating the influence of pharmaceutical excipients on transporters or carriers. Drug prescribers 693 and pharmacists should therefore be aware that in treatment of patients with polypharmacy 694 prescriptions of drug compounds that are known substrates to transporters or carriers should be 695 administered separately from drug products containing nonionic surfactants and co-surfactant polymers 696 in order to avoid unexpected interactions of drug-excipient at transporters and/or carriers, as this might 697 lead to unpredicted side effects. 698 

699

#### 6. Conclusion 700

From the present review, it is quite evident that pharmaceutical excipients are not just compounds 701 702 required for processing drug formulations, but they also possess the ability to alter drug transport across biological barriers by interacting with transporters and carriers. Pharmaceutical excipients frequently 703 used in enabling formulations, notably nonionic surfactants, alter the function of carriers and/or 704 705 transporters, thereby affecting drug transport. The main body of evidence for this is based on *in vitro* experiments using cell culture models or excised tissue, whereas pre-clinical studies available in the 706 literature are limited. Few studies have investigated if surfactants reduce transporter-mediated transport 707

and thereby increase the oral bioavailability; while to the best of our knowledge no *in vivo* study has 708 709 investigated if excipients inhibit carriers in vivo, and hence could decrease oral bioavailability. Therefore, more pre-clinical studies are needed to investigate if surfactants at concentration likely to be 710 reached in the intestinal lumen may alter the exposure of substrates of transporters and carriers. It 711 seems likely that inhibition of transporters by surfactants could be incorporated into a formulation 712 approach, while a potential inhibition of solute carriers should be avoided as this would decrease oral 713 absorption. The key points missing are what the scaling between in vitro and in vivo effects is and if 714 715 enabling formulations containing surfactants are safe i.e. without toxic effects. Such biopharmaceutical 716 insight may assist in the active development of formulations where excipients are bioactive components included for inhibition of intestinal efflux transport. Interestingly, some surfactants, e.g. 717 cremophor<sup>®</sup> EL, Solutol<sup>®</sup> HS 15 and polysorbate 20, have been shown to share inhibiting effects on 718 several transporters and carriers in vitro. In addition, the concentration of surfactants that inhibit the 719 efflux transporters P-gp, BCRP, and MRP2 were comparable in cell cultures. Hence, when drug 720 substances such as doxorubicin and etoposide are substrates for multiple efflux transporters, co-721 administration of these with surfactants can generate a complex absorption mechanism. 722

As more and more discovered compounds have limited aqueous solubility, the need for enabling formulations, that may include surfactants, are increasing. Given that surfactants can have multiple physico-chemical as well as biopharmaceutical properties, drug formulators may need to bring this perspective into consideration when defining the formulations of the future.

727

### 728 **Declaration of interest**

729 The authors do not have any conflict of interest to report.

730

#### 731 Author contribution

732 Writing - original draft: AAAA, CUN, and RBN. Writing - review & Editing: AAAA, RBN, BS, RH

and CUN. Final approval of the version submitted: AAAA, RBN, BS, RH and CUN.

734

#### 735 **References:**

Abulrob, A.-n.G., Gumbleton, M., 1999. Transport of Phosphatidylcholine in MDR3-Negative

Fighthenial Cell Lines via Drug-Induced MDR1 P-Glycoprotein. Biochem. Biophys. Res. Commun. 262,
121-126.

739 Akazawa, T., Uchida, Y., Miyauchi, E., Tachikawa, M., Ohtsuki, S., Terasaki, T., 2018. High

740 Expression of UGT1A1/1A6 in Monkey Small Intestine: Comparison of Protein Expression Levels of

- 741 Cytochromes P450, UDP-Glucuronosyltransferases, and Transporters in Small Intestine of
- 742 Cynomolgus Monkey and Human. Mol. Pharm. 15, 127-140.
- 743 Akhtar, N., Ahad, A., Khan, M.F., Allaham, A., Talegaonkar, S., 2017. The Ameliorated
- Pharmacokinetics of VP-16 in Wistar Rats: A Possible Role of P-Glycoprotein Inhibition by
- 745 Pharmaceutical Excipients. Eur. J. Drug Metab. Pharmacokinet. 42, 191-199.

- Akhtar, N., Talegaonkar, S., Ahad, A., Khar, R.K., Jaggi, M., 2015. Potential of a novel self
- nanoemulsifying carrier system to overcome P-glycoprotein mediated efflux of etoposide: In vitro and
- ex vivo investigations. J Drug Deliv Sci Technol 28, 18-27.
- Al-Ali, A.A.A., Quach, J.R.C., Bundgaard, C., Steffansen, B., Holm, R., Nielsen, C.U., 2018a.
- Polysorbate 20 alters the oral bioavailability of etoposide in wild type and mdr1a deficient Sprague-
- 751 Dawley rats. Int. J. Pharm. 543, 352-360.
- 752 Al-Ali, A.A.A., Steffansen, B., Holm, R., Nielsen, C.U., 2018b. Nonionic surfactants increase digoxin
- absorption in Caco-2 and MDCKII MDR1 cells: Impact on P-glycoprotein inhibition, barrier function,
- and repeated cellular exposure. Int. J. Pharm. 551, 270-280.
- Al-Saraf, A., Holm, R., Nielsen, C.U., 2016. Tween 20 increases intestinal transport of doxorubicin in
  vitro but not in vivo. Int. J. Pharm. 498, 66-69.
- Allen, J.D., Brinkhuis, R.F., Wijnholds, J., Schinkel, A.H., 1999. The mouse Bcrp1/Mxr/Abcp gene:
  amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or
  doxorubicin. Cancer Res. 59, 4237.
- Allen, J.D., Van Dort, S.C., Buitelaar, M., van Tellingen, O., Schinkel, A.H., 2003. Mouse breast
  cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral
  availability is limited primarily by P-glycoprotein. Cancer Res. 63, 1339-1344.

- Aller, S.G., Yu, J., Ward, A., Weng, Y., Chittaboina, S., Zhuo, R., Harrell, P.M., Trinh, Y.T., Zhang,
- Q., Urbatsch, I.L., Chang, G., 2009. Structure of P-glycoprotein reveals a molecular basis for poly-
- specific drug binding. Science 323, 1718-1722.
- Ambudkar, S.V., Cardarelli, C.O., Pashinsky, I., Stein, W.D., 1997. Relation Between the Turnover
- 767 Number for Vinblastine Transport and for Vinblastine-stimulated ATP Hydrolysis by Human P-
- 768 glycoprotein. J. Biol. Chem. 272, 21160-21166.
- Appendino, G., Della Porta, C., Conseil, G., Sterner, O., Mercalli, E., Dumontet, C., Di Pietro, A.,
- Lund, U., Centre for, A., Synthesis, Lunds, u., Centrum för analys och, s., 2003. A new P-glycoprotein
- inhibitor from the caper spurge (Euphorbia lathyris). J. Nat. Prod. 66, 140-142.
- Ashiru-Oredope, D.A.I., Patel, N., Patel, R., Forbes, B., Basit, A.W., 2011. The effect of
- polyoxyethylene polymers on the transport of ranitidine in Caco-2 cell monolayers. Int. J. Pharm. 409,
  164-168.
- Augustijns, P.F., Bradshaw, T.P., Gan, L.S.L., Hendren, R.W., Thakker, D.R., 1993. Evidence for a

Polarized Efflux System in Caco-2 Cells Capable of Modulating Cyclosporine A Transport. Biochem.
Biophys. Res. Commun. 197, 360-365.

Batrakova, E., Lee, S., Li, S., Venne, A., Alakhov, V., Kabanov, A., 1999. Fundamental Relationships
Between the Composition of Pluronic Block Copolymers and Their Hypersensitization Effect in MDR
Cancer Cells. Pharm. Res. 16, 1373-1379.

- 781 Batrakova, E.V., Li, S., Alakhov, V.Y., Elmquist, W.F., Miller, D.W., Kabanov, A.V., 2003a.
- Sensitization of Cells Overexpressing Multidrug-Resistant Proteins by Pluronic P85. Pharm. Res. 20,
  1581-1590.
- 784 Batrakova, E.V., Li, S., Alakhov, V.Y., Miller, D.W., Kabanov, A.V., 2003b. Optimal structure
- requirements for pluronic block copolymers in modifying P-glycoprotein drug efflux transporter
- activity in bovine brain microvessel endothelial cells. J. Pharmacol. Exp. Ther. 304, 845-854.
- 787 Batrakova, E.V., Li, S., Li, Y., Alakhov, V.Y., Kabanov, A.V., 2004. Effect of Pluronic P85 on
- 788 ATPase Activity of Drug Efflux Transporters. Pharm. Res. 21, 2226-2233.
- Batrakova, E.V., Miller, D.W., Li, S., Alakhov, V.Y., Kabanov, A.V., Elmquist, W.F., 2001. Pluronic
  P85 Enhances the Delivery of Digoxin to the Brain: In Vitro and in Vivo Studies. J. Pharmacol. Exp.
  Ther. 296, 551.
- Beig, A., Fine-Shamir, N., Porat, D., Lindley, D., Miller, J.M., Dahan, A., 2017. Concomitant
- solubility-permeability increase: Vitamin E TPGS vs. amorphous solid dispersion as oral delivery
  systems for etoposide. Eur. J. Pharm. Biopharm. 121, 97-103.
- Beig, A., Miller, J.M., Lindley, D., Carr, R.A., Zocharski, P., Agbaria, R., Dahan, A., 2015. Head-ToHead Comparison of Different Solubility-Enabling Formulations of Etoposide and Their Consequent
  Solubility–Permeability Interplay. J. Pharm. Sci. 104, 2941-2947.

- Bekerman, T., Golenser, J., Domb, A., 2004. Cyclosporin Nanoparticulate Lipospheres for Oral
  Administration. J. Pharm. Sci. 93, 1264-1270.
- Bittner, B., Guenzi, A., Fullhardt, P., Zuercher, G., González, R.C.B., Mountfield, R.J., 2002.
- 801 Improvement of the bioavailability of colchicine in rats by co-administration of D-α-tocopherol
- polyethylene glycol 1000 succinate and a polyethoxylated derivative of 12-hydroxy-stearic acid.
- Arzneimittelforschung 52, 684-688.
- Bogman, K., Erne-Brand, F., Alsenz, J., Drewe, J., 2003. The role of surfactants in the reversal of
  active transport mediated by multidrug resistance proteins. J. Pharm. Sci. 92, 1250-1261.
- Bogman, K., Zysset, Y., Degen, L., Hopfgartner, G., Gutmann, H., Alsenz, J., Drewe, J., 2005. PGlycoprotein and Surfactants: Effect on Intestinal Talinolol Absorption. Clin. Pharmacol. Ther. 77, 2432.
- Broberg, M.L., Holm, R., Tønsberg, H., Frølund, S., Ewon, K.B., Nielsen, A.L., Brodin, B., Jensen, A.,
- Kall, M.A., Christensen, K.V., Nielsen, C.U., 2012. Function and expression of the proton-coupled
  amino acid transporter PAT1 along the rat gastrointestinal tract: implications for intestinal absorption
  of gaboxadol. Br. J. Pharmacol. 167, 654-665.
- 813 Brück, S., Strohmeier, J., Busch, D., Drozdzik, M., Oswald, S., 2017. Caco-2 cells expression,
- regulation and function of drug transporters compared with human jejunal tissue: Transporter
- Expression, Regulation and Function in Caco-2 Cells. Biopharm. Drug Disposition 38, 115-126.

- 816 Buckingham, L.E., Buckingham, L.E., Balasubramanian, M., Emanuele, R.M., Emanuele, R.M.,
- 817 Clodfelter, K.E., Clodfelter, K.E., Coon, J.S., Coon, J.S., 1995. Comparison of Solutol HS 15,
- 818 Cremophor EL and novel ethoxylated fatty acid sulfactants as multidrug resistance modification agents.
- 819 Int. J. Cancer 62, 436-442.
- 820 Chan, L.M.S., Lowes, S., Hirst, B.H., 2004. The ABCs of drug transport in intestine and liver: efflux
- proteins limiting drug absorption and bioavailability. Elsevier B.V, Netherlands, pp. 25-51.
- 822 Chen, C.-j., Chin, J.E., Ueda, K., Clark, D.P., Pastan, I., Gottesman, M.M., Roninson, I.B., 1986.
- 823 Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene
- from multidrug-resistant human cells. Cell 47, 381-389.
- 825 Chen, T.K., Li, Y., Li, C.W., Yi, X., Wang, R.B., Lee, S.M.Y., Zheng, Y., 2017. Pluronic P85/F68
- 826 Micelles of Baicalein Could Interfere with Mitochondria to Overcome MRP2-Mediated Efflux and
- 827 Offer Improved Anti-Parkinsonian Activity. Mol. Pharm. 14, 3331-3342.
- Chen, Y., Sha, X., Zhang, W., Zhong, W., Fan, Z., Ren, Q., Chen, L., Fang, X., 2013. Pluronic mixed
  micelles overcoming methotrexate multidrug resistance: in vitro and in vivo evaluation. Int J
  Nanomedicine 8, 1463-1476.
- Chen, Z., Shi, T., Zhang, L., Zhu, P., Deng, M., Huang, C., Hu, T., Jiang, L., Li, J., 2015. Mammalian
  drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of
  the past decade. Cancer Lett. 370, 153-164.

- Chiu, Y.-Y., Higaki, K., Neudeck, B.L., Barnett, J.L., Welage, L.S., Amidon, G.L., 2003. Human
- Jejunal Permeability of Cyclosporin A: Influence of Surfactants on P-Glycoprotein Efflux in Caco-2
  Cells. Pharm. Res. 20, 749-756.
- 837 Choi, Y.A., Yoon, Y.H., Choi, K., Kwon, M., Goo, S.H., Cha, J.-S., Choi, M.-K., Lee, H.S., Song, I.-
- 838 S., 2015. Enhanced Oral Bioavailability of Morin Administered in Mixed Micelle Formulation with
- PluronicF127 and Tween80 in Rats. Biol. Pharm. Bull. 38, 208-217.
- Christiansen, A., Backensfeld, T., Weitschies, W., 2010. Effects of non-ionic surfactants on in vitro
  triglyceride digestion and their susceptibility to digestion by pancreatic enzymes. Eur. J. Pharm. Sci.
  41, 376-382.
- Colas, C., Ung, P.M.-U., Schlessinger, A., 2016. SLC Transporters: Structure, Function, and Drug
  Discovery. MedChemComm 7, 1069-1081.
- Collnot, E.-M., Baldes, C., Schaefer, U.F., Edgar, K.J., Wempe, M.F., Lehr, C.-M., 2010. Vitamin E
  TPGS P-glycoprotein inhibition mechanism: influence on conformational flexibility, intracellular ATP
  levels, and role of time and site of access. Mol. Pharm. 7, 642-651.
- 848 Collnot, E.-M., Baldes, C., Wempe, M.F., Kappl, R., Hüttermann, J., Hyatt, J.A., Edgar, K.J., Schaefer,
- 849 U.F., Lehr, C.-M., 2007. Mechanism of inhibition of P-glycoprotein mediated efflux by vitamin E
- TPGS: influence on ATPase activity and membrane fluidity. Mol. Pharm. 4, 465-474.

Coon, J.S., Knudson, W., Clodfelter, K., Lu, B., Weinstein, R.S., 1991. Solutol HS 15, nontoxic

polyoxyethylene esters of 12-hydroxystearic acid, reverses multidrug resistance. Cancer Res. 51, 897902.

- Cornaire, G., Woodley, J., Hermann, P., Cloarec, A., Arellano, C., Houin, G., 2004. Impact of
  excipients on the absorption of P-glycoprotein substrates in vitro and in vivo. Int. J. Pharm. 278, 119131.
- 857 Cuiné, J.F., McEvoy, C.L., Charman, W.N., Pouton, C.W., Edwards, G.A., Benameur, H., Porter,

858 C.J.H., 2008. Evaluation of the Impact of Surfactant Digestion on the Bioavailability of Danazol after

Oral Administration of Lipidic Self-Emulsifying Formulations to Dogs. J. Pharm. Sci. 97, 995-1012.

- Czogalla, A., 2009. Oral cyclosporine A the current picture of its liposomal and other delivery
  systems. Cell. Mol. Biol. Lett. 14, 139-152.
- B62 D'Souza, A.A., Shegokar, R., 2016. Polyethylene glycol (PEG): a versatile polymer for pharmaceutical
  applications, England, pp. 1257-1275.
- Dahan, A., Miller, J.M., Hoffman, A., Amidon, G.L., Amidon, G.E., 2010. The Solubility–Permeability
- 865 Interplay in Using Cyclodextrins as Pharmaceutical Solubilizers: Mechanistic Modeling and
- Application to Progesterone. J. Pharm. Sci. 99, 2739-2749.

- Ballas, S., Miller, D.S., Bendayan, R., 2006. Multidrug Resistance-Associated Proteins: Expression
  and Function in the Central Nervous System. Pharmacol. Rev. 58, 140-161.
- B69 Dalton, W.S., Dalton, W.S., Crowley, J.J., Crowley, J.J., Salmon, S.S., Salmon, S.S., Grogan, T.M.,
- 870 Grogan, T.M., Laufman, L.R., Laufman, L.R., Weiss, G.R., Weiss, G.R., Bonnet, J.D., Bonnet, J.D.,
- 871 1995. A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in
- patients with refractory myeloma. A southwest oncology group study. Cancer 75, 815-820.
- Devraj, R., Williams, H.D., Warren, D.B., Mohsin, K., Porter, C.J.H., Pouton, C.W., 2013. In vitro
  assessment of drug-free and fenofibrate-containing lipid formulations using dispersion and digestion
  testing gives detailed insights into the likely fate of formulations in the intestine. Eur. J. Pharm. Sci. 49,
  748-760.
- B77 Dietrich, C.G., Geier, A., Oude Elferink, R.P.J., 2003. ABC of oral bioavailability: transporters as
  B78 gatekeepers in the gut. Gut 52, 1788-1795.
- 879 Dong, X., Mattingly, C.A., Tseng, M.T., Cho, M.J., Liu, Y., Adams, V.R., Mumper, R.J., 2009.
- 880 Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by
- inhibiting P-glycoprotein and depleting ATP. Cancer Res. 69, 3918-3926.
- Boyle, L.A., Ross, D.D., 2003. Multidrug resistance mediated by the breast cancer resistance protein
  BCRP (ABCG2). Oncogene 22, 7340-7358.

- Drewe, J., Meier, R., Vonderscher, J., Kiss, D., Posanski, U., Kissel, T., Gyr, K., 1992. Enhancement of
- the oral absorption of cyclosporin in man. Br. J. Clin. Pharmacol. 34, 60-64.
- 886 Drozdzik, M., Busch, D., Lapczuk, J., Müller, J., Ostrowski, M., Kurzawski, M., Oswald, S., 2019.
- 887 Protein Abundance of Clinically Relevant Drug Transporters in the Human Liver and Intestine: A
- 888 Comparative Analysis in Paired Tissue Specimens. Clin. Pharmacol. Ther.
- 889 Drozdzik, M., Groer, C., Penski, J., Lapczuk, J., Ostrowski, M., Lai, Y., Prasad, B., Unadkat, J.D.,
- 890 Siegmund, W., Oswald, S., 2014. Protein abundance of clinically relevant multidrug transporters along
- the entire length of the human intestine. Mol. Pharm. 11, 3547-3555.
- 892 Drugbank, 2019. P-glycoprotein substrates.
- 893 <u>https://www.drugbank.ca/unearth/q?utf8=%E2%9C%93&searcher=drugs&query=P-</u>
- 894 <u>glycoprotein+substrate</u>. (accessed 01.003.2019).
- 895 Eckford, P.D.W., Sharom, F.J., 2005. The reconstituted P-glycoprotein multidrug transporter is a
- 896 flippase for glucosylceramide and other simple glycosphingolipids. Biochem. J. 389, 517-526.
- Eley, J.G., Triumalashetty, P., 2001. In vitro assessment of alkylglycosides as permeability enhancers.
  AAPS PharmSciTech 2, 81-87.
- 899 Engel, A., Oswald, S., Siegmund, W., Keiser, M., 2012. Pharmaceutical excipients influence the
- function of human uptake transporting proteins. Mol. Pharm. 9, 2577-2581.

- 901 Englund, G., Jacobson, A., Rorsman, F., Artursson, P., Kindmark, A., Rönnblom, A., Medicinska, f.,
- 902 Medicinska och farmaceutiska, v., Uppsala, u., Institutionen för medicinska, v., Institutionen för, f.,
- 903 Farmaceutiska, f., 2007. Efflux transporters in ulcerative colitis: decreased expression of BCRP
- 904 (ABCG2) and Pgp (ABCB1). Inflamm. Bowel Dis. 13, 291-297.
- 905 Erickson, R.H., Gum, J.R., Lindstrom, M.M., McKean, D., Kim, Y.S., 1995. Regional Expression and
- 906 Dietary Regulation of Rat Small Intestinal Peptide and Amino Acid Transporter mRNAs. Biochem.
- 907 Biophys. Res. Commun. 216, 249-257.
- 908 Evers, R., Kool, M., Smith, A.J., van Deemter, L., de Haas, M., Borst, P., 2000. Inhibitory effect of the
- reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated
- 910 transport. Br. J. Cancer 83, 366-374.
- 911 Fricker, G., Drewe, J., Huwyler, J., Gutmann, H., Beglinger, C., 1996. Relevance of p-glycoprotein for
- the enteral absorption of cyclosporin A: in vitro-in vivo correlation. Br. J. Pharmacol. 118, 1841-1847.
- 913 Fromm, M.F., 2004. Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol. Sci. 25,
  914 423-429.
- Föger, F., Hoyer, H., Kafedjiiski, K., Thaurer, M., Bernkop-Schnürch, A., 2006. In vivo comparison of
  various polymeric and low molecular mass inhibitors of intestinal P-glycoprotein. Biomaterials 27,
  5855-5860.

- 918 Giacomini, K.M., Huang, S.-M., Tweedie, D.J., Benet, L.Z., Brouwer, K.L.R., Chu, X., Dahlin, A.,
- 919 Evers, R., Fischer, V., Hillgren, K.M., Hoffmaster, K.A., Ishikawa, T., Keppler, D., Kim, R.B., Lee,
- 920 C.A., Niemi, M., Polli, J.W., Sugiyama, Y., Swaan, P.W., Ware, J.A., Wright, S.H., Yee, S.W., Zamek-
- 921 Gliszczynski, M.J., Zhang, L., International Transporter, C., 2010. Membrane transporters in drug
- 922 development. Nat. Rev. Drug Discov. 9, 215-236.
- 923 Gramatté, T., Oertel, R., 1999. Intestinal secretion of intravenous talinolol is inhibited by luminal
- 924 R-verapamil. Clin. Pharmacol. Ther. 66, 239-245.
- 925 Greenberg, P.L., Lee, S.J., Advani, R., Tallman, M.S., Sikic, B.I., Letendre, L., Dugan, K., Lum, B.,
- 926 Chin, D.L., Dewald, G., Paietta, E., Bennett, J.M., Rowe, J.M., 2004. Mitoxantrone, Etoposide, and
- 927 Cytarabine With or Without Valspodar in Patients With Relapsed or Refractory Acute Myeloid
- Leukemia and High-Risk Myelodysplastic Syndrome: A Phase III Trial (E2995). J. Clin. Oncol. 22,
  1078-1086.
- Gröer, C., Brück, S., Lai, Y., Paulick, A., Busemann, A., Heidecke, C.D., Siegmund, W., Oswald, S.,
  2013. LC–MS/MS-based quantification of clinically relevant intestinal uptake and efflux transporter
  proteins. J. Pharm. Biomed. Anal. 85, 253-261.
- Guan, Y., Huang, J., Zuo, L., Xu, J., Si, L., Qiu, J., Li, G., 2011. Effect of pluronic P123 and F127
  block copolymer on P-glycoprotein transport and CYP3A metabolism. Arch. Pharm. Res. 34, 17191728.

- Gupta, A., Dai, Y., Vethanayagam, R.R., Hebert, M.F., Thummel, K.E., Unadkat, J.D., Ross, D.D.,
- 937 Mao, Q., 2006. Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast
- 938 cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. Cancer
- 939 Chemother. Pharmacol. 58, 374-383.
- Gupta, A., Zhang, Y., Unadkat, J.D., Mao, Q., 2004. HIV Protease Inhibitors Are Inhibitors but Not
  Substrates of the Human Breast Cancer Resistance Protein (BCRP/ABCG2). J. Pharmacol. Exp. Ther.
  310, 334-341.
- Gupta, E., Safa, A.R., Wang, X., Ratain, M.J., 1996. Pharmacokinetic modulation of irinotecan and
  metabolites by cyclosporin A. Cancer Res. 56, 1309-1314.
- Gurjar, R., Chan, C., Curley, P., Sharp, J., Chiong, J., Rannard, S., Siccardi, M., Owen, A., 2018.
- 946 Inhibitory effects of commonly used excipients on P-glycoprotein in vitro. Mol. Pharm. 15, 4835-4842.
- Hanke, U., May, K., Rozehnal, V., Nagel, S., Siegmund, W., Weitschies, W., 2010. Commonly used
  nonionic surfactants interact differently with the human efflux transporters ABCB1 (p-glycoprotein)
  and ABCC2 (MRP2). Eur. J. Pharm. Biopharm. 76, 260-268.
- Harwood, M.D., Achour, B., Russell, M.R., Carlson, G.L., Warhurst, G., Rostami-Hodjegan, A., 2015.
  Application of an LC–MS/MS method for the simultaneous quantification of human intestinal
  transporter proteins absolute abundance using a QconCAT technique. J. Pharm. Biomed. Anal. 110, 2733.

- Harwood, M.D., Neuhoff, S., Carlson, G.L., Warhurst, G., Rostami-Hodjegan, A., 2013. Absolute
  abundance and function of intestinal drug transporters: a prerequisite for fully mechanistic in vitro–in
  vivo extrapolation of oral drug absorption. Biopharm. Drug Disposition 34, 2-28.
- 957 Hediger, M.A., 2004. The ABCs of solute carriers: physiological, pathological and therapeutic
- 958 implications of human membrane transport proteins. Pflugers Arch. 447, 465-468.
- 959 Hediger, M.A., Clémençon, B., Burrier, R.E., Bruford, E.A., 2013. The ABCs of membrane
- transporters in health and disease (SLC series): Introduction. Mol. Aspects Med. 34, 95-107.
- Higgins, C.F., Gottesman, M.M., 1992. Is the multidrug transporter a flippase? Trends Biochem. Sci.
  17, 18-21.
- Hodaei, D., Baradaran, B., Valizadeh, H., Zakeri-Milani, P., 2015. Effects of polyethylene glycols on
  intestinal efflux pump expression and activity in Caco-2 cells. BJPS 51, 745-753.
- Houghton, P.J., Germain, G.S., Harwood, F.C., Schuetz, J.D., Stewart, C.F., Buchdunger, E., Traxler,
  P., 2004. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses
  resistance to topotecan and SN-38 in vitro. Cancer Res. 64, 2333-2337.
- Hugger, E.D., Novak, B.L., Burton, P.S., Audus, K.L., Borchardt, R.T., 2002. A comparison of
  commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-glycoprotein
- 970 activity in vitro. J. Pharm. Sci. 91, 1991-2002.

- 971 HUGO Gene Nomenclature Committee, 2019. ATP binding cassette transporters (ABC).
- 972 <u>https://www.genenames.org/cgi-bin/genefamilies/set/417</u>. Solute carriers (SLC).
- 973 <u>https://www.genenames.org/cgi-bin/genefamilies/set/752</u>., (accessed 12.01.2019).
- 974 Hyafil, F., Vergely, C., Vignaud, P.D., Grand-Perret, T., 1993. In vitro and in vivo reversal of
- multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res. 53, 4595-4602.
- 976 Italia, J.L., Bhardwaj, V., Ravi Kumar, M.N.V., 2006. Disease, destination, dose and delivery aspects
- 977 of ciclosporin: the state of the art. Drug Discov Today 11, 846-854.
- Jedlitschky, G., Hoffmann, U., Kroemer, H.K., 2006. Structure and function of the MRP2 (ABCC2)
- protein and its role in drug disposition. Expert Opin. Drug Metab. Toxicol. 2, 351-366.
- Johnson, B.M., Charman, W.N., Porter, C.J.H., 2002. An in vitro examination of the impact of
- polyethylene glycol 400, pluronic P85, and vitamin E d-a-tocopheryl polyethylene glycol 1000
  succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine. AAPS
  PharmSci 4, 193-205.
- Johnson, Z.L., Chen, J., 2017. Structural Basis of Substrate Recognition by the Multidrug Resistance
  Protein MRP1. Cell 168, 1075-1085.e1079.
- Jonker, J.W., Smit, J.W., Brinkhuis, R.F., Maliepaard, M., 2000. Role of breast cancer resistance
  protein in the bioavailability and fetal penetration of topotecan. J. Natl. Cancer Inst. 92, 1651.

- Juliano, R.L., Ling, V., 1976. A surface glycoprotein modulating drug permeability in Chinese hamster
  ovary cell mutants. Biochim. Biophys. Acta 455, 152-162.
- 990 Keller, R.P., Altermatt, H.J., Nooter, K., Poschmann, G., Laissue, J.A., Bollinger, P., Hiestand, P.C.,
- 991 1992. SDZ PSC 833, a non-immunosuppressive cyclosporine: its potency in overcoming P-
- glycoprotein-mediated multidrug resistance of murine leukemia. Int. J. Cancer 50, 593-597.
- 893 Kim, Y., Chen, J., 2018. Molecular structure of human P-glycoprotein in the ATP-bound, outward-
- facing conformation. Science 359, 915-919.
- 995 Kiss, L., Hellinger, É., Pilbat, A.M., Kittel, Á., Török, Z., Füredi, A., Szakács, G., Veszelka, S., Sipos,
- 996 P., Ózsvári, B., Puskás, L.G., Vastag, M., Szabó-Révész, P., Deli, M.A., 2014. Sucrose Esters Increase
- Drug Penetration, But Do Not Inhibit P-Glycoprotein in Caco-2 Intestinal Epithelial Cells. J. Pharm.
  Sci. 103, 3107-3119.
- Koepsell, H., Lips, K., Volk, C., 2007. Polyspecific organic cation transporters: structure, function,
  physiological roles, and biopharmaceutical implications. Pharm. Res. 24, 1227-1251.
- Kool, M., de Haas, M., Scheffer, G.L., Scheper, R.J., van Eijk, M.J., Juijn, J.A., Baas, F., Borst, P.,
  1997. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the
  multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res. 57,
  3537-3547.

- 1005 Kool, M., Marcel van der, L., Haas, M.d., Scheffer, G.L., Vree, J.M.L.D., Smith, A.J., Jansen, G.,
- 1006 Peters, G.J., Ponne, N., Scheper, R.J., Ronald, P.J.O.E., Baas, F., Borst, P., 1999. MRP3, an Organic
- Anion Transporter Able to Transport Anti-Cancer Drugs. Proc. Natl. Acad. Sci. U. S. A. 96, 6914-6919.
- 1009 Kumar, H., Finer-Moore, J.S., Jiang, X., Smirnova, I., Kasho, V., Pardon, E., Steyaert, J., Kaback,
- H.R., Stroud, R.M., 2018. Crystal Structure of a ligand-bound LacY–Nanobody Complex. Proc. Natl.
  Acad. Sci. U. S. A. 115, 8769.
- Kumar, H., Kasho, V., Smirnova, I., Finer-Moore, J.S., Kaback, H.R., Stroud, R.M., 2014. Structure of
  sugar-bound LacY. Proc. Natl. Acad. Sci. 111, 1784.
- 1014 Lamprecht, A., Benoit, J.-P., 2006. Etoposide nanocarriers suppress glioma cell growth by intracellular
- 1015 drug delivery and simultaneous P-glycoprotein inhibition. J. Control. Release 112, 208-213.
- Lehnert, M., Mross, K., Schueller, J., Thuerlimann, B., Kroeger, N., Kupper, H., 1998. Phase II trial of
  dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer. Br. J. Cancer 77,
  1155-1163.
- Li-Blatter, X., Beck, A., Seelig, A., 2012. P-glycoprotein-ATPase modulation: the molecular
  mechanisms. Biophys. J. 102, 1383-1393.

- 1021 Li-Blatter, X., Nervi, P., Seelig, A., 2009. Detergents as intrinsic P-glycoprotein substrates and
- 1022 inhibitors. BBA Biomembranes 1788, 2335-2344.
- Li-Blatter, X., Seelig, A., 2010. Exploring the P-glycoprotein binding cavity with polyoxyethylene
  alkyl ethers. Biophys. J. 99, 3589-3598.
- Li, L., Yi, T., Lam, C.W.-k., 2013a. Interactions between human multidrug resistance related protein
  (MRP2; ABCC2) and excipients commonly used in self-emulsifying drug delivery systems (SEDDS).
  Int. J. Pharm. 447, 192-198.
- Li, L., Yi, T., Lam, C.W.-k., 2013b. Interactions between human multidrug resistance related protein
  (MRP2; ABCC2) and excipients commonly used in self-emulsifying drug delivery systems (SEDDS).
- 1030 Int. J. Pharm. 447, 192-198.
- Li, L., Yi, T., Lam, C.W.-K., 2014. Inhibition of human efflux transporter ABCC2 (MRP2) by selfemulsifying drug delivery system: influences of concentration and combination of excipients. J. Pharm.
  Pharm. Sci. 17, 447.
- Lin, J.H., Yamazaki, M., 2003. Role of P-glycoprotein in pharmacokinetics. Clin. Pharmacokinet. 42,
  59-98.

- Lin, Y., Shen, Q., Katsumi, H., Okada, N., Fujita, T., Jiang, X., Yamamoto, A., 2007. Effects of
- 1037 Labrasol and Other Pharmaceutical Excipients on the Intestinal Transport and Absorption of
- 1038 Rhodamine123, a P-Glycoprotein Substrate, in Rats. Biol. Pharm. Bull. 30, 1301-1307.
- 1039 Lloret-Linares, C., Miyauchi, E., Luo, H., Labat, L., Bouillot, J.-L., Poitou, C., Oppert, J.-M.,
- 1040 Laplanche, J.-L., Mouly, S., Scherrmann, J.-M., Uchida, Y., Tachikawa, M., Terasaki, T., Bergmann,
- 1041 J.-F., Declèves, X., 2016. Oral Morphine Pharmacokinetic in Obesity: The Role of P-Glycoprotein,

1042 MRP2, MRP3, UGT2B7, and CYP3A4 Jejunal Contents and Obesity-Associated Biomarkers. Mol.

1043 Pharm. 13, 766-773.

- Lo, Y.-l., 2003. Relationships between the hydrophilic–lipophilic balance values of pharmaceutical
- 1045 excipients and their multidrug resistance modulating effect in Caco-2 cells and rat intestines. J.

1046 Controlled Release 90, 37-48.

- 1047 Lown, K.S., 1997. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral
- 1048 bioavailability of cyclosporine. Clin. Pharmacol. Ther. 62, 248-260.
- Ma, L., Wei, Y., Zhou, Y., Ma, X., Wu, X.a., 2011. Effects of Pluronic F68 and Labrasol on the
  intestinal absorption and pharmacokinetics of rifampicin in rats. Arch. Pharm. Res. 34, 1939-1943.
- 1051 Maliepaard, M., Margôt, A.v.G., Tohgo, A., Hausheer, F.H., Robert, C.A.M.v.W., Laurina, A.d.J.,
- 1052 Pluim, D., Beijnen, J.H., Jan, H.M.S., 2001a. Circumvention of Breast Cancer Resistance Protein

- 1053 (BCRP)-mediated Resistance to Camptothecins in Vitro Using Non-Substrate Drugs or the BCRP
  1054 Inhibitor GF120918. Clin. Cancer. Res. 7, 935-941.
- 1055 Maliepaard, M., Scheffer, G.L., Faneyte, I.F., van Gastelen, M.A., Pijnenborg, A.C., Schinkel, A.H.,
- 1056 van de Vijver, M.J., Scheper, R.J., Schellens, J.H., 2001b. Subcellular localization and distribution of
- the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 61, 3458-3464.
- 1058 Maliepaard, M., van Gastelen, M.A., de Jong, L.A., Pluim, D., van Waardenburg, R., Ruevekamp-
- 1059 Helmers, M.C., Floot, B.G.J., Schellens, J.H.M., 1999. Overexpression of the BCRP/MXR/ABCP
- 1060 Gene in a Topotecan-selected Ovarian Tumor Cell Line, Cancer Res. 59, 4559-4563.
- Mao, Q., 2005. Role of the breast cancer resistance protein (ABCG2) in drug transport. The AAPSJournal 7, E118-E133.
- 1063 Mao, Q., Unadkat, J.D., 2015. Role of the Breast Cancer Resistance Protein (BCRP/ABCG2) in Drug
- 1064 Transport—an Update. The AAPS Journal 17, 65-82.
- 1065 Matsson, P., Pedersen, J.M., Norinder, U., Bergström, C.A.S., Artursson, P., Medicinska och
- 1066 farmaceutiska, v., Uppsala, u., Institutionen för, f., Farmaceutiska, f., 2009. Identification of novel
- 1067 specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP
- and MRP2 among registered drugs. Pharm. Res. 26, 1816-1831.

- 1069 Mechetner, E., Kyshtoobayeva, A., Zonis, S., Kim, H., Stroup, R., Garcia, R., Parker, R.J., Fruehauf,
- 1070 J.P., 1998. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer
- 1071 correlate with in vitro resistance to taxol and doxorubicin. Clin. Cancer. Res. 4, 389.
- 1072 Miller, J.M., Beig, A., Krieg, B.J., Carr, R.A., Borchardt, T.B., Amidon, G.E., Amidon, G.L., Dahan,
- 1073 A., 2011. The solubility-permeability interplay: mechanistic modeling and predictive application of the
- impact of micellar solubilization on intestinal permeation. Mol. Pharm. 8, 1848-1856.
- 1075 Miyauchi, E., Tachikawa, M., Declèves, X., Uchida, Y., Bouillot, J.-L., Poitou, C., Oppert, J.-M.,
- 1076 Mouly, S., Bergmann, J.-F., Terasaki, T., Scherrmann, J.-M., Lloret-Linares, C., 2016. Quantitative
- 1077 Atlas of Cytochrome P450, UDP-Glucuronosyltransferase, and Transporter Proteins in Jejunum of
- 1078 Morbidly Obese Subjects. Mol. Pharm. 13, 2631-2640.
- 1079 Mohsin, K., 2012. Design of Lipid-Based Formulations for Oral Administration of Poorly Water-
- 1080 Soluble Drug Fenofibrate: Effects of Digestion. AAPS PharmSciTech 13, 637-646.
- 1081 Mross, K., Kröger, N., Herbst, K., Gastl, G., Hossfeld, D., 1999. Alteration in Epirubicin
- Pharmacokinetics and Metabolism by Dexverapamil: Results from a Phase II Study in Patients with
  Metastatic Breast Cancer. Oncol Res Treat 22, 35-40.
- 1084 Nerurkar, M.M., Burton, P.S., Borchardt, R.T., 1996. The use of surfactants to enhance the
- 1085 permeability of peptides through Caco-2 cells by inhibition of an apically polarized efflux system.
- 1086 Pharm. Res. 13, 528-534.

- 1087 Nielsen, C.U., Abdulhussein, A.A., Colak, D., Holm, R., 2016. Polysorbate 20 increases oral
- absorption of digoxin in wild-type Sprague Dawley rats, but not in mdr1a(-/-) Sprague Dawley rats. Int.
  J. Pharm. 513, 78-87.
- Nies, A.T., Keppler, D., 2007. The apical conjugate efflux pump ABCC2 (MRP2). Pflugers Arch. 453,643-659.
- 1092 O'Leary, T.J., Ross, P.D., Lieber, M.R., Levin, I.W., 1986. Effects of cyclosporine A on
- 1093 biomembranes. Vibrational spectroscopic, calorimetric and hemolysis studies. Biophys. J. 49, 795-801.
- 1094 Oswald, S., Haenisch, S., Fricke, C., Sudhop, T., Remmler, C., Giessmann, T., Jedlitschky, G., Adam,
- 1095 U., Dazert, E., Warzok, R., Wacke, W., Cascorbi, I., Kroemer, H.K., Weitschies, W., Bergmann, K.,
- 1096 Siegmund, W., 2006. Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated
- 1097 protein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase 1A1 predicts the disposition and
- 1098 modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans. Clin. Pharmacol.
- 1099 Ther. 79, 206-217.
- Otter, M., Oswald, S., Siegmund, W., Keiser, M., 2017. Effects of frequently used pharmaceutical
  excipients on the organic cation transporters 1–3 and peptide transporters 1/2 stably expressed in
  MDCKII cells. Eur. J. Pharm. Biopharm. 112, 187-195.

- 1103 Patil, S., Choudhary, B., Rathore, A., Roy, K., Mahadik, K., 2015. Enhanced oral bioavailability and
- 1104 anticancer activity of novel curcumin loaded mixed micelles in human lung cancer cells.
- 1105 Phytomedicine 22, 1103-1111.
- 1106 Petersen, S.B., Nolan, G., Maher, S., Rahbek, U.L., Guldbrandt, M., Brayden, D.J., 2012. Evaluation of
- alkylmaltosides as intestinal permeation enhancers: comparison between rat intestinal mucosal sheets
- and Caco-2 monolayers. Eur. J. Pharm. Sci. 47, 701-712.
- 1109 Planting, A.S.T., Sonneveld, P., van der Gaast, A., Sparreboom, A., van der Burg, M.E.L., Luyten,
- 1110 G.P.M., de Leeuw, K., de Boer-Dennert, M., Wissel, P.S., Jewell, R.C., Paul, E.M., Purvis Jr, N.B.,
- 1111 Verweij, J., 2005. A phase I and pharmacologic study of the MDR converter GF120918 in combination
- 1112 with doxorubicin in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 55, 91-99.
- 1113 Postolache, P., Petrescu, O., Dorneanu, V., Zanini, A., 2002. Cyclosporine bioavailability of two
- 1114 physically different oral formulations. Eur. Rev. Med. Pharmacol. Sci. 6, 127-131.
- 1115 Pouton, C.W., 2006. Formulation of poorly water-soluble drugs for oral administration:
- Physicochemical and physiological issues and the lipid formulation classification system. Eur. J.Pharm. Sci. 29, 278-287.
- 1118 Radestock, S., Forrest, L.R., 2011. The Alternating-Access Mechanism of MFS Transporters Arises
  1119 from Inverted-Topology Repeats. J. Mol. Biol. 407, 698-715.

- 1120 Rao, V.V., Dahlheimer, J.L., Bardgett, M.E., Snyder, A.Z., Finch, R.A., Sartorelli, A.C., Piwnica-
- 1121 Worms, D., 1999. Choroid Plexus Epithelial Expression of MDR1 P Glycoprotein and Multidrug
- 1122 Resistance-Associated Protein Contribute to the Blood-Cerebrospinal-Fluid Drug-Permeability Barrier.
- 1123 Proc. Natl. Acad. Sci. U. S. A. 96, 3900-3905.
- 1124 Raviv, Y., Pollard, H.B., Bruggemann, E.P., Pastan, I., Gottesman, M.M., 1990. Photosensitized
- labeling of a functional multidrug transporter in living drug-resistant tumor cells. J. Biol. Chem. 265,3975-3980.
- 1127 Rege, B.D., Kao, J.P., Polli, J.E., 2002. Effects of nonionic surfactants on membrane transporters in
- 1128 Caco-2 cell monolayers. Eur. J. Pharm. Sci. 16, 237-246.
- Regev, R., Assaraf, Y.G., Eytan, G.D., 1999. Membrane fluidization by ether, other anesthetics, and
  certain agents abolishes P-glycoprotein ATPase activity and modulates efflux from multidrug-resistant
  cells. Eur. J. Biochem. 259, 18-24.
- 1132 Ries, F., Dicato, M., 1991. Treatment of advanced and refractory breast cancer with doxorubicin,
- vincristine and continuous infusion of verapamil. a phase I-II clinical trial. Med. Oncol. TumorPharmacother. 8, 39-43.
- Romsicki, Y., Sharom, F.J., 2001. Phospholipid flippase activity of the reconstituted P-glycoprotein
  multidrug transporter. Biochemistry 40, 6937-6947.

- 1137 Rosenberg, M.F., Bikadi, Z., Chan, J., Liu, X., Ni, Z., Cai, X., Ford, R.C., Mao, Q., 2010. The Human
- Breast Cancer Resistance Protein (BCRP/ABCG2) Shows Conformational Changes with Mitoxantrone.
  Structure 18, 482-493.
- 1140 Rosenberg, M.F., Bikadi, Z., Hazai, E., Starborg, T., Kelley, L., Chayen, N.E., Ford, R.C., Mao, Q.,
- 1141 2015. Three-dimensional structure of the human breast cancer resistance protein (BCRP/ABCG2) in an
- inward-facing conformation. Acta Crystallographica Section D 71, 1725-1735
- 1143 Sachs-Barrable, K., Thamboo, A., Lee, S.D., Wasan, K.M., 2007. Lipid excipients Peceol and Gelucire
- 1144 44/14 decrease P-glycoprotein mediated efflux of rhodamine 123 partially due to modifying P-
- glycoprotein protein expression within Caco-2 cells. J. Pharm. Pharm. Sci. 10, 319-331.
- 1146 Sauna, Z.E., Ambudkar, S.V., 2001. Characterization of the catalytic cycle of ATP hydrolysis by
- 1147 human P-glycoprotein. The two ATP hydrolysis events in a single catalytic cycle are kinetically similar
- but affect different functional outcomes. J. Biol. Chem. 276, 11653-11661.
- Savla, R., Browne, J., Plassat, V., Wasan, K.M., Wasan, E.K., 2017. Review and analysis of FDA
  approved drugs using lipid-based formulations. Drug Dev. Ind. Pharm. 43, 1743-1758.
- 1151 Sawangrat, K., Morishita, M., Kusamori, K., Katsumi, H., Sakane, T., Yamamoto, A., 2018a. Effects of
- 1152 Various Pharmaceutical Excipients on the Intestinal Transport and Absorption of Sulfasalazine, a
- 1153 Typical Substrate of Breast Cancer Resistance Protein Transporter. J. Pharm. Sci. 107, 2946-2956.

1154 Sawangrat, K., Yamashita, S., Tanaka, A., Morishita, M., Kusamori, K., Katsumi, H., Sakane, T.,

- 1155 Yamamoto, A., 2018b. Modulation of intestinal transport and absorption of topotecan, a BCRP
- substrate by various pharmaceutical excipients and their inhibitory mechanisms of BCRP transporter. J.Pharm. Sci.
- Seelig, A., 1998. A general pattern for substrate recognition by P-glycoprotein. Eur. J. Biochem. 251,
  252-261.
- 1160 Seelig, A., Gerebtzoff, G., 2006. Enhancement of drug absorption by noncharged detergents through
- 1161 membrane and P-glycoprotein binding. Expert Opin. Drug Metab. Toxicol. 2, 733-752.
- Shaik, N., Pan, G., Elmquist, W.F., 2008. Interactions of pluronic block copolymers on P-gp efflux
  activity: Experience with HIV-1 protease inhibitors. J. Pharm. Sci. 97, 5421-5433.
- 1164 Shen, Q., Li, W., Lin, Y., Katsumi, H., Okada, N., Sakane, T., Fujita, T., Yamamoto, A., 2008.
- 1165 Modulating effect of polyethylene glycol on the intestinal transport and absorption of prednisolone,
- 1166 methylprednisolone and quinidine in rats by in-vitro and in-situ absorption studies. J. Pharm.
- 1167 Pharmacol. 60, 1633-1641.
- Shen, Q., Lin, Y., Handa, T., Doi, M., Sugie, M., Wakayama, K., Okada, N., Fujita, T., Yamamoto, A.,
  2006. Modulation of intestinal P-glycoprotein function by polyethylene glycols and their derivatives by
  in vitro transport and in situ absorption studies. Int. J. Pharm. 313, 49-56.

- 1171 Shimomura, H., Nogami, R., Shigeno, A., Shimada, S., Aoyama, T., 2016. Influence of Food on
- 1172 Rifampicin Pharmacokinetics in Rats. Biol. Pharm. Bull. 39, 49-53.
- 1173 Shono, Y., Nishihara, H., Matsuda, Y., Furukawa, S., Okada, N., Fujita, T., Yamamoto, A., 2004.
- 1174 Modulation of Intestinal P-Glycoprotein Function by Cremophor EL and Other Surfactants by an In
- 1175 Vitro Diffusion Chamber Method Using the Isolated Rat Intestinal Membranes. J. Pharm. Sci. 93, 877-1176 885.
- Soodvilai, S., Soodvilai, S., Chatsudthipong, V., Ngawhirunpat, T., Rojanarata, T., Opanasopit, P.,
  2017. Interaction of pharmaceutical excipients with organic cation transporters. Int. J. Pharm. 520, 1420.
- Sparreboom, A., Planting, A.S., Jewell, R.C., Loos, W., Nooter, K., Chandler, L., Paul, E., Wissel, P.,
  Verweij, J., 1999. Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent
  inhibitor of MDR1 P-glycoprotein. Anti-Cancer Drugs 10, 719-728.
- Steffansen, B., Nielsen, C.U., Brodin, B., Eriksson, A.H., Andersen, R., Frokjaer, S., 2004. Intestinal
  solute carriers: an overview of trends and strategies for improving oral drug absorption. Elsevier B.V,
  Netherlands, pp. 3-16.
- Steffansen, B., Pedersen, M.D.L., Laghmoch, A.M., Nielsen, C.U., 2017. SGLT1-Mediated Transport
  in Caco-2 Cells Is Highly Dependent on Cell Bank Origin. J. Pharm. Sci. 106, 2664-2670.

- 1188 Su, L., Cheng, C.Y., Mruk, D.D., 2009. Drug transporter, P-glycoprotein (MDR1), is an integrated
- 1189 component of the mammalian blood-testis barrier. Int. J. Biochem. Cell Biol. 41, 2578-2587.
- 1190 Tsuruo, T., Tsuruo, T., Iida, H., Lida, H., Tsukagoshi, S., Tsukagoshi, S., Sakurai, Y., Sakurai, Y.,
- 1191 1981. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced
- 1192 cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 41, 1967-1972.
- 1193 Uchida, Y., Ohtsuki, S., Kamiie, J., Ohmine, K., Iwase, R., Terasaki, T., 2015. Quantitative targeted
- absolute proteomics for 28 human transporters in plasma membrane of Caco-2 cell monolayer cultured
- for 2, 3, and 4 weeks. Drug Metab. Pharmacokinet. 30, 205-208.
- van Helvoort, A., Smith, A.J., Sprong, H., Fritzsche, I., Schinkel, A.H., Borst, P., van Meer, G., 1996.
  MDR1 P-Glycoprotein Is a Lipid Translocase of Broad Specificity, While MDR3 P-Glycoprotein
- 1198 Specifically Translocates Phosphatidylcholine. Cell 87, 507-517.
- vanAsperen, J., vanTellingen, O., Sparreboom, A., Schinkel, A.H., Borst, P., Nooijen, W.J., Beijnen,
  J.H., 1997. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker
  SDZ PSC 833. Br. J. Cancer 76, 1181-1183.
- Varma, M.V.S., Panchagnula, R., 2005. Enhanced oral paclitaxel absorption with vitamin E-TPGS:
  Effect on solubility and permeability in vitro, in situ and in vivo. Eur. J. Pharm. Sci. 25, 445-453.

- 1204 Wang, H., Lee, E.-W., Cai, X., Ni, Z., Zhou, L., Mao, Q., 2008. Membrane topology of the human
- 1205 breast cancer resistance protein (BCRP/ABCG2) determined by epitope insertion and
- immunofluorescence. Biochemistry 47, 13778-13787.
- 1207 Warner, E., Hedley, D., Andrulis, I., Myers, R., Trudeau, M., Warr, D., Pritchard, K.I., Blackstein, M.,
- 1208 Goss, P.E., Franssen, E., Roche, K., Knight, S., Webster, S., Fraser, R.A., Oldfield, S., Hill, W., Kates,
- 1209 R., 1998. Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer
- 1210 who have progressed on the same anthracycline regimen. Clin. Cancer. Res. 4, 1451-1457.
- 1211 Wegler, C., Gaugaz, F.Z., Andersson, T.B., Wiśniewski, J.R., Busch, D., Gröer, C., Oswald, S., Norén,
- 1212 A., Weiss, F., Hammer, H.S., Joos, T.O., Poetz, O., Achour, B., Rostami-Hodjegan, A., van de Steeg,
- 1213 E., Wortelboer, H.M., Artursson, P., Medicinska, f., Medicinska och farmaceutiska, v.,
- 1214 Gastrointestinalkirurgi, Farmaceutiska, f., Uppsala, u., Institutionen för kirurgiska, v., Institutionen för,
- 1215 f., 2017. Variability in Mass Spectrometry-based Quantification of Clinically Relevant Drug
- 1216 Transporters and Drug Metabolizing Enzymes. Mol. Pharm. 14, 3142-3151.
- 1217 Wei, Z., Shi, Y., Chen, Y., Yu, S., Hao, J., Luo, J., Sha, X., Fang, X., 2010. Enhanced antitumor
- 1218 efficacy by Paclitaxel-loaded Pluronic P123/F127 mixed micelles against non-small cell lung cancer
- based on passive tumor targeting and modulation of drug resistance. Eur. J. Pharm. Biopharm. 75, 341-353.

- 1221 Wei, Z., Yuan, S., Hao, J., Fang, X., 2013. Mechanism of inhibition of P-glycoprotein mediated efflux
- 1222 by Pluronic P123/F127 block copolymers: Relationship between copolymer concentration and
- inhibitory activity. Eur. J. Pharm. Biopharm. 83, 266-274.
- 1224 Wojtal, K.A., Eloranta, J.J., Hruz, P., Gutmann, H., Drewe, J.r., Staumann, A., Beglinger, C., Fried, M.,
- 1225 Kullak-Ublick, G.A., Vavricka, S.R., 2009. Changes in mRNA Expression Levels of Solute Carrier
- 1226 Transporters in Inflammatory Bowel Disease Patients. Drug Metab. Dispos. 37, 1871-1877.
- 1227 Woodcock, D.M., Jefferson, S., Linsenmeyer, M.E., Crowther, P.J., Chojnowski, G.M., Williams, B.,
- 1228 Bertoncello, I., 1990. Reversal of the multidrug resistance phenotype with cremophor EL, a common
- vehicle for water-insoluble vitamins and drugs. Cancer Res. 50, 4199.
- 1230 Woodcock, D.M., Linsenmeyer, M.E., Chojnowski, G., Kriegler, A.B., Nink, V., Webster, L.K.,
- 1231 Sawyer, W.H., 1992. Reversal of multidrug resistance by surfactants. Br. J. Cancer 66, 62-68.
- 1232 Xiao, L., Yi, T., Chen, M., Lam, C.W.K., Zhou, H., 2016. A new mechanism for increasing the oral
  1233 bioavailability of scutellarin with Cremophor EL: Activation of MRP3 with concurrent inhibition of
  1234 MRP2 and BCRP. Eur. J. Pharm. Sci. 93, 456-467.
- Xu, Y., Egido, E., Li-Blatter, X., Müller, R., Merino, G., Bernèche, S., Seelig, A., 2015. Allocrite
  Sensing and Binding by the Breast Cancer Resistance Protein (ABCG2) and P-Glycoprotein (ABCB1).
  Biochemistry 54, 6195.

- 1238 Yamagata, T., Kusuhara, H., Morishita, M., Takayama, K., Benameur, H., Sugiyama, Y., 2007a. Effect
- 1239 of excipients on breast cancer resistance protein substrate uptake activity. J. Control. Release 124, 1-5.
- 1240 Yamagata, T., Kusuhara, H., Morishita, M., Takayama, K., Benameur, H., Sugiyama, Y., 2007b.
- 1241 Improvement of the oral drug absorption of topotecan through the inhibition of intestinal xenobiotic
- 1242 efflux transporter, breast cancer resistance protein, by excipients. Drug Metab. Dispos. 35, 1142-1148.
- 1243 Yamagata, T., Morishita, M., Kusuhara, H., Takayama, K., Benameur, H., Sugiyama, Y., 2009.
- 1244 Characterization of the inhibition of breast cancer resistance protein-mediated efflux of mitoxantrone
- by pharmaceutical excipients. Int. J. Pharm. 370, 216-219.
- Yoshida, N., Takagi, A., Kitazawa, H., Kawakami, J., Adachi, I., 2005. Inhibition of P-glycoproteinmediated transport by extracts of and monoterpenoids contained in Zanthoxyli Fructus. Toxicol. Appl.
  Pharmacol. 209, 167-173.
- 1249 Yu, H., Hu, Y.Q., Ip, F.C.F., Zuo, Z., Han, Y.F., Ip, N.Y., 2011. Intestinal transport of
- bis(12)-hupyridone in Caco-2 cells and its improved permeability by the surfactant Brij-35. Biopharm.
  Drug Disposition 32, 140-150.
- Yu Liang Siqi Li Ligong, C., 2015. The physiological role of drug transporters. Protein Cell 6, 334-350.

- 1254 Zhang, H., Yao, M., Morrison, R.A., Chong, S., 2003. Commonly used surfactant, Tween 80, improves
- absorption of P-glycoprotein substrate, digoxin, in rats. Arch. Pharm. Res. 26, 768-772.
- 1256 Zhao, G., Huang, J., Xue, K., Si, L., Li, G., 2013. Enhanced intestinal absorption of etoposide by self-
- 1257 microemulsifying drug delivery systems: Roles of P-glycoprotein and cytochrome P450 3A inhibition.
- 1258 Eur. J. Pharm. Sci. 50, 429-439.
- 1259 Zhao, W., Uehera, S., Tanaka, K., Tadokoro, S., Kusamori, K., Katsumi, H., Sakane, T., Yamamoto,
- 1260 A., 2016. Effects of Polyoxyethylene Alkyl Ethers on the Intestinal Transport and Absorption of
- 1261 Rhodamine 123: A P-glycoprotein Substrate by In Vitro and In Vivo Studies. J. Pharm. Sci. 105, 1526-

1262 1534.

- 1263 Zhu, S., Huang, R., Hong, M., Jiang, Y., Hu, Z., Liu, C., Pei, Y., 2009. Effects of polyoxyethylene (40)
- stearate on the activity of P-glycoprotein and cytochrome P450. Eur. J. Pharm. Sci. 37, 573-580.
- 1265 Ölander, M., Wiśniewski, J.R., Matsson, P., Lundquist, P., Artursson, P., Science for Life Laboratory,
- 1266 S., Medicinska och farmaceutiska, v., Uppsala, u., Institutionen för, f., Farmaceutiska, f., 2016. The
- Proteome of Filter-Grown Caco-2 Cells With a Focus on Proteins Involved in Drug Disposition. J.
  Pharm. Sci. 105, 817-827.
- 1269

#### 1270 Figures Legend:

**Figure 1:** Structures of membrane transport proteins in the absence and presence of a substrate.

Cartoons illustrate: a) Inward-facing P-glycoprotein (P-gp) (mouse Abcb1, left) and the outward-facing 1272 1273 P-gp (human ABCB1, right, substrate release), transmembrane domain 1 (TMD1) (1-6 transmembrane helices (TMH)), TMD2 (7-12 TMH), extracted with modifications from (Aller et al., 2009; Kim and 1274 Chen, 2018); b) Two monomers of breast cancer resistance protein (BCRP), BCRP monomer-1 (1-6 1275 1276 TMH, white) and -2 (1-6 TMH, dark gray), substrate-free state (left) using MsbA from Escherichia coli 1277 as a template, substrate-bound state (right) using mouse Abcb1 as the template, extracted with modifications from (Rosenberg et al., 2010; Rosenberg et al., 2015); c) Multidrug resistance-1278 associated protein 2 (MRP2), TM0 (1-5 TMH), TMD1 (6-11 TMH), TMD3 (12-17 TMH), Lasso motif 1279  $(L_0)$ , left is when substrate-free state, and right when substrate-bound state, the molecular structure is 1280 determined using bovine Mrp1 as a template, extracted with modifications from (Dallas et al., 2006; 1281 Johnson and Chen, 2017); d) Lactose permease of *Escherichia coli* (LacY) representing a solute carrier 1282 (SLC) member with 12 TMHs, LacY consists of two segments, each containing two repeat units of 1283 three TMHs (1-3, 4-6, 7-9 and 10-12) as dark gray, black, white and light gray rods, respectively, 1284 outward-open conformation (V-shape, substrate-free state, left) and inward-open conformation 1285 (inverted V-shape, substrate-released state, right) facing the extracellular and cytoplasmic side of the 1286 cellular membrane, respectively, extracted with modifications from (Colas et al., 2016; Kumar et al., 1287 2018; Kumar et al., 2014; Radestock and Forrest, 2011). Nucleotide binding domain (NBD), adenosine 1288 tri-phosphate (ATP), TMHs are depicted as rods, straight-dashed arrow represents the direction of 1289 substrate movement, curved arrow represents the direction of helices movement during conformational 1290 changes, post-translational modifications are not shown in the sub-figures, and black circle is a 1291 1292 substrate.

1293

**Figure 2:** Proposed mechanisms of P-glycoprotein inhibition by nonionic surfactants.

Cartoon shows: I) Surfactant-P-gp interaction via hydrogen bonding, the hydrophobic moiety of the surfactant partitions into the cell membrane, while the hydrogen bond acceptor groups in the hydrophilic moiety of the surfactant form hydrogen bonds with the hydrogen bond donor groups in Pgp, II) Alteration of membrane fluidity and/or (III) depleted intracellular ATP. Transmembrane helices are depicted as rods. Nucleotide binding domain (NBD), adenosine tri-phosphate (ATP), adenosine diphosphate (ADP), extracellular (Ex.), intracellular (In.), black triangle (P-gp substrate), red circle attached to a tail (nonionic surfactant), and black dashed lines (hydrogen bonds).

1302

Table 1: Expression of selected transporters and carriers along the human intestine and in Caco-2 cells.
 Logarithmic 10-step color scale and annotation of expression levels (very low-very high) have
 *arbitrarily* been defined for overview in the range 0-15 pmol/mg total protein and 0-450 fmol/mg total
 tissue<sup>d</sup>:

To be inserted as a footnote under Table 1: LC-MS/MS-determined protein concentrations (pmol/mg 1307 total protein) of selected transporters and carriers in Caco-2 cells and segments of the human 1308 gastrointestinal tract. Protein concentrations from Caco-2 cells were obtained three weeks after seeding. 1309 Caco-2 cells were from three different sources: American Type Culture Collection (ATCC)<sup>a</sup>, The 1310 European Collection of Authenticated Cell Cultures (ECACC)<sup>b</sup>, and Deutsche Sammlung von 1311 Mikroorganismen und Zellkulturen (DSMZ)<sup>c</sup>. The average values are depicted without statistical 1312 1313 deviation parameters. For (Akazawa et al., 2018), the average were obtained from two reported values from two humans, and if one of the two values was below the lower limit of quantification (LLOQ), the 1314 other value is depicted. Intestinal segments were adapted from (Drozdzik et al., 2014): Duodenum (D), 1315

1316 jejunum (J1-2), ileum (I1-2), and colon (C1-4). BLQ = below the LLOQ. Logarithmic 10-step-color 1317 scale and annotation of expression level (very low-very high) have arbitrarily been defined for 1318 overview in the range 0-15 pmol/mg total protein and 0-450 fmol/mg total tissue<sup>d</sup> 1319

1320 Table 2: In vitro Himpact of selected nonionic surfactants and polyethylene glycol (PEG) derivatives on 1321 P-glycoprotein-in vitro.

To be inserted as a footnote under Table 2: Accumulation (accum.), Approximately (approx.), 1322

1323

Respectively (resp.), Surfactant (surf.), Concentration (conc.), Dependent (dep.), Not specified in the study (ns), Apical to basolateral (A-B), Mucosal to serosal (M-S), Permeability (Papp), Any increase or 1324 decrease described in the table means significant P < 0.05, Resistance Modification Index (RMI), Mouse 1325 embryo fibroblasts transfected with MDR1 (NIH-MDR1-G185), Mouse embryo fibroblasts transfected 1326 with MDR1 (NIH-MDR1-G185), P-gp overexpressing human melanoma cell line (MDA-MB-1327 435/LCC6MDR1), P-gp overexpressing human ovarian carcinoma cell line (NCI/ADR-RES), 1328 Adriamycin-resistant of murine leukaemia P388 cells (P388/ADR), P-gp variant of human epithelial 1329 cells KB 3-1 (KB 8-5-11 cells), In Vitro Diffusion Chamber Method (In vitro DCM), ATPlite 1step 1330 Assay kit was from PerkinElmer, P-gp containing membranes of Chinese hamster lung fibroblasts (DC-1331 3F/ADX cells), MDR cell subline of Chinese hamster ovary cells Aux-B1(CH<sup>r</sup>C5), Bovine brain 1332 microvessel endothelial cells (BBMEC), Vinblastine-resistant derivative of Human Caucasian acute 1333 lymphoblastic leukaemia CCRF-CEM cells (R100 cells), Human lung adenocarcinoma cell line A549 1334 1335 treated with paclitaxel (A549/Taxol), Porcine kidney epithelial cell line (LLC-PK1-MDR1), LLC-PK1 stably expressing MDR1 (LLC-MDR1), P-gp overexpressing human oral epidermal carcinoma (KBv), 1336 For cremophor<sup>®</sup> EL and Solutol<sup>®</sup> HS 15, RMI was measured at 10 µg/mL, P-gp overexpressing human 1337 melanoma cell line (MDA-MB-435/LCC6MDR1), P-gp overexpressing human ovarian carcinoma cell 1338

1339	line NCI/ADR-RES, MDR cell subline of human breast carcinoma MCF-7 cells (MCF7/ADR),
1340	Resistance reversion index (Log ( $IC_{50}$ .0/ $IC_{50}$ )) was determined as a ratio of $IC_{50}$ of Doxorubicin in the
1341	assay buffer and surfactant solution, Vincristine-resistant derivative of K562 (7962 cells), Human lung
1342	cancer cells (A549), Human P-gp overexpressing membranes obtained from baculovirus-infected insect
1343	cells (High Five, BTI-TN5B1-4), Clonal isolate derived from the Spodoptera frugiperda cell line IPLB-
1344	Sf-21-AE (Sf9), The disappearance of the drug in perfusate (P <sub>lumen</sub> ) as well as the appearance of the
1345	drug in mesenteric vein blood (apparent permeability coefficient, P <sub>blood</sub> ), P-gp overexpressing of
1346	Chinese hamster ovary AA8 cells (Emt <sup>R1</sup> ). For an overview of the effects of more surfactants on P-gp,
1347	(see Table S1).

- 1348
- Table 43: Impact of nonionic surfactants on intestinal P-glycoprotein in rats. 1349
- In vivo pre-clinical studies were performed in male a: Sprague-Dawley rats, b: Wistar albino rats. 1350
- Synonyms of surfactants are available in Table 2. 1351
- 1352
- 1353
- Table 34: In vitro and in vivo Limpact of nonionic surfactants on breast cancer resistance protein, 1354 1355 BCRP, in vitro.
- To be inserted as a footnote under Table 4: Concentration (conc.), Approximately (approx.), 1356 Respectively (resp.), Plasma membrane vesicle of cells containing human ABCG2 (Membrane vesicles 1357 BCRP), Clonal isolate derived from the Spodoptera frugiperda cell line IPLB-Sf-21-AE (Sf9 insect 1358 1359
  - cells), In Vitro Diffusion Chamber Method (In vitro DCM), Serosal to mucosal (S-M), In situ closed-

1360	loop method (In situ CLM), Wild type (WT), Sprague-Dawley (SD), Synonyms of surfactants are
1361	available in Table 2.
1362	
1363	<b>Table 4:</b> Impact of nonionic surfactants on intestinal P-glycoprotein in rats.
1364	In vivo pre-clinical studies were performed in male.*: Sprague-Dawley rats, *: Wistar albino rats.
1365	Synonyms of surfactants are available in Table 2.
1366	
1367 1368	Table 5: <u>In vitro and in vivo</u> Limpact of nonionic surfactants and co-surfactants on multidrug resistance-associated protein 2, MRP2, <i>in vitro</i> .
1369	To be inserted as a footnote under Table 5: Concentration (Conc.), Respectively (resp.), Membrane
1370	vesicles prepared from Spodoptera frugiperda (Sf9) insect cells over-expressing human MRP2
1371	(Membrane vesicles of Sf9 MRP2), ATP measurements were performed using ATP
1372	luciferin/Luciferase assay, Wild type (WT), Synonyms of surfactants are available in Table 2 and 3.
1373	
13 <mark>7</mark> 4 1375	Table 6: Nonionic surfactants inhibited solute carriers (SLCs) in vitro.
1376 1377	<u>To be inserted as a footnote under Table 6:</u> $IC_{50}$ were estimated from upatke transport assay. For Regev
1378	et al. 2002, imact of surfactant on bi-directional transport assay was shown. 1-methyl-4-
1379	phenylpyridinium acetate (MPP <sup>+</sup> ), Monocarboxylic acid transporter (MCT, SLC16A1), Organic cation
1380	transporter 1 (OCT1, SLC22A1), (OCT2, SLC22A2), (OCT3, SLC22A3), Peptide transporter 1
1381	(PEPT1, SLC15A1), (PEPT2, SLC15A2), Organic anion transporting polypeptide 1A2 (OATP1A2,
1382	SLC21A3), (OATP2B1, SLC21A9). Human embryonic kidney cells stably transfected with OATP1A2

(HEK OATP1A2), or with OATP2B1 (HEK OATP2B1), Chinese hamster ovary cells stably
transfected with rbOCT1(CHO-K1 rbOCT1), Madin-Darby canine kidney cells stably transfected with
OCT1-3 (MDCKII OCT1-3), or with PEP2 (MDCKII PEPT2). Synonyms of surfactants available in
Table 2 and 5.

1387

Table S1: <u>In vitro</u> Iimpact of nonionic surfactants and polyethylene glycol (PEG) derivatives on P glycoprotein-<u>in vitro</u>.

Respectively (resp.), Accumulation (accum.), Approximately (approx.), Surfactant (surf.). 1390 Concentration (conc.), Dependent (dep.), Not specified in the study (ns), Apical to basolateral (A-B), 1391 Mucosal to serosal (M-S), Permeability (P<sub>app</sub>), Any increase or decrease described in the table means 1392 significant P<0.05, Resistance Modification Index (RMI), Mouse embryo fibroblasts transfected with 1393 MDR1 (NIH-MDR1-G185), Mouse embryo fibroblasts transfected with MDR1 (NIH-MDR1-G185), 1394 P-gp overexpressing human melanoma cell line (MDA-MB-435/LCC6MDR1), P-gp overexpressing 1395 human ovarian carcinoma cell line (NCI/ADR-RES), Adriamycin-resistant of murine leukemia P388 1396 cells (P388/ADR), P-gp variant of human epithelial cells KB 3-1 (KB 8-5-11 cells), In Vitro Diffusion 1397 Chamber Method (In vitro DCM), ATPlite 1step Assay kit was from PerkinElmer, P-gp containing 1398 membranes of Chinese hamster lung fibroblasts (DC-3F/ADX cells), Concentration of half-maximum 1399 activation  $(K_1)$ , Concentration of half-maximum inhibition  $(K_2)$ , MDR cell subline of Chinese hamster 1400 ovary cells Aux-B1(CH<sup>r</sup>C5), Bovine brain microvessel endothelial cells (BBMEC), Vinblastine-1401 resistant derivative of Human Caucasian acute lymphoblastic leukemia CCRF-CEM cells (R100 cells), 1402 Human lung adenocarcinoma cell line A549 treated with paclitaxel (A549/Taxol), Porcine kidney 1403 epithelial cell line (LLC-PK1-MDR1), LLC-PK1 stably expressing MDR1 (LLC-MDR1), P-gp 1404 overexpressing human oral epidermal carcinoma (KBv), For cremophor<sup>®</sup> EL and Solutol<sup>®</sup> HS 15, RMI 1405

was measured at 10 µg/mL, P-gp overexpressing human melanoma cell line (MDA-MB-1406 1407 435/LCC6MDR1), P-gp overexpressing human ovarian carcinoma cell line NCI/ADR-RES, MDR cell subline of human breast carcinoma MCF-7 cells (MCF7/ADR), Resistance reversion index (Log 1408 1409  $(IC_{50}.0/IC_{50}))$  was determined as a ratio of  $IC_{50}$  of Doxorubicin in the assay buffer and surfactant 1410 solution, Vincristine-resistant derivative of K562 (7962 cells), Human lung cancer cells (A549), Human P-gp overexpressing membranes obtained from baculovirus-infected insect cells (High Five, 1411 1412 BTI-TN5B1-4), Clonal isolate derived from the Spodoptera frugiperda cell line IPLB-Sf-21-AE (Sf9), The disappearance of the drug in perfusate (P<sub>lumen</sub>) as well as the appearance of the drug in mesenteric 1413 vein blood (apparent permeability coefficient, P<sub>blood</sub>), P-gp overexpressing of Chinese hamster ovary 1414 1415 AA8 cells (Emt<sup>R1</sup>).

Table 1: Expression of selected transporters and carriers along the human intestine and in Caco-2 cells. 1416 1417 LC-MS/MS-determined protein concentrations (pmol/mg total protein) of selected transporters and carriers in Caco-2 cells and segments of the human gastrointestinal tract. Protein concentrations from 1418 Caco-2 cells were obtained three weeks after seeding. Caco-2 cells were from three different sources: 1419 American Type Culture Collection (ATCC)<sup>a</sup>. The European Collection of Authenticated Cell Cultures 1420 (ECACC)<sup>b</sup>, and Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ)<sup>e</sup>. The average 1421 values are depicted without statistical deviation parameters. For (Akazawa et al., 2018), the average 1422 were obtained from two reported values from two humans, and if one of the two values was below the 1423 lower limit of quantification (LLOQ), the other value is depicted. Intestinal segments were adapted 1424 from (Drozdzik et al., 2014); Duodenum (D), jejunum (J1-2), ileum (I1-2), and colon (C1-4), BLO = 1425 below the LLOO. Logarithmic 10-step color scale and annotation of expression level (very low-very 1426

high) have *arbitrarily* been defined for overview in the range 0-15 pmol/mg total protein and 0-450

#### 1428 fmol/mg total tissue<sup>d</sup>:

		Very lo	w expression	Low exp	ression	Intermediate expressi	
	pmol protein/mg total protein	0-0.0099	0.0100-0.0248	0.0249-0.0621	0.0622-0.154	0.155-0.386	0.387-0.9
	fmol protein/mg total tissue <sup>d</sup>	0-0.299	0.300-0.747	0.748-1.86	1.87-4.65	4.66-11.5	11.6-28
1429							
1430							
1431							
1432							
1433					7		
1434							
1435							
1436							
1437							

Transp					Į	ntesti	nal seg	ment				
orter or carrier	Caco- 2	Reference	D	J1	J2	11	I2	C1	C2	C3	C4	Reference
	2.06ª	(Ölander et al., 2016)	7.67 d	33. 02 <sup>d</sup>	47.4 1 <sup>d</sup>		70.7 8 <sup>d</sup>		9.98 d			(Drozdzik et al., 2019)
	4.1 <sup>b</sup>	(Uchida et al., 2015)	0.29 0	0.4 08	0.47 5	0.7 11	1.06	0.1 45	0.30 4	0.2 28	0.3 68	(Drozdzik et al., 2014)
P-gp	1.0°	(Brück et al., 2017)		1.2 2								(Lloret-Linares et al., 2016)
1-gp				0.0	614	0.	656					(Gröer et al., 2013)
					1.89		0.20					(Harwood et al., 2015)
				2.	43	4	.93					(Akazawa et al., 2018)
	0.011 7ª	(Ölander et al., 2016)	5.51 d	19. 58 <sup>d</sup>	26.9 7 <sup>d</sup>		30.4 7 <sup>d</sup>		5.13 d			(Drozdzik et al., 2019)
	1.79 <sup>b</sup>	(Uchida et al., 2015)	0.19 0	0.2 77	0.35 6	0.4 05	0.35 9	0.1 50	0.04 38	0.1 53	0.1 60	(Drozdzik et al., 2014)
BCRP	0.5°	(Brück et al., 2017)			1.25							(Miyauchi et al., 2016)
				0.:	574	0.	241					(Gröer et al., 2013)
					2.56		1.60					(Harwood et al.,

												2015)
				4.	65	8	.07					(Akazawa et al., 2018)
	0.134 <sup>a</sup> 0.649	(Ölander et al., 2016) (Uchida et al., 2015)	11.8 8 <sup>d</sup> 0.75 8	22. 37 <sup>d</sup> 1.0 3	22.5 2 <sup>d</sup> 0.94 6	0.7 64	19.8 4 <sup>d</sup> 0.80 8	1.4 1	16.6 9 <sup>d</sup> 1.77	1.1 3	0.9 51	(Drozdzik et al., 2019) (Drozdzik et al., 2014)
	0.8°	(Brück et al., 2017)		0.1 16								(Lloret-Linares et al., 2016)
MRP2		,			07	0.	350				Ć	(Gröer et al., 2013)
					0.59		BL Q		C	C		(Harwood et al., 2015)
				0.8	335	1	.16					(Akazawa et al., 2018)
	0.423ª	(Ölander et al., 2016)	17.2 8 <sup>d</sup>	30. 47 <sup>d</sup>	31.2 5 <sup>d</sup>		22.5 8 <sup>d</sup>		28.7 9 <sup>d</sup>			(Drozdzik et al., 2019)
	BLQ <sup>b</sup>	(Uchida et al., 2015)	0.85 0	0.6 39	0.50 6	0.5 52	0.69 6	1.5 3	2.10	2.1 1	1.7 2	(Drozdzik et al., 2014)
MRP3	BLQ <sup>c</sup>	(Brück et al., 2017)		1.9 1	1							(Lloret-Linares et al., 2016)
		,		0.3	0.309		686					(Gröer et al., 2013)
				0.:	501	0.	303					(Akazawa et al., 2018)
	0.342 <sup>a</sup>	(Ölander et al., 2016)	25.6 1 <sup>d</sup>	84. 17 <sup>d</sup>	109. 6 <sup>d</sup>		107. 3 <sup>d</sup>		3.27 d			(Drozdzik et al., 2019)
	1.48 <sup>b</sup>	(Uchida et al., 2015)	2.63	3.4 9	4.23	4.6 2	4.89	0.2 98	0.21 0	0.1 88	0.3 10	(Drozdzik et al., 2014)
PEPT1	5.2°	(Brück et al., 2017)			1.60	_			Ŭ		10	(Miyauchi et al., 2016)
		2017)		2.	45	4	.73					(Gröer et al., 2013)
		0		8.	34	1	0.7					(Akazawa et al., 2018)
	2.66ª	(Ölander et al., 2016)	5.30 d	7.2 1 <sup>d</sup>	8.02 d		8.06 d		8.00 d			(Drozdzik et al., 2019)
	0.771 <sub>b</sub>	(Uchida et al., 2015)	0.42 8	0.5 56	0.48 6	0.4 64	0.48 2	0.4 78	0.73 1	0.6 38	0.5 91	(Drozdzik et al., 2014)
OATP2 B1	3.3°	(Brück et al., 2017)			0.54 0							(Miyauchi et al., 2016)
				0.2	299	0.	267					(Gröer et al., 2013)
				B	LQ	В	LQ					(Akazawa et al.,

												2018)
	BLQ <sup>b</sup>	(Uchida et	BL	BL	BL		BL		BL			(Drozdzik et al.,
		al., 2015)	Q	Q	Q	זם	Q	זם	Q	זם	זם	2019)
	BLQ <sup>c</sup>	(Brück et al., 2017)	BL Q	BL Q	BL Q	BL Q	BL Q	BL Q	BL Q	BL Q	BL Q	(Drozdzik et al., 2014)
OATP1		2017)	Y Y	Q	BL	Q	Q		Q	Q	Q	(Miyauchi et al.,
A2					Q							2016)
				ום	LQ	D	LQ					(Gröer et al.,
				DI	LŲ	D	LŲ				0	2013)
				0 3	336	0	189					(Akazawa et al.,
		(01 1	1 (1			0.			0.70			2018)
	BLQ <sup>a</sup>	(Ölander et	1.61 d	4.2 2 <sup>d</sup>	6.02 d		5.12 d		2.79 d			(Drozdzik et al.,
		al., 2016) (Uchida et	0.66	2ª 0.6	0.56	0.8	u 0.84	0.4	0.69	0.7	0.6	2019) (Drozdzik et al.,
OCT1	BLQ <sup>b</sup>	al., 2015)	5	47	6	0.8	2	69	5	25	32	(Diozdzik čt al., 2014)
0011	DI Ga	(Brück et al.,		• • •	BL	02				20	52	(Miyauchi et al.,
	BLQ <sup>c</sup>	2017)			Q							2016)
				BI	LQ	0	480					(Gröer et al.,
					-	0.4						2013)
	BLQ <sup>b</sup>	(Uchida et	BL	BL	BL		BL		BL			(Drozdzik et al.,
		al., 2015)	Q	Q	Q		Q	0.1	Q	0.1	0.1	2019)
	BLQ <sup>c</sup>	(Brück et al., 2017)	0.06 70	0.0 564	0.06 29	0.0 531	0.0 687	0.1 26	0.10 7	0.1 16	0.1 35	(Drozdzik et al., 2014)
OCT3		2017)	/0	504	BL	551	007	20	/	10	55	(Miyauchi et al.,
0015					Q							2016)
				Л	-		077					(Gröer et al.,
				BI	LQ	0.0	077					2013)
				0.4	551	B	LQ					(Akazawa et al.,
						<b>D</b> .						2018)
	1.72 <sup>a</sup>	(Ölander et	61.1	78.	75.1		43.6		112.			(Drozdzik et al.,
	0.871	al., 2016) (Uchida et	3 <sup>d</sup>	81 <sup>d</sup>	4 <sup>d</sup>		5 <sup>d</sup>		6 <sup>d</sup>			2019) (Miyauchi et al.,
MCT	0.871 b	(Ochida et al., 2015)			1.85							(Wilyaucin et al., 2016)
		ull, 2010)			<b>5</b> 4		41					(Akazawa et al.,
				1.	54	2.	.41					2018)

- 1445
- 1446

Table 2: <u>In vitro Iimpact of selected nonionic surfactants and polyethylene glycol (PEG) derivatives on</u>
 P-glycoprotein-<u>in vitro</u>.

Accumulation (accum.), Approximately (approx.), Respectively (resp.), Surfactant (surf.), 1449 Concentration (conc.), Dependent (dep.), Not specified in the study (ns), Apical to basolateral (A-B), 1450 Mucosal to serosal (M-S), Permeability (Papp), Any increase or decrease described in the table means 1451 significant P<0.05, Resistance Modification Index (RMI), Mouse embryo fibroblasts transfected with 1452 MDR1 (NIH-MDR1-G185), Mouse embryo fibroblasts transfected with MDR1 (NIH-MDR1-G185), 1453 P-gp overexpressing human melanoma cell line (MDA-MB-435/LCC6MDR1), P-gp overexpressing 1454 human ovarian carcinoma cell line (NCI/ADR-RES), Adriamycin-resistant of murine leukaemia P388 1455 cells (P388/ADR), P-gp variant of human epithelial cells KB 3-1 (KB 8-5-11 cells), In Vitro Diffusion 1456 Chamber Method (In vitro DCM), ATPlite 1step Assay kit was from PerkinElmer, P-gp containing 1457 membranes of Chinese hamster lung fibroblasts (DC-3F/ADX cells), MDR cell subline of Chinese 1458 hamster ovary cells Aux-B1(CH<sup>#</sup>C5), Bovine brain microvessel endothelial cells (BBMEC), 1459 Vinblastine-resistant derivative of Human Caucasian acute lymphoblastic leukaemia CCRF-CEM cells 1460 (R100 cells), Human lung adenocarcinoma cell line A549 treated with paclitaxel (A549/Taxol), Porcine 1461 kidney epithelial cell line (LLC-PK1-MDR1), LLC-PK1 stably expressing MDR1 (LLC-MDR1), P-gp 1462 overexpressing human oral epidermal carcinoma (KBv), For cremophor<sup>®</sup> EL and Solutol<sup>®</sup> HS 15, RMI 1463 was measured at 10 µg/mL, P-gp overexpressing human melanoma cell line (MDA-MB-1464 435/LCC6MDR1), P-gp overexpressing human ovarian carcinoma cell line NCI/ADR-RES, MDR cell 1465 1466 subline of human breast carcinoma MCF-7 cells (MCF7/ADR), Resistance reversion index (Log (IC<sub>50</sub>:0/IC<sub>50</sub>)) was determined as a ratio of IC<sub>50</sub> of Doxorubicin in the assay buffer and surfactant 1467 1468 solution, Vincristine-resistant derivative of K562 (7962 cells), Human lung cancer cells (A549), Human P-gp overexpressing membranes obtained from baculovirus-infected insect cells (High Five, 1469 BTI-TN5B1-4), Clonal isolate derived from the Spodoptera frugiperda cell line IPLB-Sf-21-AE (Sf9), 1470 The disappearance of the drug in perfusate (P<sub>lumen</sub>) as well as the appearance of the drug in mesenteric 1471

- vein blood (apparent permeability coefficient, P<sub>blood</sub>), P-gp overexpressing of Chinese hamster ovary 1472
- AA8 cells (Emt<sup>R1</sup>). For an overview of the effects of more surfactants on P-gp, (see Table S1). 1473 Accerbatic
- 1474
- 1475

	Conc.	Substrate	Cell line/Tissue	Assay	Impact	Refer
EL,	(1:1000)	Daunorubicin	R100 cells	Uptake transport	Increased intracellular accum.	(Wood 1990)
-, astor astor	(1:1000)	Daunorubicin	7962 cells	Uptake transport	Increased intracellular accum.	(Wood 1990)
5	(1:1000)	Daunorubicin	R100 cells	Uptake transport	Increased intracellular accum.	(Wood 1992)
	(1:1000)	Daunorubicin	P388/ADR	Uptake transport	Increased intracellular accum.	(Wood 1992)
	0.0001-0.1% (w/v) 100 μg/mL	Acf(N- Mef) <sub>2</sub> NH <sub>2</sub> Rh 123	Caco-2 Cell monolayers KB 8-5-11 cells	Bi-directional transport Uptake transport	Increased A-B and decreased B-A P <sub>app.</sub> Enhanced the fluorescence of Rh	(Nerun 1996) (Buck
	3-20 µg/mL	Doxorubicin	KB 8-5-11 cells	MTT	123 by 3-fold. Decreased IC <sub>50</sub> in a conc. dep. manner. RMI = $1.5 \pm 0.0$	1995) (Buck 1995)
	3-20 µg/mL	Vinblastine	KB 8-5-11 cells	MTT	Decreased IC <sub>50</sub> in a conc. dep. manner. RMI =1.1 $\pm$ 0.1	(Buck 1995)
	3-20 µg/mL	Colchicine	KB 8-5-11 cells	MTT	Decreased IC <sub>50</sub> in a conc. dep. manner. RMI = $1.3 \pm 0.1$	(Buck 1995)
	3-20 µg/mL	Etoposide	KB 8-5-11 cells	MTT	Decreased IC <sub>50</sub> in a conc. dep. manner. RMI = $1.2 \pm 0.3$	(Buck 1995)
	3-20 μg/mL,	Actinomycin D	KB 8-5-11 cells	MTT	Decreased IC <sub>50</sub> in a conc. dep. manner. RMI =1 $\pm$ 0.2	(Buck 1995)
	0.01-1 mM	Rh 123	Caco-2 cell monolayers	Bi-directional transport	Increased A-B and decreased B-A $P_{app}$ in a conc. dependent manner.	(Rege
	0.02-2% (w/v)	Cyclosporine A	Caco-2 cell monolayers	Bi-directional transport	Decreased B-A P <sub>app</sub> .	(Chiu
	0.005-0.5% (w/v)	Rh 123	Rat intestinal membrane	Bi-directional transport (In vitro DCM)	Increased S-M and decreased M-S $P_{app.}$	(Shon
	400 μΜ	Doxorubicin	Caco-2 cell monolayers	Bi-directional transport	Increased A-B P <sub>app.</sub>	(Al-Sa 2016)
	300 µM	Etoposide	Caco-2 cell monolayers	Bi-directional transport	Increased A-B and decreased B-A $P_{app.}$	(Al-A
	1% SMEDDS containing 50% (w/w) of surf.	Etoposide (SMEDDS)	Intestinal segments from rats' ileum	In situ single- pass perfusion experiments	Increased intestinal $P_{app}$ . <u>i</u> Increased $P_{Blood}$ and $P_{Lumen}$ .	(Zhao
	0.3-1000 μM	Digoxin	MDCKII MDR1	Uptake transport	Increased intracellular accum. in a conc. dependent manner. $IC_{50} = 12 \ \mu M$	(Gurja
glycol	2.5-20% (w/v)	Paclitaxel	Caco-2 cell monolayers	Bi-directional transport	Increased A-B and decreased B-A $P_{app}$ in a conc. dependent manner.	(Hugg

20% (w/v)	Paclitaxel	Caco-2 cell	Bi-directional	Increased A-B and decreased B-A	(Hugg
20/0 (11/1)		monolayers	transport	$P_{add}$ in a conc. dependent manner.	(IIUBE
20% (v/v)	Ranitidine	Caco-2 cell	<b>Bi-directional</b>	Decreased ranitidine ER.	(Ashii
		monolayers	transport		al., 20
300 µM				Increased P-gp ATPase activity.	(Ashii
1 5 1000/	<b>D</b> '''	<b>D</b> ( <b>1</b> 1			al., 20
•	Digoxin				(Johns
(W/V)		membrane	(In vitro DCM)	64%, resp., compared to control.	2002)
0.1-20% (v/v)	Rh 123	Rat intestinal	<b>Bi-directional</b>	Decreased S-M P <sub>app</sub> in a conc. dep.	(Shen
		membrane	transport (In vitro DCM)	manner.	
20% (v/v)	Ranitidine	Caco-2 cell	Bi-directional	Decreased ER.	(Ashii
		monolayers	transport		al., 20
0.5 and 1%	Ranitidine	Caco-2 cell	<b>Bi-directional</b>	Enhanced A-B and decreased B-A	(Ashii
(v/v)		monolayers	transport	P <sub>app</sub> .	al., 20
300 µM				Increased P-gp ATPase activity.	(Ashii
1 1 0 0 /	51.400	~ • 11			al., 20
1 and 2% (w/v)	Rh 123	Caco-2 cells	Uptake transport	Enhanced Rh 123 intracellular accum.	(Hoda
1 and 2% $(w/v)$		Caco-2 cells	Western blotting	Decreased P-gp expression.	(Hoda
()	Doxorubicin	KBv		$Log (IC_{50.0}/IC_{50}) = 0.7$	(Batra 1999)
	Doxorubicin	MCF7/ADR		$Log (IC_{50.0}/IC_{50}) = 0.8$	(Batra 1999)
	Doxorubicin	CHrC5		$Log (IC_{50.0}/IC_{50}) = 2$	(Batra
					1999)
Log M = -5	Rh 123	KBv	Uptake transport	Enhanced Rh 123 accum. by approx. 6.5-fold.	(Batra 1999)
0.001-1%	Rh 123	LLC-PK1-MDR1	Uptake transport	Increased Rh 123 accum.	(Batra 2001)
0.001-1%	Digoxin	LLC-PK1-MDR1	Uptake transport	Increased digoxin accum.	(Batra
	-			-	2001)
0.01-1%	Digoxin	BBMEC	A-B transport	Increased A-B transport.	(Batra
					2001)
0.01%	Digoxin	BBMEC	A-B transport		(Batra
	<b></b> .		<b>D</b> 11 1 1	-	2001)
	Digoxin			Decreased S-M flux.	(Johns
(W/V)		membrane	1		2002)
0.010/(w/w)	Dh 122	DDMEC	. , , , , , , , , , , , , , , , , , , ,	Enhanced Dh 122 accum by arrest	(Dates
0.01% (W/V)	Kn 123	RRMEC	Uptake transport	2-fold. Depleted intracellular ATP	(Batra 2003)
	300 $\mu$ M 1, 5 and 20% (w/v) 0.1-20% (v/v) 20% (v/v) 0.5 and 1% (v/v) 300 $\mu$ M 1 and 2% (w/v) 1 and 2% (w/v) Log M = -5 0.001-1% 0.001-1%	20% (v/v)       Ranitidine         300 μM       Digoxin         1, 5 and 20%       Digoxin         0.1-20% (v/v)       Rh 123         20% (v/v)       Ranitidine         20% (v/v)       Ranitidine         1.05 and 1%       Ranitidine         (v/v)       Ranitidine         1.and 2%       Rh 123         (w/v)       Doxorubicin         1 and 2%       Doxorubicin         (w/v)       Rh 123         0.00 μM       Doxorubicin         1 and 2%       Doxorubicin         0.00 μM       Digoxin         0.001-1%       Rh 123         0.001-1%       Digoxin         0.001-1%       Digoxin         0.01-1%       Digoxin         0.01       Digoxin	20% (v/v)Ranitidinemonolayers Caco-2 cell monolayers300 $\mu$ MDigoxinRat jejunal membrane1, 5 and 20% (w/v)DigoxinRat jejunal membrane0.1-20% (v/v)Rh 123Rat intestinal membrane20% (v/v)RanitidineCaco-2 cell monolayers20% (v/v)RanitidineCaco-2 cell monolayers1 and 2% (w/v) $_{300 \mu$ MRh 123Caco-2 cells Caco-2 cells1 and 2% (w/v) $_{1 and 2\%}$ Rh 123Caco-2 cells Caco-2 cells0.5 and 1% (v/v) $_{300 \mu$ MDoxorubicinKBv1 and 2% (w/v) $_{1 and 2\%}$ Rh 123Caco-2 cells0.0xorubicinMCF7/ADR DoxorubicinMCF7/ADR0.001-1%Rh 123LLC-PK1-MDR10.001-1%DigoxinBBMEC0.01-1%DigoxinBBMEC0.01%DigoxinRat jejunal membrane	$\begin{array}{ccccc} & & & & & & & & & & & & & & & & &$	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$

				.•.•.	
0.01% (w/v)	Rh 123	BBMEC	ATP luciferin/	activity. Depleted intracellular ATP content.	(Batra
0.0170 (w/v)	Kii 125	DDMLC	luciferase	Depreted influeendual ATT content.	(Datia 2003)
0.01% (w/v)	Rh 123	KBv	Pgp ATPase activity	Decreased the P-gp ATPase activity.	(Batra 2003)
0.1% w/v		P-gp membranes from Gentest Co.	P-gp ATPase Assay	Decreased $V_{max}$ and increased $K_m$ significantly.	(Batra 2004)
0.01 and 0.1% w/v	Vincristine	P-gp membranes from Gentest Co.	P-gp ATPase Assay	Decreased $V_{max}$ and increased $K_m$ significantly.	(Batra 2004)
0.5 % (w/v)	Rh 123	Rats' jejunal segments	M-S transport. (Ussing chamber)	Increased M-S P <sub>app</sub> by 1.9-fold.	(Föge
0.1% w/w		P-gp membranes (High Five, BTI- TN5B1-4)	P-gp ATPase Assay	Abolished P-gp ATPase activity completely.	(Shaik
0.01% w/w	Verapamil	P-gp membranes (High Five, BTI- TN5B1-4)	P-gp ATPase Assay	Inhibited verapamil-stimulated P-gp ATPase activity.	(Shaik
0.01% w/w	Nelfinavir	P-gp membranes (High Five, BTI- TN5B1-4)	P-gp ATPase Assay	Abolished the nelfinavir stimulated P-gp ATPase activity.	(Shaik
0.01% w/w	Nelfinavir	MDCKII MDR1	Uptake transport	Enhanced nelfinavir accum.	(Shaik
0.01% w/w	Saquinavir	MDCKII MDR1	Uptake transport	Increased saquinavir accum. by 2-fold.	(Shail
0.01% w/w	Saquinavir	LLC-PK1-MDR1	Uptake transport	Increased saquinavir accum. by 5- fold.	(Shaik
0-600 ng/mL		Membrane vesicles of Emt <sup>R1</sup> cells	Phosphate release measurements	Reduced P-gp ATPase activity in a conc. dep. manner.	(Rege
0-300 ng/mL	Doxirubicin	Large unilamellar vesicles (LUV)	Trans-bilayer movement	Decreased Flip-Flop Life-Time of doxorubicin in a conc. dep. manner.	(Rege
30-100 ng/mL	Clacein-AM	Emt <sup>R1</sup> cells	Calcein-AM efflux	Enhanced calcein-AM uptake in a conc. dep. manner.	(Rege
0.5% (w/v)	Digoxin	Rat everted gut sac model	Uptake transport	Enhanced digoxin accum.	(Corn 2004)
200 μΜ	Epirubicin	Caco-2 cell monolayers	Bi-directional transport	Increased A-B and decreased B-A $P_{app.}$	(Lo, 2
20-200 µM	Epirubicin	Caco-2 cells	Uptake transport	Enhanced fluorescent epirubicin accum. in a conc. dep. manner.	(Lo, 2
200 µM	Epirubicin	Everted sacs of rat's jejunum or ileum	M-S transport	Increased M-S P <sub>app</sub> .	(Lo, 2
200 μΜ	Doxorubicin	Caco-2 cell monolayers	Bi-directional transport	Increased A-B P <sub>app.</sub>	(Al-Sa 2016)

),

ne

	200 µM	Digoxin	Caco-2 cell	Bi-directional	Increased A-B and decreased B-A	(Niels
	200 μινι	DIGOVIII	monolayers	transport	P <sub>app</sub> .	(11015
	0.2-500 μM	Digoxin	Caco-2 cell	Bi-directional	Increased A-B and decreased B-A	(Niels
			monolayers	transport	$P_{app}$ in a conc. dep. manner.	
	0.2-500 μM	Digoxin	MDCKII MDR1	<b>Bi-directional</b>	Increased A-B and decreased B-A	(Niels
	000 500 55		cell monolayers	transport	P <sub>app</sub> in a conc. dep. manner.	/ • • ·
	200-500 μM	Etoposide	Caco-2 cell	Bi-directional	Increased A-B P <sub>app.</sub>	(Al-A
	0.2.500	Etoposido	monolayers Caco-2 cell	transport Bi-directional	Decreased D A D	( 1 1 1
	0.2 <b>-</b> 500 μM	Etoposide	monolayers	transport	Decreased B-A P <sub>app.</sub>	(Al-A
	20-500 μM	Etoposide	MDCKII MDR1	Bi-directional	Increased A-B and decreased B-A	(Al-A
		Lioposide	cell monolayers	transport	P <sub>app.</sub>	(* <b>11</b> -17
		Calcein-AM	MDCKII MDR1	Calcein-AM	Increased calcein fluorescence in a	(Al-A
				efflux	conc. dep. manner. $IC_{50} = 11 \ \mu M$ .	2018b
	200 µM	Digoxin	MDCKII MDR1	<b>Bi-directional</b>	Increased A-B and decreased B-A	(Al-A
				transport	P <sub>app.</sub>	2018b
1					Increased intracellular accum. of	
	0.0.1000 5-	D		<b>TT / 1</b>	digoxin from the apical side.	
	0.3-1000 μM	Digoxin	MDCKII MDR1	Uptake transport	Increased intracellular accum. in a	(Gurja
					conc. dependent manner. $IC_{50} = 74$	
)	200 µM	Epirubicin	Everted sacs of	M-S transport	μM. Increased M-S P <sub>app</sub>	(Lo, 2
J,	200 μινι	Lhundin	jejunum or ileum		mercused ivi-o i app	(L0, 2
ne			of rats			
oleate	20-200 μM	Epirubicin	Caco-2 cells	Uptake transport	Enhanced intracellular accum. of	(Lo, 2
	•	-		- 1	fluorescent epirubicin in a conc. dep.	
					manner.	
	200 μΜ	Epirubicin	Caco-2 cell	<b>Bi-directional</b>	Increased A-B and decreased B-A	(Lo, 2
	0.5 /	D: '	monolayers	transport	P <sub>app.</sub>	
	0.5 w/v	Digoxin	Rat everted gut	Uptake transport	Enhanced digoxin uptake.	(Corna 2004)
	0.01-1 mM	Rh 123	sac model Caco-2 cell	<b>Bi-directional</b>	Increased A-B and decreased B-A	2004) (Rege
	0.01-1 IIIIVI	NII 123	monolayers	transport	P <sub>app</sub> in a conc. dep. manner.	(Rege
		Rh 123	Caco-2	Uptake transport	Increased Rh 123 accum.	(Kiss
		1411143		Sparke transport	mercused for 125 decum.	נפוצו)
		Rh 123	Caco-2 cell	<b>Bi-directional</b>	Increased A-B and decreased B-A	(Kiss
			monolayers	transport	P <sub>app.</sub>	
		Calcein-AM	Caco-2 cells	Uptake transport	Increased calcein accum.	(Kiss
	(1:10000)	Daunorubicin	R100 cells	Uptake transport	Increased intracellular daunorubicin	(Wood
	0.000				accum.	1992)
	0.0001-1 %	Acf(N-	Caco-2 Cell	Bi-directional	Increased A-B and decreased B-A	(Neru
	(w/v)	$Mef)_2NH_2$	monolayers	transport Di directional	P <sub>app.</sub> Padward S. M/M. S. matia	1996)
	0.1% (w/v)	Rh 123	Rat intestinal	Bi-directional	Reduced S-M/M-S ratio.	(Shon
			membrane	transport		

	0.06-0.66 µM	Verapamil	Membrane	(In vitro DCM) Phosphate	Inhibition of verapamil-induced P-gp	(Li-B
	0.00-0.00 μινι	v crapanni	vesicles of NIH- MDR1-G185	release	ATPase activity.	(LI-D 2009)
	0.001-0.05	Clacein-AM	MDR1-G185 MDCKII MDR1	measurements Calcein-AM	Enhanced calcein fluorescence by	(Hank
	w/v			efflux	approx. 2-fold.	(11aiif
	150 μM	Bis(12)-	Caco-2 cell	Bi-directional	Increased A-B P <sub>app</sub> and decreased B-	(Yu e
	100 μ101	hupyridone	monolayers	transport	A P <sub>app.</sub>	(140
	10 µM	Bis(12)-	Caco-2 cell	Bi-directional	Decreased B-A P <sub>app.</sub>	(Yu e
	10 μινι	hupyridone	monolayers	transport	Decreased D III app.	(140
	200 µM	Doxorubicin	Caco-2 cell	Bi-directional	Increased A-B P <sub>app.</sub>	(Al-S
1	-00 mili		monolayers	transport	app.	2016)
	200 µM	Digoxin	Caco-2 cell	Bi-directional	Increased A-B and decreased B-A	(Niels
	200 µ.01	DIGOMI	monolayers	transport	flux.	(11012
	300 µM	Etoposide	Caco-2 cell	Bi-directional	Increased A-B and decreased B-A	(Al-A
	200 mili	Lioposide	monolayers	transport	P <sub>app.</sub>	(1111)
	1% SMEDDS	Etoposide	Intestinal	In situ single-	Increased intestinal P <sub>app.</sub> Increased	(Zhao
	containing	(SMEDDS)	segments from	pass perfusion	$P_{\text{Blood}}$ and $P_{\text{Lumen.}}$	
	50% (w/w) of		rats' ileum	experiments	- Diood where I Lumen.	
	surf.		1405 1104111	experiments		
	~~···	Calcein-AM	MDCKII MDR1	Calcein-AM	Increased calcein fluorescence in a	(Al-A
				efflux	conc. dep. manner. $IC_{50}$ = 69 $\mu$ M	2018t
	200 µM	Digoxin	MDCKII MDR1	Bi-directional	Decreased B-A $P_{app}$ .	(Al-A
	p	2.80.111		transport	Increased intracellular accum. of	2018t
					digoxin from the apical side.	_0100
	0.3-100 μM	Digoxin	MDCKII MDR1	Uptake transport	Increased intracellular accum. in a	(Gurja
	point	-0		-rpoit	conc. dep. manner. $IC_{50} = 45 \ \mu M$	(201)
5.	0.05-0.5 %	Digoxin	Rat everted gut	Uptake transport	Enhanced digoxin accum.	(Corn
5 <b>15</b> ,	(w/v)	-0	sac model	-rpoit		2004)
glycol	(1:10000)	Daunorubicin	R100 cells	Uptake transport	Increased intracellular daunorubicin.	(Woo
	( )			- r		1992)
ite,		Etoposide	C6 glioma cells	MTT	Decreased $IC_{50}$ by 10-fold.	(Lam
ted		r				Benoi
aric		Etoposide	F98 glioma cells	MTT	Decreased IC <sub>50</sub> by 3-fold.	(Lam
*		r				Benoi
		Etoposide	9L glioma cells	MTT	Decreased $IC_{50}$ by 8-fold.	(Lam
		т-2 <b>г</b> -2 <b>г</b> -2				Benoi
te	35-39%		P-gp exhibiting	ATPase kit	Decreased ATPase activity.	(Lam
	Lipid		membrane	(SPIbio®,	······································	Benoi
	nanoparticles		vesicles	Massy, France)		
	5-100 μg/mL	Rh 123	KB 8-5-11 cells	Uptake transport	Enhanced fluorescence of Rh 123 in	(Buck
				-rprint	a conc. dep. manner.	1995)
	3-20 μg/mL	Doxorubicin	KB 8-5-11 cells	MTT	Decreased $IC_{50}$ in a conc. dep.	(Buck
	0 mg/mill				manner. $RMI = 6 \pm 3.2$	1995)

	3-20 μg/mL	Vinblastine	KB 8-5-11 cells	MTT	Decreased IC <sub>50</sub> in a conc. dep. manner. RMI = $2 \pm 1$	(Buck
	2 20	Calabiai	VD 0 5 11 11	MTT		1995)
	3-20 μg/mL	Colchicine	KB 8-5-11 cells	MTT	Decreased IC <sub>50</sub> in a conc. dep.	(Buck
	2 20 u g/m I	Etomosida	VD 0 5 11 an 11-	MTT	manner. $RMI = 4.2 \pm 0.7$	1995)
	3-20 μg/mL	Etoposide	KB 8-5-11 cells	MTT	Decreased $IC_{50}$ in a conc. dep.	(Buck
	2 20  matrix	Actinomycin	KB 8-5-11 cells	MTT	manner. $RMI = 2.7 \pm 0.7$	1995)
	3-20 μg/mL	Actinomycin D	KD 8-3-11 Cells	IVI I I	Decreased IC <sub>50</sub> in a conc. dep. manner. RMI = $2.3 \pm 0.9$	(Buck 1995)
	3-20 μg/mL	Paclitaxel	KB 8-5-11 cells	MTT	Decreased IC <sub>50</sub> in a conc. dep.	(Buck
	<b>3-20 μg/IIIL</b>	racillaxei	KD 0-5-11 CC115		manner. RMI= $10 \pm 1.2$	(Buck 1995)
	0.1 – 100 μM	Colchicine	KB 8-5-11 cells	Colorimetric	Decreased $IC_{50}$ in a conc. dep.	(Coor
	$0.1 - 100 \mu W$	Colemente	KD 0-5-11 COIIS	(Crystal violet)	manner. $RMI = 34.5 \pm 2.5$	(0001
	0.1 – 100 μM	Vinblastine	KB 8-5-11 cells	Colorimetric	Decreased IC <sub>50</sub> in a conc. dep.	(Coor
	0.1 100 μivi	v morasume		(Crystal violet)	manner. $RMI = 27.7 \pm 2.3$	
	0.1 – 100 μM	Doxorubicin	KB 8-5-11 cells	Colorimetric	Decreased IC <sub>50</sub> in a conc. dep.	(Coor
	0.1 100 μivi	DUNUTUUU		(Crystal violet)	manner. $RMI = 41.7 \pm 3$	
	70 µM	Rh 123	KB 8-5-11 cells	Uptake transport		(Coor
	0.1-1% (w/v)	Etoposide	Everted sacs of	M-S and S-M	Increased A-B P <sub>app</sub>	(Akht
	0.1 1 /0 (₩/ ٧)	Ltoposide	ileum of rats	transport	increased if D i app	
	0.3-1000 μM	Digoxin	MDCKII MDR1	Uptake transport	Increased intracellular accum. in a	(Gurja
	0.5 1000 µ101	Digonii		opune numpore	conc. dep. manner. $IC_{50} = 180 \ \mu M$	(Guijt
	0.05-0.5% w/v	Digoxin	Rat everted gut	Uptake transport		(Corn
1	0.00 0.070 000	DiBoun	sac model	opunie transport		2004)
lycol	0.05 and 0.5	Celiprolol	Rat everted gut	Uptake transport	Enhanced celiprolol accum.	(Corn
	w/v	Comptotor	sac model	opunie transport		2004)
ĠS,	0.002-1	Paclitaxel	Intestinal	<b>Bi-directional</b>	Decreased B-A P <sub>app</sub> in a conc. dep.	(Varn
	mg/mL		segments from	transport	manner. Increased A-B $P_{app}$ .	Panch
lycol	0		rats' ileum	(Ussing	սթբ	
J				chamber)		
	0.1 and 1	Paclitaxel	Intestinal	In situ single-	Increased intestinal P <sub>app</sub>	(Varn
	mg/mL		segments from	pass perfusion	upp.	Panch
	C		rats' ileum	experiments		
		Verapamil	P-gp membranes	ATPase	Inhibited substrate induced ATPase	(Collr
		1	from Sf9		activity. $IC_{50} (\mu M) = 3.18 \pm 1.97$	Ì
		Quinidine	P-gp membranes	ATPase	Inhibited substrate induced ATPase	(Collr
			from Sf9		activity. $IC_{50} (\mu M) = 0.82 \pm 0.47$	
		Progesterone	P-gp membranes	ATPase	Inhibited substrate induced ATPase	(Collr
			from Sf9		activity. $IC_{50} (\mu M) = 3.25 \pm 1.29$	
		Nicardipine	P-gp membranes	ATPase	Inhibited substrate induced ATPase	(Collr
			from Sf9		activity. $IC_{50} (\mu M) = 0.40 \pm 0.17$	
	33.0 µM	Rh 123	Caco-2	<b>Bi-directional</b>	Increase A-B and decrease B-A P <sub>app</sub> .	(Collr
	-		monolayers	transport		
	33.0 µM	Digoxin	Caco-2	<b>Bi-directional</b>	Increase A-B and decrease B-A P <sub>app.</sub>	(Collr
			monolayers	transport		

	Calcein-AM	NCI/ADR-RES	Calcein-AM efflux	Dose-dependent increase in calcein fluorescence.	ı (Dong
	Calcein-AM	MDA-MB-	Calcein-AM	Dose-dependent increase in calcein	ı (Dong
		435/LCC6MDR1	efflux	fluorescence.	-
0.005%	Talinolol	Caco-2 Cell	<b>Bi-directional</b>	Increased A-B P <sub>app.</sub>	(Bogr
Dose of	of surfactant	Substrate (Dose)	Impact		Referenc
	MEDDS containing w/w) surfactant	Etoposide <sup>a</sup> (12 mg/kg)	Increased AU 1.7-fold, resp	UC, C <sub>max</sub> , and F by 1.7-, 1.3-, and pectively.	(Zhao et a
	/EDDS containing w/w) surfactant	Etoposide <sup>a</sup> (12 mg/kg)	Increased AU 1.4-fold, resp	UC, C <sub>max</sub> , and F by 1.4-, 1.3-, and pectively.	(Zhao et a
240 m	g/kg	Rifampicin <sup>b</sup>		UC by 1.5-fold, prolonged $t_{\frac{1}{2}}$ by ecreased CL to 60%	(Ma et al.
<b>s,</b> 1% (w	/v)	Etoposide <sup>b</sup> (4.5 mg/kg)	Increased AU 1.8-fold, resp	UC, $C_{max}$ , and F by 1.8-, 4.7-, and pectively.	(Akhtar e
5% (w	/v)	Etoposide <sup>b</sup> (4.5 mg/kg)	Increased AU fold, respect	UC, $C_{max}$ , and F by 3-, 7-, and 3-ively.	(Akhtar e
10% (	w/v)	Etoposide <sup>b</sup> (4.5 mg/kg)	Increased AU fold, respect	UC, $C_{max}$ , and F by 1.6-, 6-, and 1.6-ively.	(Akhtar e
8.5 mg	g/table	Rh 123 <sup>a</sup> (1.5 mg/tablet)	· 1	UC by 3.4-fold.	(Föger et
,					

 
 Table 43: Impact of nonionic surfactants on intestinal P-glycoprotein in rats.
 1478

*In vivo* pre-clinical studies were performed in male <sup>a</sup>: Sprague-Dawley rats, <sup>b</sup>: Wistar albino rats. 1479

Synonyms of surfactants are available in Table 2. 1480

58	240 mg/kg	Rifampicin <sup>b</sup>	Increased AUC by 1.5-fold, prolonged $t_{\frac{1}{2}}$ by 38%, and decreased CL to 60%.	(Ma et al.		
85	8.5 mg/table	Rh123 <sup>a</sup> (1.5 mg/tablet)	Increased AUC by 1.6-fold.	(Föger et		
20	10-25% (v/v)	Digoxin <sup>a</sup> (0.2 mg/kg)	Increased AUC by 1.4-fold, increased $C_{max}$ by 1.4-1.8-fold, increased $k_e$ by 1.4-1.6-fold, and increased F by approx.1.5-fold.	(Nielsen e		
	5 and 25% (v/v)	Etoposide <sup>a</sup> (20 mg/kg)	Increased AUC by 1.8-fold, increased $C_{max}$ by 1.5-2.1-fold, CL decreased by half, and increased F by 1.7-fold.	(Al-Ali et		
80	1 and 10%(v/v)	Digoxin <sup>a</sup> (0.2 mg/kg)	Increased AUC by 1.3-1.6-fold and increased $C_{max}$ by 2.5-fold	(Zhang et		
	10%	Rifampicin <sup>b</sup> (30 mg/kg)	Increased AUC by 1.7-fold and decreased $t_{\frac{1}{2}}$ to 36%.	(Shimom 2016)		
	1% SMEDDS containing 50% (w/w) surfactant	Etoposide <sup>a</sup> (12 mg/kg)	Increased $C_{max}$ by 3.5-fold, increased F and AUC by 2.5-fold.	(Zhao et a		
7, orylic / rides	1 mg/kg	Digoxin <sup>a</sup> (0.25 mg/kg)	Increased AUC by 1.4-fold and decreased $t_{max}$ by 4.5-fold.	(Cornaire		
15	10%	Colchicine (5mg/kg)	Increased AUC by 4-fold.	(Bittner e		
	10%	Colchicine (5mg/kg)	Increased AUC by 2-fold.	(Bittner e		
	50 mg/kg	Paclitaxel <sup>a</sup> (25 mg/kg)	Increased AUC, C <sub>max</sub> , and F by 6.3-, 3.1-, and 6.4-fold, respectively.	(Varma a Panchagn		
1481	0			0		
1482						
1483	GV					
1484	_	ilmpact of nonionic	surfactants on breast cancer resistance protein,			
1485	BCRP <del>, <i>in vitro</i> and <i>in vivo</i>.</del>					
1486	Concentration (conc.), Approximately (approx.), Respectively (resp.), Plasma membrane vesicle of					
1487	cells containing human AE	BCG2 (Membrane v	vesicles BCRP), Clonal isolate derived from the			
1488	Spodoptera frugiperda cell lir	ne IPLB-Sf-21-AE (S	Sf9 insect cells), In Vitro Diffusion Chamber Method	:		
4						

side, (C <sub>6</sub> -malt)vesicles BCRPmeasurementsactivitglycol,0.05% and 0.075%SulfasalazineRat intestinal membraneIn vitro DCMDecre transpene (9) lauryl0.05 %SulfasalazineWT male Wistar ratIn situ CLMIncreat 1.45 a90.1 %SulfasalazineWT male Wistar ratIn situ CLMIncreat 2.2 an50 and 100MitoxantroneMDCKII BCRPUptake transportIncreat approxene (4) lauryl b, Brij® L4µMIncreat approxIncreat approx		Ref
klycol,0.075%membranetranspne (9) lauryl0.05 %SulfasalazineWT male WistarIn situ CLMIncrea rat90.1 %SulfasalazineWT male WistarIn situ CLMIncrea rat0.1 %SulfasalazineWT male WistarIn situ CLMIncrea rat50 and 100MitoxantroneMDCKII BCRPUptake transportIncrea approxne (4) laurylμMapprox, Brij® L41489(In vitro DCM), In situ closed loop method (In situ CLM), Wild type (WT), Sprag1490Synonyms of surfactants are available in Table 2.1491	ted Pgp ATPase ty. $K_2 = 4.6 \ 10^3 \ \mu M$	(Xu
9       rat       1.45 a         0.1 %       Sulfasalazine       WT male Wistar       In situ CLM       Increa         rat       50 and 100       Mitoxantrone       MDCKII BCRP       Uptake transport       Increa         ne (4) lauryl       μM       approx       approx         , Brij <sup>®</sup> L4       1489       (In vitro DCM), In situ closed-loop method (In situ CLM), Wild type (WT), Sprag         1490       Synonyms of surfactants are available in Table 2.       1491	ased <u>S-M</u> B-A ort_	(Sav 201
rat 2.2 an 50 and 100 Mitoxantrone MDCKII BCRP Uptake transport Increa approx 14 89 ( <i>In vitro</i> DCM), <i>In situ</i> closed-loop method ( <i>In situ</i> CLM), Wild type (WT), Sprag 14 90 Synonyms of surfactants are available in Table 2. 1491	sed AUC and C <sub>max</sub> by nd 1.4- folds, resp.	(Sav 201
50 and 100       Mitoxantrone       MDCKII BCRP       Uptake transport       Increating approximation         Brij <sup>®</sup> L4       1489       (In vitro DCM), In situ closed loop method (In situ CLM), Wild type (WT), Sprage       1490         Synonyms of surfactants are available in Table 2.       1491	used AUC and C <sub>max</sub> by d 2.1-folds, resp.	(Sav 201
<ul> <li>1489 (<i>In vitro</i> DCM), <i>In situ</i> closed-loop method (<i>In situ</i> CLM), Wild type (WT), Sprag</li> <li>1490 Synonyms of surfactants are available in Table 2.</li> <li>1491</li> </ul>	used the uptake by x. 1.7-fold.	(Ya 200
1491	ue-Dawley (SD),	
1472		
1492		
1495		
1494		
1496		
1497		
1498		
1499		
1500		
1501		
1502		
1503		
1504		

olyoxyethylene	0.01% and 0.05%	Sulfasalazine	Rat intestinal membrane	In vitro DCM	Decreased <u>S-M</u> B-A transport.	(Sav 2018
er	0.1 %	Sulfasalazine	WT male Wistar rat	In situ CLM	Increased AUC and $C_{max}$ by 1.8 and 2.3-fold, resp.	(Sav 2018
EL	50 µM	Mitoxantrone	MDCKII BCRP	Uptake transport	Increased the uptake by approx. 1.4-fold.	(Yai 200
	6.25-100 nM	Scutellarin	Membrane vesicles of Sf9 BCRP	Uptake transport	Increased the uptake in a conc. dependent manner.	(Xia 2010
	1 and 5 μg/mL	Scutellarin	MDCKII BCRP	Bi-directional transport	Increased A-B and decreased B-A P <sub>app.</sub>	(Xia 2010
	5 μg/mL	Scutellarin	WT Male SD rats		Increased AUC and $C_{max2}$ by 1.6 and 1.9-folds, resp.	(Xia 2010
	0.025 and 0.05% (w/v)	Topotecan	Caco-2 cell monolayers	Bi-directional transport	Increased A-B and/or decreased B-A P <sub>app.</sub>	(Sav 2018
	0.05 % (w/v)	Topotecan	WT male Wistar rat	In situ CLM	Increased AUC 2.3-folds.	(Sav 2018
nethyl-β-D- side, (Cymal-1)			Membrane vesicles BCRP	Phosphate release measurements	Reduced P-gp ATPase activity. $K_2 = 1.51 \ 10^4 \ \mu M$	(Xu
	0.075%	Sulfasalazine	Rat intestinal membrane	In vitro DCM	Decreased <u>S-M</u> B-A transport.	(Sav 2018
	0.025 and 0.05% (w/v)	Topotecan	Caco-2 cell monolayers	Bi-directional transport	Increased A-B P <sub>app.</sub>	(Sav 2018
8	0.025 and 0.05% (w/v)	Topotecan	Caco-2 cell monolayers	Bi-directional transport	Decreased B-A P <sub>app.</sub>	(Sav 2018
5	20 µM	Mitoxantrone	MDCKII BCRP	Uptake transport	Increased the uptake by approx. 1.8-fold.	(Yai 200'
	250 mg kg <sup>-1</sup> (Oral)	Topotecan (Oral)	WT mice		Increased the AUC by 2-folds.	(Yai 200
	20 μM	Topotecan	Everted sacs from WT mice ileum	Transport	Increased the intestinal absorption rate of topotecan.	(Yai 200'
	20 μΜ	Mitoxantrone	MDCKII BCRP	Uptake transport	Increased the uptake.	(Yai 2009
ene (8) lauryl vloctaglyol,			Membrane vesicles BCRP	Phosphate release measurements	Reduced Pgp ATPase activity. $K_2 = 6.93 \mu M$	(Xu
20	100 and 250 μΜ	Mitoxantrone	MDCKII BCRP	Uptake transport	Increased the uptake by approx. 1.6-fold.	(Yai 200
	100 mg kg <sup>-1</sup>	Topotecan	WT mice		Increased the AUC by 2-	(Yaı

	(Oral	l) (O	ral)			fold.	200
	250 µ	иМ То	potecan	Everted	Transport	Increased the intestinal	(Yaı
	Conc.	Substrate	Cells or	animal	Assay	Impact of surfactant	Refere
EL	0.005-0.05%	Calcein-AN	1 MDCKII	MRP2	Bi-directional	Decreased B-A P <sub>app</sub> .	(Hanke
	(v/v)				transport		
	100 µg/mL	Scutellarin	Membrai Sf9 MRF		Uptake transport	Increased the uptake.	(Li et a
	0.1%			membrane		transport.	201
	0.025		potecan	Caco-2 cell	<b>Bi-directional</b>	Increased A-B and	(Sav
		% (w/v)		monolayers	transport	decreased B-A P <sub>app.</sub>	201
	0.05	% (w/v) To	potecan	WT male Wist	tar In situ CLM	Increased AUC 2.5-folds.	(Sav
	100	M M		rat			2013 (V
1 4	100 µ	IM Mi	toxantrone	MDCKII BCR	P Uptake transpor	1 1	(Yai
nolaurat						approx. 1.4-fold.	200
1505							
1506							
1000							
1507							
1508							
1209							
1509	Table 5: In v	vitro and in vi	vo impact of	f nonionic surfac	tants and co-surfacta	ants on multidrug resistance-	
1510			-				
1510	ussociated pi						
1511	Concentratio	n (Conc.), Re	espectively (1	esp.), Membrane	e vesicles prepared f	rom Spodoptera frugiperda	
1512	(Sf9) insect c	cells over-exp	ressing hum	an MRP2 (Mem	brane vesicles of Sf	<del>) MRP2), ATP</del>	
			K				
1513	measurement	ts were perfor	med using A	TP-luciferin/Lu	ciferase assay, Wild	type (WT), Synonyms of	
	0		TT 11 0	1.2			
1514	surfactants a	re available ii	n Table 2 and	<del>13.</del>			
1515		7					
1313							
1516							

	100 µg/mL	Scutellarin	Caco-2 cell	Bi-directional	Decrease ER.	(Li et a
			monolayers	transport		
	0.1-100	Scutellarin	Caco-2 cell	<b>Bi-directional</b>	Decreased ER in a conc.	(Li et a
	µg/mL		monolayers	transport	dependent manner.	
	0.1-100 μg/mL	Scutellarin	Membrane vesicles of Sf9 MRP2	Uptake transport	Increased the uptake in a conc. dependent manner.	(Li et a
	6.25-100 nM	Scutellarin	Membrane vesicles of Sf9 MRP2	Uptake transport	Increased the uptake in a conc. dependent manner.	(Xiao
	1 and 5 $\mu$ g/mL	Scutellarin	MDCKII MRP2	Bi-directional transport	Decreased B-A P <sub>app</sub> .	(Xiao
	5 µg/mL	Scutellarin	WT Male Sprague- Dawley rats	1	Increased AUC and $C_{max2}$ by 1.6 and 1.9-folds, resp.	(Xiao
2L + 7	100 μg/ml + 100 μg/ml	Scutellarin	Membrane vesicles of Sf9 MRP2	Uptake transport	Increased the uptake.	(Li et a
L +	100 μg/ml + 100 μg/ml	Scutellarin	Membrane vesicles of Uptake transport Increased the uptake. Sf9 MRP2		(Li et a	
H 40	0.02-0.04% (v/v)	Calcein-AM	MDCKII MRP2	Bidirectional transport	Decreased B-A P <sub>app</sub> .	(Hanke
	100 µg/mL	Scutellarin	Membrane vesicles of Sf9 MRP2	Uptake transport	Increased the uptake.	(Li et a
	100 µg/mL	Scutellarin	Caco-2 cell monolayers	Bi-directional transport	Decreased ER.	(Li et a
	0.1-100 μg/mL	Scutellarin	Caco-2 cell monolayers	Bi-directional transport	Decreased ER in a conc. dependent manner.	(Li et a
	0.1-100 μg/mL	Scutellarin	Membrane vesicles of Sf9 MRP2	Uptake transport	Increased the uptake in a conc. dependent manner.	(Li et a
	μg/mL	Scutellarin	Caco-2 cell monolayers	Bi-directional transport	Decreased ER.	(Li et a
	100 μg/mL	Scutellarin	Membrane vesicles of Sf9 MRP2	Membrane vesicles transport assay	Increased the uptake.	(Li et a
	100 µg/mL	Scutellarin	Caco-2 cell monolayers	Bi-directional transport	Decreased ER.	(Li et a
	0.1-100 μg/mL	Scutellarin	Membrane vesicles of Sf9 MRP2	Uptake transport	Increased the uptake in a conc. dependent manner.	(Li et a
	0.1-10 μg/mL	Scutellarin	Caco-2 cell monolayers	Bi-directional transport	Decreased B-A P <sub>app</sub> .	(Li et a
	100 µg/mL	Scutellarin	Caco-2 cell monolayers	Bi-directional transport	Increased A-B P <sub>app.</sub>	(Li et a
	100 µg/mL	Scutellarin	Membrane vesicles of Sf9 MRP2	Uptake transport	Increased the uptake.	(Li et a
	100 μg/mL	Scutellarin	Caco-2 cell	<b>Bi-directional</b>	Decreased ER.	(Li et a

	0.1-100	Scutellarin	monolayers Caco-2 cell	transport Bi-directional	Decreased ER.	(Li ot e
		Scutenarin	monolayers		Decreased ER.	(Li et a
	μg/mL 0.1-100	Scutellarin	Sf9 MRP2	transport Uptake transport	Increased the uptake in a	(Li et a
		Scutenanni	519 WIKF 2	Optake transport	conc. dependent manner.	(LI CI d
	μg/mL	a . 11 .		<b>TT</b> . <b>1</b>	1	( <b>-</b> •
	100 µg/mL	Scutellarin	Membrane vesicles of Sf9 MRP2	Uptake transport	Increased the uptake	(Li et a
	100 µg/mL	Scutellarin	Caco-2 cell monolayers	Bi-directional transport	Decreased ER.	(Li et a
	0.1-100	Scutellarin	Caco-2 cell	Bi-directional	Decreased ER.	(Li et a
	μg/mL	Soutonarin	monolayers	transport	Beereusea Ert.	
	$10 \mu\text{g/mL}$	Baicalcein	MDCKII MRP2	Bi-directional	Increased A-B P <sub>app</sub> and	(Chen
	10 p.8,	2		transport	decreased B-A P <sub>app</sub> .	(enen
	100 μg/mL	Scutellarin	Caco-2 cell	Bi-directional	Decreased ER.	(Li et a
	10		monolayers	transport		
	0.1-100	Scutellarin	Caco-2 cell	Bi-directional	Decreased ER in a conc.	(Li et a
	µg/mL		monolayers	transport	dependent manner.	
	0.1-100	Scutellarin	Membrane vesicles of	Uptake transport	Increased the uptake in a	(Li et a
	µg/mL		Sf9 MRP2		conc. dependent manner.	
	10 μg/mL	Baicalcein	MDCKII MRP2	<b>Bi-directional</b>	Decreased B-A P <sub>app.</sub>	(Chen
				transport		
	0.00005-		MDCKII MRP2	ATP	Decreased ATP levels.	(Batral
	0.005% (w/w)			measurements		2003)
	0.01-0.5%	Vincristine	MDCKII MRP2	Uptake transport	Increased intracellular accum.	(Batra
	(w/w)				in a conc. dependent manner.	2003)
					Decreased $IC_{50}$ value by 6.6	
					times.	-
	0.01-0.5%	Doxorubicin	MDCKII MRP2	Uptake transport	Increased intracellular accum.	(Batral
	(w/w)				in a conc. dependent manner.	2003)
					Decreased $IC_{50}$ value by 125	
	010(())		D1 1 0	D1 1 1 1	times.	
	0.1 % (w/v)		Plasma membranes of	Phosphate release	Decreased $V_{max}$ .	(Batral
	010/(/)	• • • •	MDCKII MRP2	measurements		2004)
	0.1 % (w/v)	Vincristine	Plasma membranes of	Phosphate release	Decreased $V_{max}$ and increased	(Batral
	10 / 1	D · 1 ·	MDCKII MRP2	measurements	$K_m$ .	2004)
	10 μg/mL	Baicalcein	MDCKII MRP2	Bi-directional	Increased A-B P <sub>app</sub> and	(Chen
	10	Deiselesin		transport	decreased B-A P <sub>app</sub> .	(Class
1	10 μg/mL	Baicalcein	MDCKII MRP2	Bi-directional	Increased A-B P <sub>app</sub> and	(Chen
I				transport	decreased B-A P <sub>app.</sub>	
	$10 \mu a/mI$	Daiaalaain	MDCKII MRP2	<b>Bi-directional</b>	Increased A D D and	(Chan
1	10 μg/mL	Baicalcein	WIDCKII WIKP2		Increased A-B $P_{app}$ and	(Chen
I				transport	decreased B-A P <sub>app.</sub>	
	10 μg/mL	Baicalcein	MDCKII MRP2	<b>Bi-directional</b>	Increased A-B P <sub>app</sub> and	(Chen
	10 µg/11L	Duituiteilli			mercused in D i app and	(Unon

+

+ 7

+

5				transport	decreased B-A P <sub>app.</sub>			
5	10 µg/mL	Baicalcein	MDCKII MRP2	Bi-directional transport	Increased A-B P <sub>app</sub> and decreased B-A P <sub>app</sub>	(Chen		
)	0.05% (v/v)	Calcein-AM	MDCKII MRP2	Bi-directional transport	Decreased B-A $P_{app}$ .	(Hank		
	0.01-0.05% (v/v)	Calcein-AM	MDCKII MRP2	Bi-directional transport	Decreased B-A P <sub>app</sub> .	(Hank		
	100 μg/mL	Scutellarin	Membrane vesicles of Sf9 MRP2	Uptake transport	Increased the uptake.	(Li et a		
	100 µg/mL	Scutellarin	Caco-2 cell monolayers	Bi-directional transport	Decreased ER.	(Li et a		
	0.1 and 1μg/mL	Scutellarin	Caco-2 cell monolayers	Bi-directional transport	Decrease ER.	(Li et a		
	$0.1 \text{ and } 100  \mu\text{g/mL}$	Scutellarin	Membrane vesicles of Sf9 MRP2	Uptake transport	Increased the uptake in a conc. dependent manner.	(Li et a		
1517								
4				P		I		
1518						l		
1519						I		
-						i		
1520	Tahle 6. Nor	ionic surfactor	ts inhibit <del>ed</del> solute carrier	s(SLCs) in vitro		i		
1521						i		
1522						i		
1523	IC <sub>50</sub> were es	timated from u	ipatke transport assay. F	or Regev et al. 200	02, imact of surfactant on bi-	i		
1524	directional tr	ansport assay w	ras shown. 1-methyl-4-pl	henylpyridinium ace	etate (MPP <sup>+</sup> ), Monocarboxylic			
1525	acid transpo	vrter (MCT, S	LC16A1), Organic cati	i <del>on transporter 1 (</del>	<del>(OCT1, SLC22A1), (OCT2,</del>			
1526	<del>SLC22A2),</del> -	(OCT3, SLC22	2A3), Peptide transporte	<del>er 1 (PEPT1, SLC</del>	215A1), (PEPT2, SLC15A2),			
1527	Organic anio	n transporting I	polypeptide 1A2 (OATP	1 <del>A2, SLC21A3), (O</del> .	ATP2B1, SLC21A9). Human			
1528	embryonic kidney cells stably transfected with OATP1A2 (HEK OATP1A2), or with OATP2B1 (HEK							
1529	<del>OATP2B1), -</del>	OATP2B1), Chinese hamster ovary cells stably transfected with rbOCT1(CHO-K1 rbOCT1), Madin-						
1530	Darby canine	Darby canine kidney cells stably transfected with OCT1-3 (MDCKII OCT1-3), or with PEP2 (MDCKII						
1581	PEPT2). Syn	onyms of surfac	ctants available in Table 2	2 and 5.		ļ		
1532								

1534				
1535				
1536				
1537				
1538				
1539 1540				
1540				
1541			Star Star	
Nonionic surfactant	Transporter <u>SLC</u>	Substrate	Cells	IC <sub>50</sub> Impact of surfactant
Solutol <sup>®</sup> HS 15	OATP1A2	Estrone-3-sulfate	HEK OATP1A2	0.0074%
	OATP1A2	Taurocholate	HEK OATP1A2	0.0041%
	OATP2B1	Estrone-3-sulfate	HEK OATP2B1	0.011%
	OATP2B1	Bromosulfophthalein	HEK OATP2B1	0.00095%
	OCT1	MPP <sup>+</sup>	MDCKII OCT1	0.008%
	OCT2	$MPP^+$	MDCKII OCT2	0.046%
	OCT3	MPP <sup>+</sup>	MDCKII OCT3	0.019%
	PEPT2	Glycyl sarcosine	MDCKII PEPT2	0.014%
Cremophor <sup>®</sup> EL	OATP1A2	Estrone-3-sulfate	HEK OATP1A2	0.00054%
	OATP1A2	Taurocholate	HEK OATP1A2	0.00034%
	OATP2B1	Estrone-3-sulfate	HEK OATP2B1	0.0011%

	OATP2B1	Bromosulfophthalein	HEK OATP2B1	0.0098%
	OCT1	MPP <sup>+</sup>	MDCKII OCT1	0.019%
	OCT2	MPP <sup>+</sup>	MDCKII OCT2	0.46%
	OCT3	MPP <sup>+</sup>	MDCKII OCT3	9.77%
	PEPT2	Glycyl sarcosine	MDCKII-PEPT2	0.16%
Vallinkar® D 100	МСТ ОСТЗ	Benzoic acid	Caco-2 <u>cells</u> MDCKII OCT3	Decreased A-B $P_{app}$ of the substrate in a concentration dependent manner.
Kolliphor <sup>®</sup> P 188, Po <mark>l</mark> oxamer 188	0013	MPP <sup>+</sup>	MDCKII UC13	0.024%
Kolliphor <sup>®</sup> P407	OCT1	MPP <sup>+</sup>	MDCKII OCT1	1.85 %
Polysorbate 20	OCT1	MPP <sup>+</sup>	MDCKII OCT1	0.002%
	OCT1	$MPP^+$	CHO-K1 rbOCT1	$85 \pm 1.12 \ \mu g/ml$
	OCT2	$MPP^+$	MDCKII OCT2	0.033%
	OCT2	$MPP^+$	CHO-K1 rbOCT2	$295 \pm 1.48 \ \mu\text{g/ml}$
	OCT3	$MPP^+$	MDCKII OCT3	0.011%
	PEPT2	Glycyl sarcosine	MDCKII-PEPT2	0.005%
Polysorbate 60, Tween® 60,	OCT1	$MPP^+$	CHO-K1 rbOCT1	$50 \pm 1.26 \ \mu g/ml$
Polyoxyethylene (20) sorbitan stearate	OCT2	MPP <sup>+</sup>	CHO-K1 rbOCT2	$42 \pm 1.15 \ \mu g/ml$
Polysorbate 80	OCT1	$MPP^+$	MDCKII OCT1	0.0007%
	OCT1	$MPP^+$	CHO-K1 rbOCT1	$106 \pm 1.20 \ \mu g/ml$
	OCT2	$MPP^+$	MDCKII OCT2	0.039%
	OCT2	$MPP^+$	CHO-K1 rbOCT2	$185 \pm 1.20 \ \mu g/ml$
	OCT3	$MPP^+$	MDCKII OCT3	0.011%
	PEPT2	Glycyl sarcosine	MDCKII PEPT2	0.037%
	PEPT1	Glycyl sarcosine	Caco-2 cells	Decreased A-B $P_{app}$ of the substrate in a concentration dependent manner.

1551	
1552	
1553	Declaration of interest
1554	The authors do not have any conflict of interest to report.
1555	
1556	Author contribution
1557 1558	Writing - original draft: AAAA, CUN, and RBN. Writing - review & Editing: AAAA, RBN, BS, RH and CUN. Final approval of the version submitted: AAAA, RBN, BS, RH and CUN.
1559	
1560	ACCERTIC

